medicines together prevail annual report nopqbristolmyers squibbs mission companys mission extend enhance human life providing highestquality pharmaceutical related health care products pledgeto patients customersto employees partnersto shareholders neighbors world serveto act belief priceless ingredient every product honor integrity maker cover bristolmyers squibbwe develop medicines related health care products help people live full active livesa patients customers pictured coverthese patients profiled special reportbeginning stockholders challenging transitional year bristolmyers squibb experienced significant negative impact generic competition pharmaceutical business made difficult decision change leadership companywe also achieved preliminary settlement investigation drug pricing sales marketing practices began many years ago time successful launching several promising new products expanding key businesses advancing robust pipelineall areas serious unmet medical need result bristolmyers squibb well positioned begin growing sales earnings build shareholder value financial performance companys net earnings sales earnings adversely affected august canadian pharmaceutical continuing operations gaap generally several developments yearfirstas company apotex launched generic version accepted accounting principles basis expectedwe lost exclusivity pravacholour plavix usflooding market billionor per diluted sharefrom net cholesterollowering medicinein usand several weeks sales halted sales continuing operations billion several european countriesfor many years court orderthis action apotex reduced compares earnings billionor pravacholwas one leading products plavix sales range billion per diluted shareon sales billion recentlywe experienced negative billion reflected nongaap basisexcluding impact generic competition top overall percent decline plavix sales specified itemsnet earnings continuing selling product plavix clopidogrel bisulfatean yearwe expect generic supply operations billionor antiplatelet medicine bristolmyers squibb market residual impact per diluted sharecompared sanofiaventis sanofi codeveloping plavix sales billionor per diluted sharein cocommercializing around world annual report bristolmyers squibb plavix situation several years agoapotex filed request clearlyour plavix businessand com spryceland orenciacame usfood drug administration fda panys financial strength reputationwere laboratoriesand continue invest sell generic clopidogrel product seriously damaged turn eventsit extensive clinical programs exploring range usdespite existence patents plavix major setback sincerely regret potential uses promising medicines held sanofi bristolmyers squibb bristolmyers squibb sanofi entered help even patients futurewe usand countriesbelieving patents negotiations apotex good faith pursuing pipeline within product valid infringedwe sued apotex pursue workable solution benefiting parties approach key products well protect valuable intellectual property rights plavix patent trial concluded addition launcheswe expanded bristolmyers squibb sanofi invested february yearand court reach newer pharmaceuticals extensively plavix decade expected rule next months erbituxa cancer treatment conduct clinical research demonstrating hopeful validity intel codeveloping copromoting benefits patients lectual property rights upheldin imclone systems incorporatedcontinues way uslaw area meantimewe encouraged demand grow treatment advanced structuredapotex able apply plavix continues growpointing refractory colorectal cancer andmore receive permission market generic positive future therapy helping even recentlyhead neck cancer clopidogrel useven though dispute patientsand continue invest abilifyan antipsychotic therapy validity plavix patent behind brand codeveloping copromoting yet settledin early fda otsuka pharmaceutical coltdis benefiting approved apotexs requestenabling product highlights additional formulations company launch generic product launched several noteworthy approved usalthough action could put risk pharmaceutical products baracludea treatment chronic hepatitis b legal sanctions orencia promising new treatment continues gain shareincluding asia concerns mindthe parties option many patients suffering disease widespreadwe currently dispute entered discussions rheumatoid arthritisa disfiguring launching baracludein japan well march announced tentative settlement disabling disease erode quality europe patent infringement litigationhowever life shorten lifespanorencia fda approved mg single capsule government approve proposed gaining share usand expect formulation reyatazin combination settlementand july announced launch europe later year therapy adults hiv patent infringement litigation would resume spryceladdresses serious often deadly key pharmaceuticals shortly thereafterapotex launched generic form chronic myelogenous leukemia exception plavixgrew solid clopidogrel uswe responded seeking patients resistant intolerant doubledigit ratesseveral additional products preliminary injunction federal court gleevecthe current standard care approached surpassed billion mark halt distributionthe court granted sprycelis currently marketed us total revenue sales includingabilifyreyataz preliminary injunction august recently launched europe andin mead johnson nutritionals busi remains force atripla onetabletoncedaily combination nessthe enfamilinfant formula line sustivamedicine treatment mead johnson related health gilead sciencesatripla joins sustiva care companiesconvatec bristolmyers reyatazin growing portfolio squibb medical imagingcontinue provide innovative therapies hivaids strength stability companypartic emsamlicensed somerset pharma ularly transitional time pharma ceuticalsis transdermal patch ceutical portfoliomany key health care introduced usfor treatment brands solid additional growth potential serious depression adults including mead johnson asia latin americawhere market expansion robust bristolmyers squibb annual reportjames robinson iii chairman board left james cornelius chief executive officer pipeline achievements pipeline continued move forward addition new drug launches already mentionedwe transitioned one com poundapixabanpotentially deep vein thrombosisto latestage phase iii develop mentwe six compounds phase iii addressing areas significant unmet medical needthree sixixabepilonevinflunine ipilimumabare oncologyan area historical strength bristolmyers squibb pipeline productivity tied several factorsfirstwe consistently increased investments research development even past five yearswhen exclusivity losses drained substantial sums revenue basesecondwe restructured refocused rd organization improve growing importance organizational changes processesenhance quality drug candidates biologics company made several leadership increase efficiency clinical development fight serious diseasebiologics changes septemberwe announced finallyin era cost pricing pressures proteinderived therapiesare playing departure peter rdolan chief industrywe believe critically impor increasingly prominent roleerbitux orencia executive officer appointment tantto strategically manage pipeline biologicsas ipilimumabfor cancerand james mcorneliusa member board ensure efficient use resources effectively belataceptfor solid organ transplant rejection directorsas ceo interim basispeter manage risk uncertaintyto end pipelineproducing biologics complex prime architect behind bristolmyers squibb successfully pursued costlyand making significant invest companys strategic focus serious diseases number strategic partnerships mentsto build capabilities area grateful many successes biotech pharmaceutical companies began several years ago executing strategy putting bristolmyers strengthen product portfolioenhance conversion longstanding manufacturing squibb solid path forwardthe search technology sustain productivity site syracusenew yorkto biologics center new ceo continuing lead pipeline excellencein announced nearly ership jim robinsonwho working closely earlier yearwe announced worldwide billion new commitments biologics board committee effort collaboration astrazeneca codevelop manufacturingincluding expansion company also promoted andrew rj cocommercialize saxagliptin existing plant puerto rico con bonfieldchief financial officerand elliott sigal dapagliflozintwo diabetes compounds struction new stateoftheart facility mdphdchief scientific officer president developmentwe concluded similar devensmassachusettswe looking forward pharmaceutical research instituteto executive agreement otsuka pharmaceutical co breaking ground devens location vice presidentthey join lamberto andreotti ltdfor saxagliptin japanconsistent year presidentworldwide pharmaceuticalswho strategythese collaborations enable earlier named executive vice presi us share costs risks innovative dentthese three executives played potential products area significant critical roles developing executing unmet medical need strategyandtogether many outstanding leaders across company committed success annual report bristolmyers squibb pharmaceutical development pipeline bristolmyers squibb researchers driving current future growth ability bring new dedicated discovering also undergoing continued products patients need developing innovative medicines clinical development determine find new uses current address serious unmet medical whether additional indications products dependent upon needs key disease areas formulations benefit patients demonstrating safety efficacy areas listed chart right throughout special report favorable benefitrisk rela selected emphasis beginning call tionship via systematic testing remain significant attention importance patients volunteer patient needs well opportuni ongoing clinical trials participate studies ties leadership company highlight responses like scientific compounds research individual clinical trial patients endeavor clinical testing novel programs discoveryare results may unpredictable compounds complex time earliest stages research one participant consuming resourceintensive compounds exploratory individual experimental study process guaranteed results developmentare preclinical personal accounts illustrate bristolmyers squibb committed early clinical development importance participation pursuing clinical develop full developmentcompounds clinical trials essential ment helping investigational drugs development next patients prevail latestage clinical development generation medical innovation submitted regulatory true test whether agencies approval life cycle document real clinical benefit managementcompounds across significant number among approved medicines research participants corporate governance compliance several key developments additional ways strengthen commitment yearwe also cooperating fully corporate governance compliance intensive employee training compliance ongoing investigation antitrust areasin board amended bylaws matters continuesand honored division usdepartment justice company adopt majority voting receive best practicesaward november relating proposed settlement standard directorsand recently organization compliance plavix litigation adopted corporate governance guideline professionalsrecognizing ushealthcare recallthe company operating requiring supermajority independent law compliance field handbook deferred prosecution agreement directors approve compensation late last yearwe announced agreement usattorney new jerseywe ceowe believe measures principle usdepartment continue work closely monitor enhance accountability transparency justice usattorney massachusetts appointed usattorney ensure benefit stockholders well settle several investigations involving full compliance letter spirit stakeholders companys drug pricingand sales marketing agreement compliance remains top priority activitiesthese investigations began several us bristolmyers squibbthe compliance years agoas part civil resolutionthe processes mechanisms company company agreed pay million enter put place past several years corporate integrity agreement operating welland always looking usdepartment health human services hope conclude agreement later bristolmyers squibb annual reportexploratory full life cycle disease areas focus discovery development development management oncology cancer cardiovascular atherosclerosis metabolic thrombosis diseases diabetes obesity neuroscience psychiatric disorders alzheimers disease virology hepatitis hivaids immunology rheumatoid arthritis solid organ transplant rejection discovered internally inlicensed discovery alliance program goals beyond following productive solid progress productivity initiative everscience companys focused executing strategy maximize track achieve foundationand many respects success shareholder valueassuming million cost reductions alone determined focus scientific successful defending plavix patentas savings solely result excellencewe see commitment every day well growing key products advancing onetime spending cuts rather reflect outstanding work rd organi pipelinewe expect sales earnings systematic approach aimed streamlining zationand efforts thousands increase yearand exclusivity processessimplifying governance perma employees transform innovative losses expected near termwe nently removing lowvalue workin respect research products services looking sustain build growth part largerand criticaleffort extend enhance human life next several years transform company efficient excellence science also priority stillthe overall environment challenging flexible dynamic organization future boardand pleased last year companies across pharmaceutical year plan look additional welcome two new members industrypricing pressures particular opportunities drive efficiencies reduce strong backgrounds science medicine growingincluding uswhere new costsagain largely scrutinizing way vicki lsatophdis professor management prescription drug benefit medicare operate businesswe pretend practice harvard business school impact process painlessacross entire professor practice department maintain forward momentumwe industrycompanies facing difficult choices molecular cell biology harvard must constantly examine cost base restructurefor usit important universityrsanders williamsmdis senior ensure thatto maximum extent possi lead process way builds strength vice chancellor academic affairs duke bleit supporting investment growth confidence commitment better university medical center dean duke opportunitiesover past yearwe made future bristolmyers squibb university school medicine annual report bristolmyers squibb together prevail drssato williams serve boards ultimatelythrough efforts science africaour million securethe science technology committeewhich business many areaswe aim help future initiative continues make head established last yearthe committee patients prevail fight serious way fight hivaids providing chaired laurie hglimchermdirene heinz diseasethat heart mission communitybased treatment care given professor immunologyharvard guiding spirit behind strategyit inspires opened third pediatric aids clinic school public healthand professor us succeed company build value africain swazilandand broken medicineharvard medical schoolwho stockholdersour employees ground similar centers burkina faso member board since demonstrated extraordinary commitment ugandathese centersfunded believe imperative board resiliency challenging timesas bristolmyers squibbare operating part fully involved developing stayed focused mission values nership baylor college medicine seeing companys rd strategyand help people prevail innovative national governmentsand bringing assessing opportunitiesand risksin products make difference lives critically needed medical care thousands strategy also help providing free medicines children families living hiv also want welcome board patients needand seeking reduce special report followsyou michael grobsteinwho distinguished health disparities around world learn remarkable people retired vice chairman ernst younghe work bristolmyers squibb foundation prevailed significant health challenges serve boards audit committee last yearthe company provided free great courage determinationwe medications worth million proud company could play approximately people us part inspiring storiesas look andtogether foundation aheadwe excited prospect contributed million healtheducation helping create many stories community projects around world hope triumphthat vision continue drive us make bristolmyers squibb best possibly james drobinson iii chairman board james mcornelius chief executive officer march bristolmyers squibb annual reportspecial report bristolmyers squibb medicines helped countless patients prevail serious diseases cancer hivaids mental illnesswe stood beside patients help battle rheumatoid arthritis hepatitis heart disease diabetes health care products enhanced lives millions philanthropic programs given new hope vulnerable people world sets us apart bristolmyers squibbwe believe commitment patients serious diseasesour focus finding innovative medicines combat diseasesand dedication extending enhancing human life special report describes done change course disease people everywherethe stories section capture determination individuals helped medicines together prevail annual report bristolmyers squibb cancer prevailing year marked th anniversary head neck cancerthe development executing strategy intended national cancer actwith actthe erbitux clearly illustrates companys com provide patients broad range product usdeclared war canceralthough much mitment patients cancersays caforio typestraditional cellkilling chemotherapeutic progress made since thenthe war bristolmyers squibb building agentstargeted biologicssignal transduction far wonworldwidenearly million commitmentspryceldasatinibfor treat inhibitors prevent tumor growth people diagnosed cancer annually ment patients chronic myelogenous immunomodulators use bodys yetfrom earliest days struggle leukemia philadelphia chromosomepositive immune system fight cancersays martin right todaybristolmyers squibb acute lymphoblastic leukemia resistant birkhofermdvice presidentoncology remained front lines intolerant prior therapywas discovered global medical affairs swhen oncology bristolmyers squibb developed bristolmyers squibbs commitment cottage industrysays robert kramerphd record timesprycelwas approved us patients remains hallmark legacy vice presidentoncology immunology drug june europe november innovative cancer treatmentspeople always ask discoverybristolmyers squibb became clinical trials way evaluate cure cancersays renzo first company drive research treatments effectiveness sprycel hematologic canettamdvice presidentoncology global point impact malignancies solid tumors clinical researchwith early detection cancer treatment medicines among oncology compounds morepowerful treatmentsi see early company entry cytoxan latestage clinical development ixabepilone patients well every dayincreasingly cyclophosphamidea medicine still use compound new class drugs discovered understand cancer something today thes saw approval several developed company labs treat patients live withnot die additional anticancer therapiesincluding ment breast cancervinfluninelicensed cisplatincarboplatin etoposidethere pierre fabre medicament treat time nearly patients diagnosed ment bladder cancerand ipilimumab cancer died soon diagnosissays licensed medarexincfor treatment giovanni caforiomdsenior vice president metastatic melanoma usoncologythese new agents began change thesbristolmyers squibb took significant challengethe development taxol paclitaxelpreviouslypaclitaxel derived solely bark pacific yew treeand quantities severely limited within monthsthe company devised method dramatically improve production paclitaxel natural sourceslargescale clinical trials supported company proved efficacy taxolin treatment multiple types cancerthereby changing course cancer care many patients company advanced fight targeted therapies entered agreement imclone systems incorporated develop erbitux cetuximab approved usin february certain patients metastatic colorectal cancer march erbitux became first drug approved years treatment jan johnsen london diagnosed chronic myelogenous leukemiahe recallsit shocking day lifewhen johnsens treatments failedhis doctor suggested enter clinical trial sprycel almost impossible describe joy feel know treatment helps fight lifethreatening illnessjohnsensays bristolmyers squibb annual reportsharon coordsbelvin two weeks wedding sharon coordsbelvinseen husbandrobthought bronchitisbut diagnosis left breathless metastatic melanomai literally fell backwards saysdespite chemotherapythe tumors quickly spread lungslymph nodes brainthenshe enrolled clinical trial ipilimumaban investigational biologictoday sharon appears well talk husband dreams future brings tears eyes frank leea research fellow discovery biology bristolmyers squibbhas spent life studying cancer find better treatmentsim cancer research simply want behe saysi know people waiting us come better medicineswith hope cureits makes come work every day annual report bristolmyers squibb ophelia haanyama ophelia haanyamaa swedish citizen born zambia living stockholmtested positive hiv understand something small virus couldnt curedhaanyama determined fight backshe began treatmentcompleted high school education went study microbiologyphysiology public healthtodayshe senior adviser noahs arkred cross foundation swedenan hivaids education information support program part treatmenthaanyama takes reyatazher hope future simple one aidsfree world world open proud healthy bristolmyers squibb annual reporthiv hepatitis prevailing hivaids aids first identified company pursuing opportunities two years agothere treatment options new classes drugsattachment inhibitors hepatitis available patientsnowwhile still integrase inhibitorsthat attack aids worldwideabout million people curesdrug treatmentssuch videx ec virus novel waysdrug candidates chronically infected hepatitis b virus hbv didanosinezerit stavudinesustiva efavirenz already tested early clinical trialsif percent asia reyataz atazanavir sulfate atripla efavirenz two three new classes hiv drugs million china alone mgemtricitabine mgtenofovir disoproxil introduced addition existing classes baracludeentecavir discovered fumarate mgall marketed doctors able provide patients bristolmyers squibb scientists found comarketed bristolmyers squibbhave sufficient options fight hiv long time block three stages hbv dna replication turned hiv treatable disease many says richard colonnophdvice president medication approved usin today million people infectious diseases drug discovery march since become available north america western europe living unfortunatelyoutside north america patients countries regions hivaids western europemany hivpositive including chinabaracludereduces viral hivsays ann kolokathismdvice individualsparticularly southern africa load hepatitis b infected andin presidentvirologyglobal medical affairs adequate access medicines certain patient populationsstudies shown important provide patients health carethrough programs secure baracludeto reduce viral load undetectable effective treatments also simplify futurebristolmyers squibb helping levels many patientskolokathis says therapiesthats makes compound address needsfor hepatitis c another serious viral infection like atripla importantatriplathe result groundbreaking effortsplease see result cirrhosis liver cancer joint venture bristolmyers squibb million million people gilead scienceswas approved marketing infected worldwidehepatitis c usin july firstever leading cause liver transplants us oncedailysingletablet regimen intended company hard work pursuing multiple standalone therapy part combination targets potential drug combinations therapy medicines treatment achieve oral regimenwhat colonno calls hiv adults holy grail hepatitis c treatment peng zhaoran likes learnspending free time libraries bookstores beijingbut learned something could change life forevera routine blood test revealed infected hepatitis b virusi suffer painzhaoran saysbut worriedhis doctor recommended treatment baraclude treasure day familyi feel lucky person brian coppedgeleftpatient community affairs manager bristolmyers squibbwith francisco valdsa treatment adherence counselor altamed health services east los angelesim hivpositive myselfsays coppedgeso understand hurdles hiv patients must overcomewhile patient may need take one pill dayit still lifelong regimen must carefully maintainedstaying healthy ongoing effort annual report bristolmyers squibb autoimmune prevailing rheumatoid arthritis autoimmune disease bodys defense cells mistakenly attack joints bodyleaving victims paindisabled sometimes crippled lifeabout percent worlds population afflicted rheumatoid arthritis including million americansabout percent affected women rheumatoid arthritis often requires longterm therapybut many treatments provide inadequate reliefmany patients still live paindiscomfort decreased quality life orenciaabatacept discovered developed scientists bristolmyers squibb first approved usin december orenciais novel biologic adult patients moderate severe rheumatoid arthritis helped medica tionsorenciaoffers novel way treating rheumatoid arthritis patientssays mark kreston vice presidentimmunoscience global brand commercialization orenciaalso represents pipeline potential new indications autoimmune disorders investigational trials lupus yearsbarbara whitehead finding difficult simple things lifelike crohns disease ulcerative colitis getting chair playing grandchildren belatacept investigational biologic got point hurt timewhitehead engineered bristolmyers squibb scientists diagnosed rheumatoid arthritisafter several target immune system different unsuccessful courses treatmentshe entered clinical purposeto prevent solid organ transplant trial orenciaafter three treatments orencia saysi could feel differenceit felt like hope rejectionit currently phase iii clinical trials kidney transplant patientswe hope belatacept ultimately help transform pressurehigh cholesterol levelsdiabetes practice transplant medicinesays kidney toxicitytransplant patients risk cardio elliott levymdvice presidentimmunology vascular disease premature graft loss global clinical research says levyif meet standard currentlymore patients efficacy improve safety profile usand europe live transplanted organs current transplant drugs belataceptthat receive new transplants huge advance every yearto prevent rejectiontransplant kreston addswith five different disease recipients require lifelong therapy potent programs clinicrheumatoid arthritis immunosuppressive drugscurrent drugs crohns diseaseulcerative colitislupus effective preventing acute rejection solid organ transplant rejectionplus heavy cost terms side manufacturing commitment new biologics effectslevy saysin long termimmuno facility built devensmassachusetts suppressive drugs contribute high blood see clear commitment biologics translates great many possi bilities making real difference patients biologics process operator jill reinhard colleague monitor liter fermentation bioreactors cells grown produce orenciaeach bioreactor contains trillion cells equals one treatment rheumatoid arthritis patientsit takes days exacting processes manufacture bulk product company 's syracusenew yorkfacility bristolmyers squibb annual reportdisorders james harris july dialysis six yearsjames harris got new lease lifea kidney transplant dialysis took lot saysafter transplantharris entered clinical trial belatacept investigational treatment designed prevent organ transplant rejection since transplantharris spending time family time fishing im enjoying life annual report bristolmyers squibb joshua joshua never thought would able control debilitating mood swings part bipolar disorder plagued many yearsnowafter starting treatment abilify yearold salesman feels turned corneremotionally im feeling healthy says get life bristolmyers squibb annual reportyuwen liphdprincipal scientist neuroscience biologyconfers colleagueresearch scientist kelly lengyelautoradiographic images human brain sections tell us drug target located explainsthis technology allows us rapidly effec tively design next generation drugs treat serious psychiatric neurological disorderssuch major depressive disorder alzheimers disease susan fredriksen psychiatrist knows well pain depression years haunted recurrent depressive episodesthenin fell serious depressionin july fredriksen prescribed emsammy best friend told sound like betteri told herthats mental illness prevailing many patients schizophrenia recentlyabilify injectionfor agitation associated abilify emsam backed growing serious mental illnesses cycle medicine schizophrenia bipolar maniatogether pipeline compounds development medicine may even discontinue treatment otsuka pharmaceutical coltdbristol crf receptor antagonist depression patients often unable tolerate side myers squibb continues develop clinical early clinical developmentand effects achieve adequate symptom programs potential expanded uses abilify compounds focus novel approaches controlsays kevin trappvice president million patients treat anxiety schizophreniaas well neuroscience marketingcertain side effects prescribed abilify dateschizophrenia compounds help slow progression weight gain sedationmay influence bipolar disorder debilitating diseasessays alzheimers diseaseclosely followthe company persons willingness ability stay adam lenkowskydirectorneuroscience also extended research alliance medication strategyyet meet lexicon genetics look different studies suggest abilify aripiprazole may patients treated abilify genes expressed brain potential work differently antipsychotic hear talk lives novel targets future psychiatric drugs medicationsraising levels certain neuro changedits truly touching weve made great strides treatment transmitters low reducing focus mental illness psychiatric neurological illnessesyet levels highbecause bristolmyers squibb begins abilify remain areas significant unmet medical unique profile benefits patientsabilify emsam selegiline transdermal systema need many patientssays jack grebbmd enjoyed extraordinary sales growth since transdermal patch major depressive disorder vice presidentneuroscience global clinical introduction approved february resulting researchour hope continuing revenues certainly importantfor partnership somerset pharmaceuticals advances geneticswe identify new abilify teamhelping patients prime transdermal patchemsam directly molecular targets brain able concernin four yearsabilify continuously absorbed bloodstream direct innovative drugs granted five indicationsacute maintenance treatment schizophreniaacute mainte nance treatment bipolar mania andmost annual report bristolmyers squibb heart disease prevailing million patients diabetes prescribed plavix clopidogrel bisulfate since first made available patients plavix provides balanced safety efficacy profile broad range indicated patients used reduce risk heart attack always believed plavix diabetes another area intensive research patients recent heart attack potential dramatically improve standard even among patients treated recent ischemic stroke diagnosed care millions patients diabetesonly half successfully peripheral artery diseasein plavix risk future atherothrombotic eventssays controlledsays chris cannvice president taken aspirinwas approved reduce brian gavinphdexecutive directorglobal global brand commercializationthe company risk death cause risk medical affairsthats spent currently two novel compounds later heart attackstroke death patients hundreds millions dollars exploring new stages developmentsaxagliptin dapagli experienced severe form benefits patients also continuing flozinin january bristolmyers squibb heart attackthis additional indication expanded improve current usages astrazeneca agreed develop market use plavixtaken aspirinto reduce behind plavixa new generation oral two drugs partnershipin japan risk heart attack stroke across antithrombotic agents emerging saxagliptin developed commercial entire spectrum acute coronary syndrome research pipelineincluding apixabannow ized partnership otsuka pharmaceutical plavix exhaustively studied phase iii clinical trials coltd one largest clinical trial programs ever bristolmyers squibbs focus patient obesity also growing health issue world developedinvolving patients extends many areasincluding hyper wideand major contributor cardiovascular many yearsyetfor bristolmyers squibb tensionmost people hypertension disease diabetescurrently phase ii clinical partner sanofiaventisthe work adequately controlling high blood pressure trials cb antagonist targeting receptors find additional benefits treatment options says pablo lapuertamdexecutive director help control appetite patients far global medical affairstogether sanofi job bristolmyers squibb live trials way patients aventisbristolmyers squibb studying companys mission extend enhance peripheral bypass graftspatients atrial avaproavalide irbesartanan advanced human lifesays sharon henrymdvice fibrillationand undergoing angioplasty antihypertensivefor additional usesincluding presidentcardiovasculars metabolics global another trial ongoing children firstline treatment severe hypertension medical affairsas scientists clinicians congenital heart diseasemore heart failure atrial fibrillation must stay focused patient patients enrolled worldwide new investigational studies kim smitha registered nurse bristolmyers squibb clinical pharmacology unit hamilton new jersey takes vital signs healthy volunteer testing one companys new investigational compounds diabeteshealth care professionals stateof june richard harper stepped broken glasshe didnt feel pain didnt know theartbed facility perform first clinical assessments injuredbut days later foot became swollenharper diagnosed diabetic neuropathy compounds approved phase clinical trialssays smithour causes peripheral numbnessi didnt even know diabeteshe saysharper entered first priority safety volunteers clinical trial saxagliptinan investigational new drug type diabeteshe also made lifestyle changesimproving diet exercisingnowhe saysi feel better bristolmyers squibb annual reporttom gibson tom gibson believed busy heart attack made weekly coasttocoast trips rarely time exercise eating right relaxingall changed april heart attack found time doctor told youre heartbeat away woke part therapygibson prescribed plavixnowhe saysive learned whats important take time myselfi exercise eat rightand take time family annual report bristolmyers squibb enhancing lives prevailing health challenges bristolmyers squibbs health care group consists mead johnson nutritionals convatec bristolmyers squibb medical throughout mead johnsons enfamil imagingplays important part com infant formulas well toddlersand childrens medical imaging panywith billion sales nutritional products continued earn helping customers patients prevail role health care group trust parents health care professionals challenges literally heartof line bristolmyers squibbs strategy worldwidethe companys intercontinental medical imaging businesssays bristol delivering strength stability way business distinguished strong sales myers squibb medical imaging president enhances shareholder valuesays health growth regionsmost notably asia tim ravenscroftthe business helps physicians care group president john celentanowe latin americaenfafranchise productsincluding enhance cardiovascular patient care succeeded role enfaproenfagrowand enfakidfueled growth pioneering cardiovascular imaging agents already building committed continued growth cardiolitekit preparation importantfocusing intensely competitive industryduring technetium tcm sestamibi injection broad enduring commitment help remain focused executing definity vial perflutren lipid customersthe health care groups strategies flawlessly investing key microsphere injectable suspension three businesses help fulfill companys growth driverssays mead johnson president commitment continue guide mission enhance human life stephen wgolsby us work hard extend benefits related health care products services definityto patients europe throughout convatec parts world adds mead johnson nutritionals convatecbristolmyers squibbs wound matter live language therapeutics ostomy care business speakparents worldwide united achieved landmark billion sales one desirethey want children first time convatec president david best start lifemead johnson johnson attributes milestone perform approximately employees worldwide ance customerdriven focus dedicated help proposition companys employeesthis milestone thatsays luanne flikkemavice president reflection heritagepassion vision mead johnson global marketing resources saysourcustomers know us driving force behind developing mead tory bringingneeded products market johnson productsby meeting needs compassionand integrity parents around worldwere serve patientsand innovative tech making effortwere making difference nologies qualityproducts product examplemead johnson world related services provide leader providing innovativesciencebased among convatecs industryleading products nutritional products infants children surfit naturaand esteemostomy systems company pioneered products flexisealfms fecal management system help inborn metabolic disorders key brands wound therapeutics including grow develop full potential aquacelwound dressings aquacel ag mead johnsons commitment healthy infants antimicrobial wound dressingsincorporating well small number families innovative hydrofibertechnology dealing inborn metabolic disorders reflects care exacting attention company brothers alex lazarusagebrennen cubicage gives brandname william cubicage dont share dna products available countries share rareinherited metabolic disorderphenylketonuriaor pkuthe boyswho began life thousands miles apartbecame family brennen adopted russia alexs parentsbarbara john cubicthe boysbodies cant metabolize phenylalaninean essential amino acid found proteinsbutsays momthat never break spiritbrothers ways onethey stick together manage strictlowprotein diet includes mead johnsons phenylfree phenylfree hp phenylalaninefree dietary powders bristolmyers squibb annual reportabby ryan diagnosed ulcerative colitis months oldabby ryan lot overcomeat age large intestine removedat age received full ileostomy age diagnosed crohns diseaseryan fitted drainable convatec pouching systemi fear wouldnt life says realize limitations set mind ryana senior university wisconsinla crosseis deans listshe involved miss america pageant titles miss lacrosseoktoberfest miss western wisconsinmiss midwest miss mississippi valleywhats moreryan travels motivational speakerdelivering personal message hope suffer crohns disease colitis definityvial perflutren lipid microsphere injectable suspensionthe leading echocardiography contrast agent usenables physicians improve patient care converting suboptimal images evaluable onesdefinityconsists gasfilled microspheres exposed ultrasound wavesechoback strong signalscreating increased level contrastthe image right represents definityenhanced echocardiogram suboptimal image left obtained study using echocardiography alone annual report bristolmyers squibb health prevailing disparities additionallybristolmyers squibb makes hiv medicines available subsaharan africa number lowincome countries prices reflecting profit companythe company also provides millions around worldwhen first contingent north pediatric hiv formulations significant get sicktreatments limited american pediatricians family practitioners discount countries availableall oftenpatients disadvan arrived posts africa part company became founding taged financiallysocially geographicallyand pediatric aids corpsthese doctors partner new pediatric initiative certain groupsincluding womenchildren treating hivpositive children families presidents emergency plan aids relief minoritiesare likely others childrens clinical centers excellence first timesays donne newbury experience barriers health care developed bristolmyers squibb coordinates companys global hiv bristolmyers squibb recognizes health baylor college medicineover next access programsa publicprivate partnership disparities seeks address themin early five yearsphysicians pediatric aids created address need bristolmyers squibb foundation corps expected treat pediatric formulations help open announced embarking new hivinfected children train hundreds access hiv treatments millions initiativeto help strengthen communitybased health care workers addition effortsbristolmyers health care worker capacity integrate aids pandemic demanded squibb consolidated patient assistance medical care communitybased supportive innovative partnershipsin february programs usinto single lifelines servicesthe aimto mobilize communities bristolmyers squibb announced landmark careinitiative continues provide fight disease improve health outcomes agreement two generic manufacturers assistance qualifying patients financial foundation targeting four specific india south africa full technology hardshipsduring approximately diseases regionshepatitis asiaserious transfer voluntary licenses covering patients usbenefitedwith donated mental illness uscancer europe subsaharan africa reyatazthe companys products valued million hivaids africa advanced protease inhibitorbristolmyers squibb wholesale list price although initiative beginning also granted immunity suit cornerstone already laid videxand zeritto generic manufacturers work done africa bristolmyers benefit patients region squibb secure futureprogram addressing women children affected hivaidsour focus children projects joanna leyenaarmda pediatrician ottawa canadatreating hivpositive infant like pediatric aids corps childrens childrens clinical center excellence clinical centers excellence helped us lesothoi joined pediatric aids corps better understand build bridges help people really need careshe says better healthsays foundation president pediatric hiv care lagged behind john damontiand work community many countriesits great see children lesotho receiving carerecovering thriving based treatment support sites given us new appreciation role communities play improving health outcomes bristolmyers squibb baylor college medicine established first medical center lesotho dedicated caring hivaidsinfected infantschildren familiesother pediatric centers excellence established botswana swazilandcenters burkina faso uganda scheduled open bristolmyers squibb annual reportfinancialreview managements discussion analysis financial condition results operations consolidated financial statements notes consolidated financial statements reports management controls procedures reports independent registered public accounting firms fiveyear financial summarybristolmyers squibb managements discussion analysis financial condition results operations executive summary company bristolmyers squibb company bms company bristolmyers squibb worldwide pharmaceutical related health care products company whose mission extend enhance human life providing highest quality pharmaceutical related health care products company engaged discovery development licensing manufacturing marketing distribution sale pharmaceuticals related health care products company three reportable segmentspharmaceuticals nutritionals health care pharmaceuticals segment comprised global pharmaceutical international consumer medicines business accounted approximately companys net sales nutritionals segment consists mead johnson nutritionals mead johnson primarily infant formula childrens nutritionals business accounted approximately companys net sales health care segment consists convatec medical imaging businesses accounted approximately companys net sales financial highlights company made progress longrange strategy despite significant challenges occurred year including atrisk launch generic clopidogrel bisulfate product another company adversely impacted plavix sales loss exclusivity pravachol united states us certain european markets increase litigation reserves company launched several important products including orencia sprycel gilead sciences inc gilead atripla orencia sprycel continue gain market share along double digit sales growth abilify reyataz erbitux sustiva franchise baraclude key components strong product line longterm growth company continues invest late stage compounds development new products growing importance biologics february company completed land purchase major new biologics facility devens along expansion existing facilities syracuse ny manati puerto rico construction devens facility scheduled begin early worldwide net sales continuing operations decreased billion compared worldwide net sales products company views growth drivers increased compared period excluding plavix worldwide net sales growth drivers increased compared period products company considers growth drivers plavix avaproavalide abilify reyataz erbitux net income billion compared billion results include million increase reserves pricing sales litigation settlement million early debt retirement costs results included million gain sale consumer medicines business plavix companys largest product ranked net sales plavix clopidogrel bisulfate us sales billion billion billion composition matter patent plavix expires currently subject patent litigation us apotex inc apotex corp apotex generic companies well less significant jurisdictions company previously disclosed certain developments pending plavix litigation apotex including atrisk launch generic product apotex august noted apotex launched generic clopidogrel bisulfate product competes plavix august august us district court southern district new york court granted motion company product partner sanofiaventis sanofi enjoin sales apotexs generic clopidogrel bisulfate product order apotex recall product customers courts grant preliminary injunction affirmed appeal trial underlying patent litigation ended february court expected rule following posttrial briefing atrisk launch generic clopidogrel bisulfate significant adverse effect net sales plavix company estimates range billion billion particular launch significant adverse effect sales third quarter company estimates range million million well fourth quarter company estimates range million million first second third fourth quarters us net sales plavix million million million million respectively estimated total us prescription demand clopidogrel bisulfate branded generic increased compared estimated annual report total us prescription demand branded plavix decreased period company expects generic clopidogrel bisulfate sold distribution channels following apotex atrisk launch august residual impact plavix net sales company 's overall financial results full impact apotexs launch generic clopidogrel bisulfate product company reasonably estimated time depend number factors including among others amount generic product sold apotex whether company sanofi companies prevail underlying patent litigation even companies prevail pending patent case extent launch apotex permanently adversely impact pricing prescription demand plavix amount damages would sought andor recovered companies apotexs ability pay damages loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity companys us territory partnership alliance sanofi also plaintiff three additional pending patent infringement lawsuits dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt related us patent patent trial date action dr reddy 's set patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex although teva cobalt appeal outcome litigation dr reddys teva filed abbreviated new drug application anda us food drug administration fda exclusivity periods statutory stay periods hatchwaxman act expired exception month stay applies teva expires february accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages company continues believe plavix patents valid infringed sanofi vigorously pursuing enforcement patent rights plavix possible time reasonably assess ultimate outcome ongoing patent litigation apotex plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies however apotex prevail trial company would expect face renewed generic competition plavix apotex promptly thereafter previously disclosed antitrust division us department justice conducting criminal investigation regarding proposed settlement pending patent plavix litigation apotex company cooperating fully investigation possible time reasonably assess outcome investigation impact company also possible time reasonably assess impact investigation companys compliance deferred prosecution agreement dpa us attorneys office district new jersey usao also previously disclosed usao initiated investigation conducted monitor dpa monitor usao corporate governance issues relating companys negotiations proposed settlement apotex included review whether violation federal securities laws connection proposed settlement apotex terms previously disclosed consent order company entered us securities exchange commission august consent sec consent monitor completed investigation submitted report investigation usao monitors report find violation consent federal securities laws connection proposed settlement monitor concluded company violated certain paragraphs dpa related governance matters violations cited monitor report relate among things communication failures including insufficient communications companys former chief executive officer ceo former general counsel board directors board members senior management well failure comply certain internal company policies procedures monitor make findings respect whether company knowingly materially breached dpa make recommendations usao advised company believes matters cited monitors report fully remediated accordingly intend take action dpa respect monitors report additional discussion legal matters including plavix patent litigation antitrust division investigation related proposed settlement apotex terms dpa sec consent see note legal proceedings contingencies outlook sec consent order deferred prosecution agreement bristolmyers squibb business environment company conducts business primarily within pharmaceutical industry highly competitive subject numerous government regulations many competitive factors may significantly affect companys sales products including product efficacy safety price costeffectiveness marketing effectiveness product labeling quality control quality assurance manufacturing operations research development new products successfully compete business health care industry company must demonstrate products offer medical benefits well cost advantages currently companys new product introductions compete products already market therapeutic category addition potential future competition new products competitors may introduce company manufactures branded products priced higher generic products generic competition one companys leading challenges globally pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity product loses exclusivity longer protected patent subject new competing products form generic brands upon exclusivity loss company lose major portion products sales short period time us internationally health care industry subject various governmentimposed regulations authorize prices price controls continue impact companys sales us congress state legislatures considered number proposals enacted laws could effect major changes health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others addition january medicare prescription drug improvement modernization act became effective provides outpatient prescription drug coverage senior citizens us company assessing impact legislation could business including potential negative impact us pharmaceuticals business due legislative andor regulatory changes could result additional pricing pressures controls many markets outside us company operates environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited united kingdom uk instance operation profit control plan germany operation reference price system companies also face significant delays market access new products national markets two years elapse drug approval new medicines become available growth managed care organizations mcos us played large role competition surrounds health care industry mcos seek reduce health care expenditures participants making volume purchases entering longterm contracts negotiate discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos become important part companys strategy companies compete inclusion mco formulary company generally successful major products included company believes developments managed care industry including continued consolidation continue generally downward pressure prices pharmaceutical production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become important companys product portfolio company continue make arrangements thirdparty manufacturers make substantial investments increase internal capacity produce biologics commercial scale including building new stateoftheart manufacturing facility production biologics devens construction commence early company maintained competitive position market strives uphold position dependent success discovering developing innovative costeffective products serve unmet medical needs company subsidiaries subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcome investigations litigations management continues believe previously disclosed next years aggregate impact beyond current reserves legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity additional discussion legal matters see note legal proceedings contingencies annual report strategy company continues execute strategy longterm growth currently track strategic transition strategy consists increasing investments behind growth brands new specialty products focusing companys research development programs products pharmaceutical pipeline disease areas address significant unmet medical needs aligning sales marketing emphasis specialists high value primary care prescribers implementing initiatives designed achieve maintain efficient cost base companys pharmaceutical portfolio continued transition away products lost exclusivity towards growth drivers recently launched products include plavix abilify aripiprazole avaproavalide irbesartanirbesartanhydrochlorothiazide reyataz atazanavir sulfate sustiva efavirenz franchise erbitux cetuximab orencia abatacept baraclude entecavir sprycel dasatinib us net sales products accounted companys us pharmaceutical net sales compared worldwide net sales products accounted companys worldwide pharmaceutical net sales compared company experienced last series major anticipated exclusivity losses market exclusivity expiration pravachol pravastatin sodium us certain markets europe expect significant new exclusivity losses next several years order support production specialty products pharmaceutical portfolio including biologics board directors approved capital expenditures approximately million bulk biologics manufacturing facility us february company completed land purchase acre site locate new largescale expandable multiproduct bulk biologics manufacturing facility devens construction expected begin early facility projected operationally complete company expects submit site regulatory approval commercial production biologic compounds anticipated begin addition company expand manati puerto rico facility targeted startup expansion add new space renovate existing space filling finishing company 's sterile products biologic compounds including orencia several investigational compounds given companys current limited capacity commercial volumes biologic products company also received approval fda may permits thirdparty manufacture orencia additional facility facility together another thirdparty facility pending submission approval fda support increased production capacity necessary meet expected longterm demand orencia initial requirements biologics products commercialized keeping strategy company invested billion research development representing growth rate research development dedicated pharmaceutical products including milestone payments inlicensing development programs billion compared billion part strategy company reexamining operating costs achieve maintain efficient cost base end company launched initiative identify realize productivity savings initiative company reexamined operating model focus resources high value priorities simplify streamline business processes improve governance decision making build capabilities sustain cost reductions long term company plan achieve goal realizing minimum million productivity savings incremental million well making company productive efficient effective new product pipeline developments january company astrazeneca plc astrazeneca announced collaboration develop commercialize two investigational compounds saxagliptin dapagliflozin studied treatment type diabetes company discovered compounds collaboration compounds worldwide except japan separately company also announced collaboration otsuka pharmaceutical co ltd otsuka develop saxagliptin japan november fda granted fast track designation ipilimumab used combination chemotherapy dacarbazine previously untreated metastatic melanoma patients fda also granted fast track designation ipilimumab used monotherapy previously treated metastatic melanoma patients october company moved investigational antithrombosis compound apixaban phase iii development apixaban oral direct factor xa inhibitor october company received fda approval new oncedaily mg single capsule formulation reyataz treatment human immunodeficiency virus hiv infection adults part combination therapy replace two bristolmyers squibb reyataz mg capsules appropriate patients company onepill oncedaily hiv medicine options available three drug classes part combination therapy company otsuka received approval fda september european medicines evaluation agency emea october abilify injection first readytouse singledose vial atypical antipsychotic control agitation adults schizophrenia bipolar mania august company sanofi received approval fda emea additional indication plavix reduce rate death cause rate combined endpoint reinfarction stroke death patients acute stsegment elevation myocardial infarction july atripla firstever oncedaily single tablet threedrug regimen hiv intended standalone therapy combination antiretrovirals received approval fda product combines sustiva efavirenz manufactured company truvada emtricitabine tenofovir disoproxil fumarate manufactured gilead company gilead merck co inc submitted marketing authorization approval atripla emea october addition company gilead submitted atripla regulatory approval canada september june company received approval sprycel dasatinib fda treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia philadelphia chromosomepositive acute lymphoblastic leukemia phall resistance intolerance prior therapy including gleevec imatinib mesylate sprycel launched us july november company also received approval sprycel committee medicinal products human use emea product launched austria germany france finland sweden uk february company received approval sprycel without phall indication switzerland april company launched emsam selegiline transdermal system us emsam first transdermal patch delivery monoamine oxidase inhibitor treatment major depressive disorder adults emsam developed somerset pharmaceuticals inc joint venture mylan laboratories inc mylan watson pharmaceuticals inc watson company obtained exclusive distribution rights commercialize emsam us canada markets emsam existing neuroscience sales force march fda approved erbitux copromoted company imclone systems incorporated imclone use treatment squamous cell carcinoma head neck erbitux previously indicated treatment metastatic colorectal cancer february company launched baraclude treatment hepatitis b china company also launched baraclude several new markets third quarter including germany france uk japan baraclude approved countries regions worldwide february company launched orencia treatment signs symptoms rheumatoid arthritis us receiving approval fda december june company received approval orencia canada launched product august outlook company expects reductions net sales products lost exclusivity previous years range billion billion compared billion billion company expects generic clopidogrel bisulfate inventory market continued residual impact plavix net sales company expect plavix net sales earnings growth assuming absence renewed additional generic competition company expects increased prescription demand plavix well key brands newly launched products compared gross margin expected improve due growth higher margin products lower margin erosion related exclusivity losses improved manufacturing efficiencies marketing selling administrative expense expected remain relatively unchanged efficiency savings largely offset inflationary cost increases company continues focus high value primary care specialist physicians implements various productivity initiatives company expects continue increase investments develop additional new compounds support introduction new products company subsidiaries subject number significant pending lawsuits claims proceedings investigations including pending plavix litigation described assurance increase scope matters future lawsuits claims proceedings material company addition increasing trend foreign governments scrutinize sales marketing activities pharmaceutical companies assurance investigations investigations material possible time reasonably annual report assess final outcome investigations litigations management continues believe previously disclosed next years aggregate impact beyond current reserves pending plavix patent litigation litigations investigations legal matters affecting company reasonably likely material company 's results operations cash flows may material financial condition liquidity companys expectations next several years described reflect potential impact litigation companys results operations previously disclosed composition matter patent plavix expires subject litigation us apotex trial underlying patent litigation ended february court expected rule following post trial briefing apotex prevail trial patent litigation company would expect face renewed generic competition plavix promptly thereafter pending plavix patent litigations us less significant markets product us companys us territory partnership alliance sanofi plaintiff three additional pending patent infringement lawsuits dr reddys teva cobalt related patent dr reddys teva filed anda fda exclusivity periods statutory stay periods hatchwaxman act expired exception month stay applies teva expires february accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us although launch point time would atrisk adverse damages award companies prevail underlying patent litigation company continues believe plavix patents valid infringed sanofi vigorously pursuing cases possible time reasonably assess ultimate outcome patent litigation apotex plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix generic pharmaceutical companies loss market exclusivity plavix andor development sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity plavix companys largest product net sales us net sales plavix billion billion billion respectively previously disclosed antitrust division us department justice conducting criminal investigation regarding proposed settlement pending plavix patent litigation apotex company cooperating fully investigation possible time reasonably assess outcome investigation impact company also possible time reasonably assess impact investigation companys compliance dpa usao also previously disclosed usao initiated investigation conducted monitor dpa usao companys negotiations proposed settlement apotex included review corporate governance issues whether violation federal securities laws connection proposed settlement apotex terms previously disclosed consent company entered securities exchange commission sec monitor completed investigation submitted report investigation usao monitors report find violation consent federal securities laws connection proposed settlement monitor concluded company violated certain paragraphs dpa related governance matters violations cited monitor report relate among things communication failures including insufficient communications companys former ceo former general counsel board members senior management well failure comply certain internal company policies procedures monitor make findings respect whether company knowingly materially breached dpa make recommendations usao advised company believes matters cited monitors report fully remediated accordingly intend take action dpa respect monitors report additional discussion legal matters including plavix patent litigation antitrust division investigation related proposed settlement apotex terms dpa sec consent see executive summaryplavix sec consent order deferred prosecution agreement note legal proceedings contingencies bristolmyers squibb results operations following discussions companys results continuing operations exclude results related oncology therapeutics network otn business previously presented separate segment prior divestiture segregated continuing operations reflected discontinued operations periods presented see discontinued operations companys results operations follows change dollars millions vs vs net sales earnings continuing operations minority interest income taxes net sales provision income taxes effective tax rate earnings continuing operations net sales net sales net sales continuing operations decreased billion compared us net sales decreased billion compared international net sales decreased billion compared including favorable foreign exchange impact net sales continuing operations decreased billion compared us net sales decreased billion compared international net sales billion remained relatively constant compared including favorable foreign exchange impact changes net sales follows analysis change total change volume price foreign exchange vs vs general companys business seasonal information us pharmaceutical prescriber demand reference made table within business segments pharmaceuticals section sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain companys top pharmaceutical products products company views current future growth drivers sold within us company operates three reportable segmentspharmaceuticals nutritionals health care may company completed sale otn previously presented separate segment results operations otn presented part companys results discontinued operations accordance statement financial standards sfas accounting impairment disposal longlived assets accordingly otn results operations prior periods reclassified discontinued operations conform current year presentations companys net sales segment follows net sales change dollars millions vs vs pharmaceuticals net sales nutritionals net sales health care net sales health care group total annual report company recognizes revenue net various sales adjustments arrive net sales reported consolidated statement earnings adjustments referred grosstonet sales adjustments described critical accounting policies reconciliations companys gross sales net sales significant category grosstonet sales adjustments follows years ended december dollars millions gross sales grosstonet sales adjustments prime vendor chargebacks women infants children wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments total grosstonet sales adjustments net sales decrease grosstonet sales adjustments compared affected number factors including changes customer mix portfolio shift case towards products required lower rebates well changes contract status decrease prime vendor chargebacks primarily result lower plavix net sales volume erosion highly rebated paraplatin carboplatin taxol paclitaxel due generic competition well impact discontinued commercialization tequin gatifloxacin managed health care rebates contract discounts decreased primarily result reversal reserves related tricare retail pharmacy refund program well exclusivity loss pravachol also reduced medicaid rebates addition lower plavix net sales shift patient enrollment medicaid medicare medicare part resulted decrease medicaid rebates partially offset corresponding increase managed health care rebates decrease cash discounts primarily due exclusivity loss pravachol lower plavix sales volumes increase sales returns primarily due higher return trends nonexclusive brands well discontinued commercialization tequin decrease prime vendor chargebacks managed health care rebates primarily due lower relative sales volume segment related product mix decrease sales returns primarily due lower returns certain products including tequin pravachol sustiva decrease adjustments due lower sales discounts government rebates international businesses bristolmyers squibb activities ending balances significant category grosstonet sales adjustments follows managed health care women infants rebates prime vendor children contract medicaid dollars millions chargebacks wic rebates discounts rebates cash discounts sales returns adjustments total balance january provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december company recorded grosstonet sales adjustments related sales made prior periods significant items included charges sales returns million primarily related higher expected return trends certain nonexclusive products well discontinued commercialization tequin credits contract discounts million primarily due reversal reserves related tricare retail pharmacy refund program significant items included charges million medicaid rebates primarily result higher expected medicaid utilization various products credits million adjustments primarily result lower expected rebates foreign governments credits million sales returns resulting lower returns certain products including tequin avaproavalide plavix significant revisions made estimates grosstonet sales adjustments pharmaceuticals changes pharmaceutical sales follows analysis change foreign total change volume price exchange vs vs worldwide pharmaceuticals sales decreased million us pharmaceuticals sales decreased million million primarily due lower sales plavix resulting atrisk launch generic clopidogrel bisulfate august loss exclusivity pravachol offset continued growth abilify erbitux reyataz sustiva franchise avaproavalide sales newer products including orencia baraclude sprycel aggregate estimated us wholesaler inventory levels companys key pharmaceutical products sold us pharmaceuticals business end approximately two half weeks international pharmaceuticals sales decreased million million primarily due decline pravachol taxol paclitaxel sales resulting increased generic competition europe partially offset increased sales newer products including reyataz abilify baraclude worldwide pharmaceuticals sales decreased million us pharmaceuticals sales decreased million compared million primarily due continued impact exclusivity losses paraplatin glucophage franchise increased competition pravachol partially offset increased sales growth drivers including plavix abilify erbitux reyataz aggregate estimated wholesaler inventory levels companys key pharmaceutical annual report products sold us pharmaceuticals business end end approximately threetenths month approximately two half weeks decline inventory levels negatively impacted sales performance certain products international pharmaceuticals sales decreased including favorable foreign exchange impact million primarily due increased generic competition pravachol taxol paclitaxel partially offset increased sales newer products including reyataz abilify well growth plavix key pharmaceutical products sales representing total pharmaceutical sales respectively follows change dollars millions vs vs cardiovascular plavix pravachol avaproavalide coumadin monopril virology reyataz sustiva franchise total revenue zerit baraclude infectious diseases cefzil oncology erbitux taxol paclitaxel sprycel affective psychiatric disorders abilify total revenue emsam immunoscience orencia pharmaceuticals efferalgan change excess sales plavix platelet aggregation inhibitor part companys alliance sanofi decreased million sales plavix decreased us million primarily result launch generic clopidogrel bisulfate product august market exclusivity plavix expected expire us major european markets composition matter patent plavix subject litigation including litigation apotex noted trial underlying patent litigation ended february court rule following posttrial briefing apotex prevail trial underlying patent litigation additional competition plavix thirdparty generic pharmaceutical companies plavix would face renewed generic competition sales increased including favorable foreign exchange impact million million us sales increased million million primarily due increased demand additional information plavix litigations well generic launch apotex see executive summaryplavix note legal proceedings contingencies sales pravachol hmg coa reductase inhibitor decreased including unfavorable foreign exchange impact million due market exclusivity expiration april resulting generic competition product strengths us generic competition key european markets estimated total us prescription demand decreased approximately compared sales pravachol decreased million million primarily due lower demand resulting increased competition related reduction wholesaler inventory levels partially offset lower managed health care rebates market exclusivity european union eu ended exception sweden expiration occurred march italy expiration occur bristolmyers squibb january france generic competition authorized company commenced july previously disclosed company authorized watson distribute pravastatin sodium tablets us sales avaproavalide angiotensin ii receptor blocker treatment hypertension also part sanofi alliance increased including favorable foreign exchange impact million us sales increased million compared primarily due higher average net selling prices higher volume estimated total us prescription demand increased approximately compared international sales increased including favorable foreign exchange impact million compared sales increased including favorable foreign exchange impact million million us sales increased million compared million international sales increased including favorable foreign exchange impact million million primarily due increased sales canada france germany market exclusivity avaproavalide known eu aprovelkarvea expected expire including pediatric extension us countries eu avaproavalide currently marketed japan sales coumadin warfarin sodium oral anticoagulant used predominantly patients atrial fibrillation deep venous thrombosispulmonary embolism increased million compared primarily due higher average net selling prices partially offset lower demand driven continued competition estimated total us prescription demand decreased approximately compared sales decreased million million due continued competition market exclusivity coumadin expired us sales monopril second generation angiotensin converting enzyme inhibitor treatment hypertension sold almost exclusively nonus markets decreased million sales million decrease including favorable foreign exchange impact million sales declines years due product supply issues key european markets market exclusivity protection monopril expired us expired expected expire countries eu monopril currently marketed japan sales reyataz protease inhibitor treatment hiv increased including favorable foreign exchange impact million primarily due increased demand us europe latin america estimated total us prescription demand increased approximately compared us sales increased million million primarily due higher demand higher average net selling prices international sales increased including favorable foreign exchange impact million compared sales million compared million primarily due increased demand us europe reyataz launched second quarter market exclusivity reyataz expected expire us countries eu japan total revenue sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv increased including favorable foreign exchange impact million due higher demand launch atripla third quarter estimated total us prescription demand sustiva franchise increased approximately compared july company gilead launched atripla oncedaily single tablet three drug regimen hiv intended standalone therapy combination antiretrovirals total revenue sustiva franchise includes sales sustiva well revenue bulk efavirenz included combination therapy atripla company records revenue bulk efavirenz component atripla upon sales atripla gilead joint venture thirdparty customers sustiva sales increased million million primarily due increased demand higher average selling prices lower sales returns market exclusivity sustiva expected expire us countries eu company others market sustiva japan additional information revenue recognition sustiva franchise see note alliances investments sales zerit stavudine antiretroviral agent used treatment hiv decreased million primarily result lower demand us europe estimated total us prescription demand decreased approximately compared zerit sales decreased including favorable foreign exchange impact million million primarily result decrease demand us market exclusivity protection zerit expected expire us countries eu japan sales baraclude oral antiviral agent treatment chronic hepatitis b increased million compared million baraclude launched us april china february uk germany july france japan september company composition matter patent expires us germany france uk annual report sales cefzil antibiotic treatment mild moderately severe bacterial infections decreased million primarily due generic competition us estimated total us prescription demand decreased approximately compared cefzil sales decreased including favorable foreign exchange impact million million primarily due lower demand market exclusivity expired december us expected expire eu sales erbitux sold company almost exclusively us increased million million driven continued growth related usage treatment colorectal cancer treatment head neck cancer new indication approved fda march sales increased million million erbitux marketed company distribution copromotion agreement imclone use patent relating combination therapy cytotoxic treatments expires patent covering monotherapy currently generic versions biologic products approved us law however law could change future even absence new legislation fda taking steps toward allowing generic versions certain biologics competitors seeking approval biologic products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations companys right market erbitux north america japan agreement imclone expires september company others market erbitux countries eu previously disclosed imclone yeda research development company ltd yeda litigation ownership use patent combination therapy cytotoxic treatments relating erbitux september court granted yeda complete ownership patent imclone appealed courts decision information pertaining legal proceedings involving erbitux see note alliances investments note legal proceedings contingencies sales taxol paclitaxel anticancer agent sold almost exclusively nonus markets million compared million sales taxol paclitaxel decreased including unfavorable foreign exchange impact primarily due increased generic competition europe generic entry japan third quarter taxol paclitaxel sales decreased including unfavorable foreign exchange impact million million primarily result increased generic competition europe market exclusivity protection taxol paclitaxel expired us countries eu two generic paclitaxel products received regulatory approval japan one generic product entered market sprycel oral inhibitor multiple tyrosine kinases treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate launched us july certain european markets fourth quarter sales million market exclusivity sprycel expected expire us total revenue abilify antipsychotic agent treatment schizophrenia acute bipolar mania bipolar disorder increased million us sales increased million million primarily due higher demand higher average net selling prices estimated total us prescription demand increased approximately compared total revenue abilify million compared million primarily due demand growth us continued growth europe achieved sales million total revenue abilify primarily consists alliance revenue representing companys share net sales countries copromotes otsuka product sold otsuka affiliate distributor otsukas market exclusivity protection abilify expected expire us including granted patent term extension otsuka received formal notices six generic pharmaceutical companies stating filed anda fda various dosage forms aripiprazole company otsuka comarket us abilify notices states anda contains piv certification directed us patent patent covers aripiprazole expires october addition notices purports provide otsuka respective piv certification certifications contain various allegations regarding enforceability ' patent andor validity andor infringement claims therein otsuka sole rights enforce ' patent company also right copromote abilify several european countries uk france germany spain act exclusive distributor product rest eu composition matter patent force germany uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplemental protection certificate countries except romania denmark data exclusivity eu expires companys contractual right market abilify expires november us puerto rico countries eu company exclusive right market abilify june additional information revenue recognition abilify see note alliances investments bristolmyers squibb emsam transdermal patch delivery monoamine oxidase inhibitor treatment major depressive disorder adults launched us april sales million third quarter result lower expected sales emsam company recorded million impairment charge emsam related assets emsam developed somerset joint venture mylan watson company obtained exclusive distribution rights commercialize emsam us canada markets emsam us existing neuroscience sales force new drug formulation emsam received three years hatchwaxman data exclusivity expires us orencia fusion protein indicated adult patients moderate severe rheumatoid arthritis inadequate response one currently available treatments methotrexate antitumor necrosis factor therapy launched us february sales million substantially us company composition matter patent expires us patent may eligible patent term restoration could possibly extend term noted generic versions biologic products approved us law law could change future sales efferalgan paracetamol formulation acetaminophen pain relief sold principally europe decreased million primarily due change government reimbursement sales increased including favorable foreign exchange impact million million primarily due increased sales italy spain result strong flu season estimated us prescription change data provided includes information retail mail order channels reflect information channels hospitals institutions longterm care among others estimated prescription prescription change data based national prescription audit npa data provided ims health ims supplier market research pharmaceutical industry described instances basic exclusivity loss date indicated expiration date patent claims active ingredient drug method using drug approved indication instances basic exclusivity loss date indicated expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval prior expiration data exclusivity period submitting clinical trial data obtain marketing approval company assesses market exclusivity period products case bycase basis length market exclusivity companys products difficult predict certainty complex interaction patent regulatory forms exclusivity factors assurance particular product enjoy market exclusivity full period time company currently anticipates estimates market exclusivities reported business planning purposes intended reflect companys legal opinion regarding strength weakness particular patent legal position annual report estimated enduser demand us pharmaceuticals following tables set forth companys top pharmaceutical products based annual net sales products company views current future growth drivers sold us pharmaceuticals business years ended december changes reported us net sales period b estimated total us prescription growth retail mail order channels calculated company based npa data nextgeneration prescription services ngps version data provided ims months ended december estimated us therapeutic category share applicable product calculated company based npa data ngps data provided ims year ended december month ended december estimated trx change us change us total prescriptions therapeutic category share net sales npa data b ngps data c npa data b ngps data c abilify total revenue avaproavalide baraclude e cefzil coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyataz sprycel j sustiva franchise k total revenue tequin videxvidex ec zerit year ended december month ended december estimated trx change us change us total prescriptions therapeutic category share net sales npa data b ngps data c npa data b ngps data c abilify total revenue avaproavalide baraclude e cefzil coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyataz sprycel j sustiva tequin videxvidex ec zerit bristolmyers squibb year ended december month ended december estimated trx change us change us total prescriptions therapeutic category share net sales npa data b ngps data c npa data b ngps data c abilify total revenue avaproavalide baraclude e cefzil coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyataz sprycel j sustiva tequin videxvidex ec zerit reflects percentage change net sales dollar terms including change average selling prices wholesaler buying patterns b based simple average estimated number prescriptions retail mail order channels provided ims c based weightedaverage estimated number prescription units tablets milliliters retail mail order channels based data provided ims therapeutic categories determined company products considered direct competition companys products products listed compete following therapeutic categories abilify antipsychotics avaproavalide angiotensin receptor blockers baraclude oral antiviral agents cefzil branded oral solid liquid antibiotics coumadin warfarin erbitux oncology glucophage franchise oral antidiabetics kenalog intraarticularintramuscular steroids orencia fusion proteins paraplatin carboplatin plavix antiplatelet agents pravachol hmg coa reductase inhibitors reyataz protease inhibitors excluding norvir sprycel tkis leukemia sustiva franchise antiretrovirals third agents excluding norvir trizivir tequin branded oral solid antibiotics videxvidex ec zerit nucleoside reverse transcriptase inhibitors e baraclude launched us april f erbitux paraplatin specifically parenterally administered oncology products general prescriptionlevel data physicians write prescriptions products company believes therapeutic category share information provided thirdparties products may reliable accordingly none presented g company prescription level data kenalog product dispensed retail pharmacy company believes therapeutic category share information provided thirdparties product may reliable accordingly none presented h orencia launched us february company prescription level data product dispensed retail pharmacies prior year estimated trx therapeutic category share percentage recalculated conform current year presentation following cefzil recalculated percentage share based combined oral liquidsuspension markets reyataz recalculated percentage share protease inhibitors excluding norvir sustiva franchise recalculated percentage share antiretrovirals third agents excluding norvir trizivir j sprycel launched us july k beginning third quarter sustiva franchise total revenue includes sales sustiva well revenue bulk efavirenz included combination therapy atripla therapeutic category share information change us total prescriptions growth sustiva franchise antiretrovirals third agents excluding norvir trizivir includes branded sustiva atripla prescription units change excess company historically reported estimated total us prescription change estimated therapeutic category share based npa data ims makes available public subscription basis simple average estimated number prescriptions retail mail order channels third quarter company began disclosing estimated total us prescription change estimated therapeutic category share based npa ngps version data ngps version data collected ims new revised methodology released ims limited basis pilot program ims announced ngps version data available public subscription basis starting january legacy npa ngps version discontinued company believes ngps data provided ims provides superior estimate prescription data companys products retail mail order channels company calculated estimated total us prescription change estimated therapeutic category share based ngps data weightedaverage basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions company believes calculation estimated total us prescription change estimated therapeutic category share based ngps data annual report weightedaverage approach respect retail mail order channels provides superior estimate total prescription demand company uses methodology internal demand forecasts estimated prescription change data estimated therapeutic category share reported throughout annual report include information retail mail order channels reflect information channels hospitals institutions longterm care among others data provided ims product ims recordkeeping processes estimates based sampling procedures subject inherent limitations estimates based sampling addition ngps version data part pilot program replaced ims incorporated ngps version released january company continuously seeks improve quality estimates prescription change amounts therapeutic category share percentages ultimate patientconsumer demand review methodologies processes calculation estimates review analysis thirdparties ' data used calculations company expects continue review refine methodologies processes calculation estimates continue review analyze thirdparties ' data used calculations international pharmaceuticals nutritionals health care following table sets forth companys key pharmaceutical products growth drivers sold companys international pharmaceuticals business including top pharmaceutical products sold companys major non us countries based net sales key products sold reporting segments listed percentage change companys estimated ultimate patientconsumer demand months december september compared period prior year company commenced collecting estimated ultimate patientconsumer demand reporting segments march period company believes yeartoyear comparison provides meaningful comparison changes sales quarter quartertopriorquarter comparisons previously provided change demand constant us dollar basis december september vs december vs september international pharmaceuticals abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva franchise total revenue taxol paclitaxel videxvidex ec nutritionals enfamilenfagrow nutramigen health care convatec ostomy wound therapeutics medical imaging cardiolite change excess bristolmyers squibb estimated inventory months hand distribution channel us pharmaceuticals following tables set forth companys top pharmaceutical products based annual net sales products company views current future growth drivers sold companys us pharmaceuticals business us pharmaceuticals net sales estimated number months hand applicable product us wholesaler distribution channel quarters ended december september company believes estimated number months hand quarters ended december september three preceding years provide meaningful comparison estimated enduser demand us pharmaceuticals disclosed companys former practice providing six recent quarters december december december months months months dollars millions net sales hand net sales hand net sales hand abilify total revenue avaproavalide baraclude cefzil coumadin erbitux glucophage franchise kenalog orencia paraplatin plavix pravachol reyataz sprycel sustiva franchise total revenue tequin videxvidex ec zerit september september september months months months dollars millions net sales hand net sales hand net sales hand abilify total revenue avaproavalide baraclude cefzil coumadin erbitux glucophage franchise kenalog orencia paraplatin plavix pravachol reyataz sprycel sustiva franchise total revenue tequin videxvidex ec zerit beginning third quarter sustiva franchise includes sales sustiva well revenue bulk efavirenz included combination therapy atripla estimated months hand product us wholesale distribution channel include branded sustiva inventory baraclude launched us april anticipation launch companys us wholesalers built inventories product meet expected demand september baraclude inventory us wholesaler distribution channel exceeded one month hand estimated value baraclude inventory us wholesaler distribution channel worked less one month hand subsequent quarters annual report december september estimated value cefzil inventory us wholesaler distribution channel exceeded one month hand approximately million million respectively demand cefzil decreased significantly due reduced wholesaler outmovements generic competition began us december december estimated value cefzil inventory exceeded one month hand approximately million company built higher inventories product meet expected higher demand typically experienced winter months us company continues monitor cefzil sales objective work wholesaler inventory levels one month hand less december estimated value glucophage franchise products inventory glucophage xr glucophage ir glucovance metaglip us wholesaler distribution channel exceeded one month hand approximately million products months hand estimate glucophage franchise products average months hand stockkeeping units skus product group increase months hand glucophage franchise products end fourth quarter one month hand resulted primarily purchase wholesalers certain skus giving effect purchases increased months hand skus less one month hand however increased months hand skus averaged skus glucophage franchise products aggregate estimated months hand exceeded one month march estimated value glucophage franchise products inventory us wholesaler distribution channel worked approximately one month hand worked remained less one month hand subsequent quarters december september estimated value kenalog inventory us wholesaler distribution channel exceeded one month hand approximately million million respectively due high levels goodsin transit caused shipping delays subsequent quarters estimated value kenalog inventory us wholesaler distribution channel worked less one month hand october us pediatric exclusivity period paraplatin expired resulting entry multiple generic competitors paraplatin led significant decrease demand paraplatin turn led months hand product us wholesaler distribution channel exceeding one month hand december september september december september estimated value paraplatin inventory us wholesaler distribution channel one month hand approximately million december million september million september million december million september company longer produces paraplatin us market continue monitor paraplatin wholesaler inventory levels depleted september estimated value plavix inventory us wholesaler distribution channel exceeded one month hand approximately million due atrisk launch generic clopidogrel bisulfate august demand plavix decreased precipitously following atrisk launch generic clopidogrel bisulfate december plavix inventory us wholesaler distribution channel worked less one month hand sprycel launched us july consistent customary practice time new product launch companys us wholesalers built inventories product meet expected demand december september estimated value sprycel inventory us wholesaler distribution channel exceeded one month hand approximately million million respectively company continues monitor sprycel inventory sales objective work wholesaler inventory levels one month hand less first quarter company made decision discontinue commercialization tequin commercial reasons company stopped shipping product us wholesalers june established accrual estimated returns tequin inventory july company notified us wholesaler retail distribution channels would allow return product regardless expiry dates estimated value tequin inventory us wholesaler distribution channel exceeded one month hand de minimis september december company aware significant amounts tequin inventory remaining us wholesaler distribution channel company expects tequin inventory us channels reduced nominal levels first quarter estimated value videxvidex ec didanosine inventory us wholesaler distribution channel exceeded one month hand de minimis december approximately million september result generic competition us commencing fourth quarter demand videxvidex ec decreased significantly products erbitux orencia company determines months hand estimates dividing estimated amount product us wholesaler distribution channel estimated amount outmovement product us wholesaler distribution channel period days calculated described factors may influence bristolmyers squibb companys estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data represent recordkeeping processes may also reflect estimates company maintains inventory management agreements imas us pharmaceuticals wholesalers account nearly total gross sales us pharmaceutical products current terms imas companys three largest wholesaler customers provide company weekly information respect inventory levels product hand amount outmovement products three wholesalers accounted approximately total gross sales us pharmaceutical products inventory information received wholesalers excludes inventory held intermediaries sell retailers hospitals excludes goods transit wholesalers company uses information provided three wholesalers friday closest quarter end calculate amount inventory hand wholesalers applicable quarter end amount increased companys estimate goods transit wholesalers applicable friday reflected weekly data provided wholesalers companys revenue recognition policy sales recorded substantially risks rewards ownership transferred us pharmaceuticals business generally product shipped cases goods transit wholesaler owned applicable wholesaler accordingly reflected calculation inventories wholesaler distribution channel company estimates amount goods transit using information provided wholesalers respect open orders applicable friday companys records sales wholesalers respect open orders company determines outmovement product wholesalers period days using recent four weeks outmovement product provided wholesalers extrapolating amount day basis company estimates inventory levels hand outmovements us pharmaceuticals business wholesaler customers three largest wholesalers product based assumption amounts bear relationship three largest wholesalers inventory levels outmovements product percentage aggregate sales products wholesalers applicable quarter bears aggregate sales products companys three largest wholesalers quarter finally company considers whether adjustments necessary extrapolated amounts based factors historical sales individual products made wholesalers thirdparty market research data related prescription trends patient demand addition company receives inventory information wholesalers selective basis certain key products companys us pharmaceuticals business imas discussed arrangements substantially direct wholesaler customers requires wholesalers maintain inventory levels one month demand response atrisk launch generic clopidogrel bisulfate august company offered certain us mcos incremental rebates wholesaler list price plavix certain conditions march small number mcos accepted offer offers rejected qualify terminated prior time issuance preliminary injunction august offers made company also provided temporary price reduction federal supply schedule plavix veterans administration limited period august september primarily result limited participation rebate offer company estimates impact two programs plavix net sales third fourth quarters de minimis orencia launched february launch second quarter company distributed orencia exclusive distribution arrangement single distributor following approval supplemental biologics license application sbla allows thirdparty manufacture orencia additional site exclusive distribution arrangement terminated july company expanded distribution network orencia multiple distributors estimates months hand calculated dividing inventories orencia held distributors end quarter movement product last day period reported distributors inventory hand outmovements reported distributors product distributors recordkeeping processes may mckesson corporation mckesson one companys wholesalers provided warehousing packing shipping services erbitux mckesson held erbitux inventory consignment companys revenue recognition policy company recognized revenue inventory shipped mckesson endusers mckesson also held inventories erbitux account upon divestiture otn may company discontinued consignment arrangement mckesson mckesson longer held inventories account thereafter company sold erbitux intermediaries wholesalers specialty oncology distributors shipped erbitux directly endusers product customers intermediaries beginning third quarter company expanded distribution model include one companys wholesalers held erbitux inventory company recognizes revenue upon shipment consistent revenue recognition policy annual report estimate months hand calculated dividing inventories erbitux held wholesaler account reported wholesaler end quarter outmovements product reported wholesaler last day period inventory levels reported wholesaler product wholesalers recordkeeping process previously disclosed companys pharmaceuticals business outside us nutritionals health care business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly company relies variety methods estimate direct customer product level inventory calculate months hand business units estimated inventory months hand distribution channel following table sets forth companys key products sold businesses listed net sales applicable product quarters ended december september december september estimated number months hand applicable product direct customer distribution channel businesses end four quarters company believes estimated number months hand quarters ended december september two preceding years provide meaningful comparison estimated enduser demand international pharmaceuticals nutritionals health care disclosed companys former practice providing four recent quarters estimates months hand key products described international pharmaceuticals business based data collected companys significant business units outside us also described information nonkey products amount inventory hand direct customers approximately one month impact de minimis nonpharmaceuticals reporting segments estimates based data collected us significant business units outside us december september months months dollars millions net sales hand net sales hand international pharmaceuticals abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva franchise total revenue taxol paclitaxel videxvidex ec nutritionals enfamilenfagrow nutramigen health care convatec ostomy wound therapeutics medical imaging cardiolite beginning third quarter sustiva franchise includes sales sustiva well revenue bulk efavirenz included combination therapy atripla estimated months hand product distribution channel include branded sustiva inventory bristolmyers squibb december september months months dollars millions net sales hand net sales hand international pharmaceuticals abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva franchise total revenue taxol paclitaxel videxvidex ec nutritionals enfamilenfagrow nutramigen health care convatec ostomy wound therapeutics medical imaging cardiolite months hand information represents companys estimates aggregate product level inventory hand direct customers divided expected demand applicable product expected demand estimated ultimate patientconsumer demand calculated based estimated enduser consumption direct customer outmovement data recent day period reasonable period factors may affect companys estimates include generic competition seasonality products direct customer purchases light price increases new product product presentation launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations company relies variety methods calculate months hand businesses reporting segments available company relies information provided thirdparties determine estimates aggregate product level inventory hand direct customers expected demand businesses reporting segments listed however company limited information direct customer product level inventory enduser consumption direct customer outmovement data quality thirdparty information available varies widely circumstances case new products seasonal products historical enduser consumption outmovement information may available applicable cases company uses estimated prospective demand cases direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available company developed variety methodologies calculate estimates data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand september company entered exclusive distributorship arrangements certain products several eastern central european markets september december september dafalgan analgesic product sold principally europe approximately months inventory hand respectively direct customers level inventory hand due primarily private pharmacists purchasing dafalgan approximately every eight weeks seasonality product annual report september efferalgan analgesic product sold principally europe approximately months inventory hand direct customers level inventory hand due primarily private pharmacists purchasing efferalgan approximately every eight weeks seasonality product september reyataz antiviral product approximately months inventory hand direct customers increased level inventory hand due primarily government purchasing patterns brazil december september videxvidex ec antiviral product approximately months inventory hand direct customers increased level inventory hand due primarily government purchasing patterns brazil company contractually obligated provide videxvidex ec brazilian government upon placement order product government terms contract company control inventory levels relating orders company however expects inventory levels videxvidex ec worked december september nutramigen infant nutritional product sold principally us approximately months inventory hand direct customers level inventory hand end quarter ended december due primarily holiday stocking retailers quarter ended september due primarily impact retailers holding higher levels inventory response hurricane katrina company continuously seeks improve quality estimates months hand inventories held direct customers including thorough review methodologies processes calculation estimates thorough review analysis thirdparties data used calculations company expects continue review refine methodologies processes calculation estimates continue review analyze thirdparties data calculations company also continue take steps expedite receipt processing data non us pharmaceuticals businesses health care group combined revenues health care group increased million compared period despite unfavorable impact divestiture us canadian consumer medicines consumer medicines business third quarter combined revenues health care group increased million compared period nutritionals changes nutritionals sales follows analysis change total change volume price foreign exchange vs vs key nutritionals product lines sales representing total nutritional sales respectively follows change dollars millions vs vs infant formulas enfamil toddlerchildrens nutritionals enfagrow worldwide nutritionals sales increased including favorable foreign exchange impact million worldwide nutritionals sales million increase including favorable foreign exchange impact despite unfavorable impact divestiture adult nutritional business million first quarter company divested adult nutritional business international sales increased including favorable foreign exchange impact million primarily due increased sales childrens nutritional products international sales increased including favorable foreign exchange impact despite unfavorable impact divestiture adult nutritional business million million primarily due increased sales enfamil enfagrow bristolmyers squibb us sales increased million primarily due increased sales enfamil us sales increased despite unfavorable impact divestiture adult nutritional business million million primarily due increased sales enfamil health care health care segment includes convatec medical imaging business well consumer medicines business third quarter company sold consumer medicines business related assets composition changes health care segment sales follows analysis change total change volume price foreign exchange vs vs health care sales decreased million compared period included unfavorable impact divestiture consumer medicines business health care sales decreased million compared period included unfavorable impact divestiture consumer medicines business health care sales business key products years ended december follows change dollars millions vs vs convatec ostomy wound therapeutics medical imaging cardiolite consumer medicines worldwide convatec sales increased including favorable foreign exchange impact million ostomy sales increased million including favorable foreign exchange impact sales wound therapeutic products increased including favorable foreign exchange impact million million primarily due continued growth aquacel franchise worldwide convatec sales increased including favorable foreign exchange impact million million primarily due increase worldwide sales wound therapeutic products worldwide medical imaging sales increased million growth primarily due increase technelite technetium tcm generator sales resulting competitors market absence first quarter increase definity sales competitors continued absence market cardiolite sales decreased million million primarily due decreased price medical imaging sales increased million million primarily due increased demand cardiolite geographic areas general companys products available countries world largest markets us france japan canada spain italy mexico germany companys sales geographic areas follows change dollars millions vs vs united states total europe middle east africa total western hemisphere total pacific total total annual report sales us decreased primarily result lower sales plavix loss exclusivity pravachol april decrease sales partially offset growth remaining pharmaceutical growth drivers recently launched products sales us decreased result lower sales paraplatin glucophage franchise due continuing impact earlier exclusivity losses pravachol due lower demand resulting increased competition decrease sales mostly offset increased sales growth drivers including plavix abilify erbitux reyataz well strong sales growth enfamil sales europe middle east africa decreased result sales decline pravachol taxol paclitaxel resulting increased generic competition decrease sales partially offset increased sales major european markets reyataz avaproavalide sales decreased including favorable foreign exchange impact result sales decline taxol paclitaxel due increased generic competition pravachol due exclusivity loss select markets including uk netherlands decrease sales partially offset increased sales major european markets reyataz abilify launched europe second quarter sales western hemisphere countries increased including favorable foreign exchange impact primarily due increased sales avaproavalide canada key nutritional products partially offset decreased sales tequin pharmaceutical products sales increased including favorable foreign exchange impact primarily due increased sales plavix canada mexico reyataz brazil canada avaproavalide canada sales pacific region remained consistent compared sales increased result increased sales taxol paclitaxel japan enfagrow enfamil china expenses change vs vs dollars millions cost products sold net sales marketing selling administrative net sales advertising product promotion net sales research development net sales acquired inprocess research development net sales provision restructuring net net sales litigation charges net net sales gain sale businesses net sales equity net income affiliates net sales expense net net sales total expenses net net sales change excess bristolmyers squibb cost products sold percentage sales increased compared company included million percentage sales certain costs cost products sold reported marketing selling administrative expenses prior year results addition reclassification increase primarily due unfavorable impact pharmaceutical net sales mix including lower sales plavix impairment charges tequin emsam related assets well manufacturing facility cost products sold percentage sales unfavorable impact gross margins resulting change us pharmaceuticals sales mix offset tequin impairment charges million net litigation charges recorded marketing selling administrative expenses decreased million compared including decrease resulting abovementioned reclassification addition reclassification decrease primarily due lower sales force expenses resulting previously announced restructuring us primary care sales organization became effective march lower expenses pravachol partially offset impact adoption stock option expensing marketing selling administrative expenses increased million million primarily due higher legal costs higher pension expenses reflecting increased amortization unrecognized net losses well change actuarial assumptions partially offset lower sales force expenses resulting focus specialists high value primary care physicians marketing selling administrative expenses percentage sales included decrease reclassification compared respectively advertising product promotion expenditures decreased million compared primarily driven divestiture consumer medicines business lower spending mature brands partially offset increased investments new products including orencia sprycel advertising product promotion expenditures increased million compared million primarily due increased investments directtoconsumer marketing campaigns plavix abilify increased costs associated prelaunch activities orencia launch baraclude partially offset lower spending mature products companys investment research development million increase investment research development million represented increase million increases reflect companys strategy continued investments latestage compounds developing pipeline disease areas address significant unmet medical needs research development costs also included charges consisting primarily upfront milestone payments million primarily exelixis pharmaceuticals inc solvay global solvay million primarily medarex pierre fabre medicament sa pierre fabre million primarily pierre fabre solvay percentage sales research development expenses compared percentage sales impacted lower plavix sales acquired inprocess research development million related purchase acordis ukbased company additional information acquisition see note acquisitions divestitures restructuring programs implemented realign streamline operations order increase productivity reduce operating expenses rationalize companys manufacturing network research facilities sales marketing organizations actions restructuring program expected substantially complete actions restructuring programs substantially completed december result actions company expects future annual benefit earnings continuing operations minority interest income taxes approximately million million million programs respectively additional information restructuring see note restructuring litigation charges net settlement income insurance recoveries million million million million net charge consisted increase reserves million settlement principle certain pricing sales investigations partially offset insurance recoveries million unrelated matter million income settlement litigation matter million net charge consisted increases reserves million liabilities primarily related private litigations governmental investigations partially offset insurance recoveries million million charge consisted million related private litigation governmental investigations related wholesaler inventory issues accounting matters million related platinol litigation settlement million related pharmaceutical pricing sales practices additional information litigation see note legal proceedings contingencies annual report gain sale businesses million million net tax related sale inventory trademark patent intellectual property rights related dovonex gain sale businesses million million net tax related sale consumer medicines business related assets gain sale business million million net tax related sale adult nutritional business additional information transactions see note acquisitions divestitures equity net income affiliates million compared million million respectively equity net income affiliates principally related companys joint venture sanofi investment imclone million increase equity net income affiliates primarily due increased net income joint venture sanofi income equity investment imclone compared loss million increase equity net income affiliates primarily reflects increase net income sanofi joint venture partially offset net loss investment imclone additional information equity net income affiliates see note alliances investments expense net million million million respectively expense net includes net interest expense foreign exchange gains losses income thirdparty contract manufacturing royalty income expense debt retirement costs gains losses disposal property plant equipment gains losses sale marketable securities certain litigation matters million increase expense net primarily due higher debt retirement costs connection repurchase billion notes due compared repurchase billion notes due well million nonrecurring income resulting termination muraglitazar collaborative agreement partially offset lower net foreign exchange losses million decrease expense net primarily due deferred income recognized termination collaborative agreement muraglitazar partially offset debt retirement costs connection repurchase billion notes due higher net foreign exchange losses additional information see note expense net stockbased compensation expense recognized sfas revised sharebased payment sfas r year ended december million charges recorded cost product sold marketing selling administrative expenses research development expenses stockbased compensation expense recognized accounting principles board apb years ended december million million respectively expenses recorded marketing selling administrative expenses bristolmyers squibb years ended december company recorded several expenseincome items affected comparability results periods presented herein discussion items see note alliances investments note restructuring items note acquisitions divestitures note income taxes note intangible assets note shortterm borrowings longterm debt note legal proceedings contingencies expenseincome items affected comparability results follows year ended december litigation research marketing provision settlement cost selling restructuring expense expense gain sale dollars millions products sold development admin net income income net product asset total litigation matters pharmaceutical pricing sales litigation product liability claim damages commercial litigations insurance recovery debt retirement costs accelerated depreciation asset impairment contract termination upfront milestone payments streamlining worldwide operations gain sale product asset income taxes items change estimate taxes prior year items reduction net earnings continuing operations year ended december litigation research provision gain settlement cost sale expense expense dollars millions products sold development restructuring business income income net total litigation matters private litigation governmental investigations erisa liability matters pharmaceutical pricing sales litigation insurance recoveries accelerated depreciation asset impairment debt retirement costs streamlining worldwide operations upfront milestone payments loss sale fixed assets gain sale equity investment termination muraglitazar agreement gain sale consumer medicines businesses income taxes items adjustment taxes repatriation foreign earnings increase net earnings continuing operations annual report year ended december acquired litigation research process gain provision settlement expense cost research sale restructuring expense income dollars millions products sold development development business net income net total litigation matters private litigation governmental investigations product liability antitrust litigation pharmaceutical pricing sales litigation commercial litigation product liability insurance recovery accelerated depreciation streamlining worldwide operations acordis iprd writeoff upfront milestone payments gain sale adult nutritional business income taxes items deferred taxes anticipation repatriation foreign earnings tax adjustments reduction net earnings continuing operations earnings minority interest income taxes companys earnings minority interest income taxes follows earnings continuing operations minority interest income taxes change dollars millions vs vs pharmaceuticals nutritionals health care health care group total segments corporateother total change excess earnings continuing operations minority interest income taxes decreased million million decrease primarily driven net impact items affected comparability results discussed lower net sales pharmaceutical products resulting lower plavix net sales loss exclusivity pravachol increased spending research development partially offset increase equity net income affiliates lower advertising promotion expenses earnings continuing operations minority interest income taxes increased million million increase primarily result growth nutritionals segment net impact items affected comparability results discussed partially offset lower sales gross margin pharmaceutical products primarily due exclusivity losses increased spending research development primarily latestage pharmaceutical compounds bristolmyers squibb pharmaceuticals earnings minority interest income taxes million decrease primarily due lower net sales result lower plavix sales loss exclusivity pravachol investment research development continued investment key growth drivers new products earnings minority interest income taxes million decreased million primarily due lower net sales gross margin primarily related exclusivity losses higher advertising product promotion investments behind growth drivers increased spending research development health care group nutritionals earnings minority interest income taxes million increase primarily due sales growth childrens nutritional products partially offset increased investments advertising expense research development programs earnings minority interest income taxes million increased million primarily due increased worldwide sales infant formula products international sales toddler children 's nutritional products partially offset increased investments advertising product promotion research development programs health care earnings minority interest income taxes million increase primarily driven increased sales convatec medical imaging businesses earnings minority interest income taxes million decreased million primarily due sale consumer medicines business third quarter higher spending research development partially offset sales growth convatec medical imaging businesses corporateother loss minority interest income taxes million increase primarily due higher debt retirement costs compared lower gain sale product asset compared consumer medicines business million income resulting termination muraglitazar collaborative agreement well lower insurance recoveries compared partially offset lower litigation charges compared loss minority interest income taxes million decreased million primarily due increase gain sales businessesproduct lines deferred income recognized termination collaborative agreement muraglitazar reduction litigation charges net income taxes effective income tax rate earnings continuing operations minority interest income taxes compared increase effective tax rate compared resulted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible tax benefits associated settlement internal revenue service irs examination favorable adjustment taxes special dividends american jobs creation act ajca partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions decrease effective tax rate due primarily charge approximately million taxes special dividends ajca charge related establishment valuation allowance certain charitable contributions tax benefits discussed partially offset lower estimated foreign tax credits company recorded significant deferred tax assets related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit carryforwards amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets discussion plavix related matters see note legal proceedings contingencies annual report companys us federal income tax returns currently examination irs irs proposed significant disallowance certain litigation settlement expenses significant reduction us foreign tax credits claimed following companys previously disclosed international restructuring irs position latter matter also affects us foreign tax credits claimed company although year currently examination company believes strong positions respect issues intends contest irs positions possible predict outcome issues company established tax contingency reserves reflect best estimate probable tax liability matters company prevail final nonappealable determination matters amount loss excess established reserves could material adverse effect companys results operations however company believe determination would material adverse effect cash flows minority interest minority interest net taxes decreased million million primarily due lower earnings companys partnership sanofi territory covering americas resulting impact august atrisk launch generic clopidogrel bisulfate discontinued operations may company completed sale otn one equity partners llc cash proceeds million including impact preliminary working capital adjustment company recorded pretax gain million million net tax presented gain sale discontinued operations consolidated statement earnings otn previously presented separate segment discussions otn see note discontinued operations amounts related otn business segregated continuing operations reflected discontinued operations periods presented amounts related otn business follows year ended december dollars millions net sales loss income taxes loss net taxes financial position liquidity capital resources cash cash equivalents marketable securities approximately billion december compared billion december company continues maintain sufficient level working capital approximately billion december decreasing billion december noted recent developments pending patent litigation involving plavix including generic launch apotex august currently subject preliminary injunction halted sales apotex trial underlying patent litigation ended february court expected rule following posttrial briefing apotex prevail trial company would expect plavix would face renewed generic competition promptly thereafter subject risks company currently believes absence renewed additional generic competition plavix generic pharmaceutical companies future periods cash generated us operations together existing cash borrowings capital markets sufficient cover cash needs working capital capital expenditures company expects include substantial investments facilities increase maintain companys capacity provide biologics commercial scale milestone payments dividends paid us cash cash equivalents marketable securities conversion working capital items borrowings expected fund nearterm operations circumstances renewed additional generic competition plavix would material companys sales plavix results operations cash flows could material companys financial condition liquidity additional information pending plavix patent litigation recent adverse developments included executive summary plavix note legal proceedings contingenciesintellectual propertyplavix litigation fourth quarter company disclosed anticipated repatriating approximately billion special dividends recorded million provision deferred income taxes pursuant ajca enacted pending matters company repatriated approximately billion foreign subsidiaries first quarter repatriated remaining balance approximately billion fourth quarter company used expects continue use special dividends accordance requirements established ajca us treasury department second quarter us treasury department issued ajca related guidance clarifying grossup foreign taxes associated special dividends also qualifies tax rate established ajca result bristolmyers squibb guidance company reduced million provision recording benefit approximately million tax provision except earnings associated special dividends discussed us income taxes provided balance unremitted earnings nonus subsidiaries since company invested expects invest earnings permanently offshore december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided cash cash equivalents december primarily consisted us dollar denominated bank deposits original maturity three months less marketable securities december primarily consisted us dollar denominated floating rate instruments aaaaaa credit rating due nature instruments company considers reasonable expect fair market values significantly impacted change interest rates liquidated cash short notice average interest yield invested cash cash equivalents december respectively interest yields marketable securities averaged respectively september company sanofi posted million towards million bond court collateral support preliminary injunction company pledged issuer bond collateral million bond consisting shortterm high quality securities collateral reported marketable securities companys consolidated balance sheet december terms pledge agreement company entitled receive income generated marketable securities make certain investment strategy decisions restricted using million pledged securities purpose time bond cancelled december company completed sale leaseback several administrative facilities new jersey million resulting pretax gain transaction million deferred reduce future lease rental costs lease periods ranging years shortterm borrowings end million million respectively company maintains cash balances shortterm investments excess shortterm borrowings longterm debt billion december compared billion december fourth quarter company restructured longterm debt retiring outstanding billion principal amount notes due cash tender offer subsequent redemption issuing million aggregate principal notes due million aggregate principal notes due well billion aggregate principal notes due company incurred aggregate pretax expense approximately million connection early redemption notes termination related interest rate swaps included writeoff related unamortized discount issuance costs deferred loss interest rate lock longterm debt december also included japanese yen debt billion yen december company replaced prior billion revolving credit facility new billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions substantially similar prior facility including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december august whollyowned subsidiary company entered new billion term loan facility syndicate lenders borrowings facility guaranteed company subsidiaries borrower certain european subsidiaries company facility contains fiveyear tranche billion twoyear tranche million fully drawn december fourth quarter company repaid entire million twoyear tranche million fiveyear tranche company subject substantially covenants included december revolving credit facility company also subject restrictions including certain financial covenants prior borrowing proceeds facility company obtained waiver lenders covenant default facility due onetime intercompany distribution december company full compliance covenants annual report second quarter company repurchased outstanding billion aggregate principal amount notes due incurred aggregate pretax loss approximately million connection early redemption notes termination related interest rate swaps majority companys debt fixed rate company however entered fixed floating interest rate swaps billion longterm debt including billion euro interest expense net interest swap gains million million million respectively increase interest expense primarily due higher interest rates moodys investors service moodys longterm shortterm credit ratings company currently prime respectively following downgrade longterm credit rating third quarter moodys longterm credit rating amended negative outlook stable outlook third quarter standard poors sp longterm shortterm credit ratings company currently respectively sps longterm credit rating remains negative outlook fitch ratings fitch longterm shortterm credit ratings company currently f respectively fitch placed company rating watch negative working capital years ended december follows december dollars millions working capital decrease working capital million december december impacted decrease cash marketable securities primarily due repayment longtem debt lower receivables primarily due lower plavix sales loss exclusivity pravachol mostly offset higher receivables due alliance partners increase inventories support growth drivers recently launched products mostly offset reduction pravachol inventory resulting loss exclusivity reduction deferred tax assets primarily due litigation settlement payments lower accounts payable due lower purchases pravachol raw materials increase deferred income resulting higher deferred alliance revenue lower accrued rebates returns primarily due exclusivity loss pravachol volume erosion highly rebated paraplatin taxol paclitaxel lower plavix volumes partially offset higher sales returns cash flow activities years ended december follows year ended december dollars millions cash flow provided byused operating activities investing activities financing activities net cash provided operating activities billion billion million increase compared mainly attributable significant changes adjustments net earnings million net changes operating assets liabilities million offset lower net earnings million significant positive changes adjustments net earnings compared million mainly included million positive cash flow variance deferred income tax expensebenefit due lower level increase deferred tax benefit compared increase deferred tax benefits associated us research development foreign tax credits increase litigation reserves increase deferred tax benefits associated reversal tax liability related repatriation special dividends ajca million positive cash flow variance due lower gain sale product asset compared sale business million positive cash flow variance deferred income recognized related termination muraglitazar collaborative agreement bristolmyers squibb net positive changes operating assets liabilities compared million mainly included million negative cash flow variance receivables increase cash flow driven increases receivables due alliance partners partially offset lower trade receivable volume increase cash flow driven collection foreign withholding taxes alliance partners million positive cash flow variance inventories primarily due increase inventories resulting growth newer products anticipation new product launches reduction inventories resulting pravachol exclusivity loss million negative cash flow variance litigation primarily due settlement payments million dpa vanlev litigation partially offset unrelated insurance recoveries million million positive cash flow variance income taxes payable primarily related payments settlement examinations irs years repatriation special dividends ajca net cash provided investing activities million compared net cash provided million million negative cash flow variance primarily attributable million negative cash flow variance mainly sale marketable securities million negative cash flow variance lower proceeds sale product asset compared sale consumer medicines otn businesses million negative cash flow variance milestone payments primarily related imclone million positive cash flow variance proceeds disposal properties connection sale lease back transaction net cash used financing activities million compared million million positive cash flow variance mainly attributable million positive cash flow variance repayment shortterm borrowings negative cash flow variance retirement longterm debt company repaid debt million retired notes due million company retired notes due million net cash provided operating activities billion billion million decrease compared mainly attributable significant changes adjustments net earnings million net changes operating assets liabilities million offset higher net earnings million significant negative changes adjustments net earnings compared million mainly included million negative cash flow variance due primarily reversal million ajca deferred tax provision recorded million negative cash flow variance due lower litigation settlement expenses million negative cash flow variance due higher gain sale businesses compared net changes operating assets liabilities compared million mainly included million positive cash flow variance receivables increase cash flow receivables driven lower sales volume increase foreign withholding taxes receivable million positive cash flow variance primarily due lower litigation settlement payments well insurance recoveries million negative cash flow variance accounts payable accrued expenses primarily due vendor payments prior sale otn business lower accrued rebates returns compared million negative cash flow variance income taxes payable primarily related payments settlement examinations irs years repatriation special dividends ajca net cash provided investing activities million compared net cash used million million positive cash flow variance primarily attributable million positive cash flow variance mainly sale marketable securities compared purchases million positive cash flow variance higher proceeds sale consumer medicines otn businesses compared sale adult nutritionals business million positive cash flow variance due milestone payment imclone million positive cash flow variance due purchase acordis specialty fibres annual report net cash used financing activities million compared million million negative cash flow variance mainly attributable million negative cash flow variance retirement commercial paper compared purchases million negative cash flow variance due repurchase billion notes due million positive cash flow variance proceeds borrowings new term loan facility cash provided operations borrowings primarily used past three years pay dividends approximately billion company also invested approximately billion past three years capital expansion improve plant efficiency maintain superior research facilities past three years company repurchase common stock total shares acquired since share repurchase programs inception million shares share repurchase program authorizes company purchase common stock time time open market private transactions market conditions permit program intended reduce increase shares outstanding option exercises obtain shares general corporate purposes dividends declared per common share december company declared quarterly dividend per common share indicated dividend full year per share dividend decisions made quarterly basis companys board directors companys financial condition liquidity could affected obligations make milestone onetime payments outcome pending litigations investigations including challenge plavix patent andor potential renewed additional generic competition plavix information see note alliances investments note legal proceedings contingencies contractual obligations payments due period companys contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt operating leases purchase obligations standby letters creditperformance guarantees pension liabilities total current portion longterm debt obligations included shortterm borrowings companys consolidated balance sheet december balances approximate outstanding nominal longterm debt values contractual obligations table excludes interest payment obligations companys convertible debenture included due payment contains put call feature addition company committed make potential future milestone payments thirdparties part inlicensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded companys consolidated balance sheet discussion contractual obligations see note shortterm borrowings longterm debt note financial instruments note leases note pension postretirement benefit plans bristolmyers squibb sec consent order deferred prosecution agreement previously disclosed august company entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit companys quarterly report form q period ended september terms consent company agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice company also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer companys accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring companys budget process gives appropriate weight inputs come bottom top come top bottom adequately documenting process company agreed consent retain independent advisor date companys form k year ended filed sec independent advisor continues serve monitor dpa discussed previously disclosed june company entered dpa usao district new jersey resolving investigation usao company relating wholesaler inventory various accounting matters covered companys settlement sec pursuant dpa usao filed criminal complaint company alleging conspiracy commit securities fraud defer prosecution company dismiss complaint two years company satisfies requirements dpa copy dpa filed exhibit form k filed company june dpa among things company agreed include forms q k filed sec annual report shareholders following information estimated wholesalerdirect customer inventory levels top fifteen products sold us pharmaceuticals business b major nonus countries estimated aggregate wholesalerdirect customer inventory levels top fifteen pharmaceutical products sold countries taken whole measured aggregate annual sales countries c arrangements policies concerning wholesalerdirect customers distributors products including efforts company control monitor wholesalerdistributor inventory levels data concerning prescriptions measures enduser demand products pursuant dpa company also agreed include filings reports information acquisition divestiture restructuring reserve policies activity rebate accrual policies activity company also agreed implement remedial measures already undertaken mandated consent settlements derivative litigation federal securities class action relating wholesaler inventory various accounting matters addition company agreed undertake additional remedial actions corporate reforms actions including appointing additional nonexecutive director acceptable usao b establishing maintaining training education program topics include corporate citizenship financial reporting obligations c making additional million payment shareholder compensation fund established connection consent engaging attempting engage criminal conduct term defined dpa e continuing cooperate usao including respect ongoing investigation regarding individual current former employees company f retaining monitor also part dpa board directors board separated roles chairman chief executive officer ceo company june elected nonexecutive chairman noted dpa company agreed engage attempt engage criminal conduct criminal conduct defined dpa crime related companys business activities committed one executive officers directors b securities fraud accounting fraud financial fraud business fraud materially affecting books records publicly filed reports company c obstruction justice usao discretion may prosecute company federal crimes usao knowledge including matters subject criminal complaint referenced usao determine company committed criminal conduct monitor defined powers responsibilities dpa including responsibility least april oversee companys compliance terms dpa consent settlements derivative action federal securities class action monitor authority require company take steps believes necessary comply terms dpa company required adopt recommendations made monitor unless annual report company objects recommendation usao agrees adoption recommendation required addition monitor reports usao least quarterly basis companys compliance dpa implementation effectiveness internal controls financial reporting disclosure processes related compliance functions company september board announced companys current ceo general counsel would leaving respective positions effective immediately announcement took place board received considered reports companys outside counsel issues relating plavix patent litigation apotex preliminary recommendation monitor terminate employment individuals monitors recommendation followed investigation initiated usao conducted monitor usao corporate governance issues relating companys negotiations proposed settlement apotex company advised monitor usao investigation involve matters subject ongoing investigation antitrust division department justice plavix settlement agreement time monitor made preliminary recommendation monitor usao also advised company found violation dpa unlawful conduct company employees investigation included review whether violation federal securities laws connection proposed settlement apotex terms sec consent monitor completed investigation submitted report investigation usao monitors report find violation consent federal securities laws connection proposed settlement monitor concluded company violated certain paragraphs dpa related governance matters violations cited monitor report relate among things communication failures including insufficient communications companys former ceo former general counsel board members senior management well failure comply certain internal company policies procedures monitor make findings respect whether company knowingly materially breached dpa make recommendations usao advised company believes matters cited monitors report fully remediated accordingly intend take action dpa respect monitors report additional information pending plavix patent litigation antitrust division investigation see note legal proceedings contingencies company established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis company maintains imas us pharmaceutical wholesalers account nearly total gross sales us pharmaceutical products current terms imas companys three largest wholesaler customers provide company weekly information respect months hand product level inventories amount movement products three wholesalers currently account total gross sales us pharmaceutical products inventory information received wholesalers together companys internal information used estimate months hand product level inventories wholesalers company estimates months hand product inventory levels us pharmaceuticals businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers company considers whether adjustments necessary extrapolated amounts based factors historical sales individual products made wholesalers thirdparty market research data related prescription trends patient demand contrast companys pharmaceuticals business outside us nutritionals health care business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly company relies variety methods estimate months hand product level inventories business units company discloses top fifteen pharmaceutical products based net sales pharmaceutical products company views current future growth drivers sold us pharmaceuticals business amount net sales estimated number months hand us wholesaler distribution channel end immediately preceding quarter end applicable quarter well corresponding information prior year quarterly annual reports forms q k company discloses corresponding information top fifteen pharmaceutical products pharmaceutical products company views current future growth drivers sold within major nonus countries described business units company discloses quarterly basis key product level inventories information required estimate months hand product level inventories direct customer distribution nonus pharmaceuticals businesses available prior filing quarterly report form q applicable quarter accordingly company discloses information website approximately days end applicable quarter furnishes form k companys form q following quarter addition foregoing quarterly disclosure bristolmyers squibb company include foregoing information business units immediately preceding quarter applicable quarter well corresponding information prior year annual report products described inventory direct customers exceeds approximately one month hand company disclose estimated months hand products except impact company de minimis company enhanced continue seek enhance methods estimate months hand product inventory levels us pharmaceuticals business nonus pharmaceuticals businesses around world taking account complexities described company also taken continue take steps expedite receipt processing data nonus pharmaceuticals businesses company believes abovedescribed procedures provide reasonable basis ensure compliance consent dpa provides sufficient information comply disclosure requirements recently issued accounting standards company adopted sfas r sharebased payment requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb accounting stock issued employees periods beginning january march sec issued staff accounting bulletin sab sharebased payment relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fasb staff position fsp r transition election related accounting tax effects sharebased payment awards determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stock based compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r february financial accounting standards board fasb issued sfas fair value option financial assets financial liabilities permits entity measure certain financial assets financial liabilities fair value objective sfas improve financial reporting allowing entities mitigate volatility reported earnings caused measurement related assets liabilities using different attributes without apply complex hedge accounting provisions sfas entities elect fair value option instrument report unrealized gains losses earnings subsequent reporting date fair value option election irrevocable unless new election date occurs sfas establishes presentation disclosure requirements help financial statement users understand effect entity 's election earnings eliminate disclosure requirements accounting standards assets liabilities measured fair value must displayed face balance sheet statement effective fiscal years beginning november company evaluating potential impact pronouncement september fasb issued sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r pronouncement requires employer recognize overfunded underfunded status defined benefit postretirement plan multiemployer plan asset liability statement financial position recognize changes funded status year changes occur comprehensive income business entity pronouncement also requires employer measure funded status plan date yearend statement financial position limited exceptions pronouncement require prior periods restated reflect impact sfas company adopted sfas fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated comprehensive income stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows september fasb issued sfas fair value measurements pronouncement defines fair value establishes framework measuring fair value expands disclosures fair value measurements statement effective fiscal years beginning november adoption accounting pronouncement expected material effect companys consolidated financial statements annual report september sec issued staff accounting bulletin sab considering effects prior year misstatements quantifying misstatements current year financial statements expresses staff 's views regarding process quantifying financial statement misstatements bulletin effective interim period first fiscal year ending november sab requires companies utilize dual approach assess quantitative effects financial statement misstatements dual approach includes income statement focus balance sheet focus assessment adoption bulletin effect companys consolidated financial statements july fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end annual reporting period including tabular reconciliation unrecognized tax benefits accordance fin company report difference net amount assets liabilities recognized statement financial position prior application fin cumulative effect adjustment opening balance retained earnings adoption accounting pronouncement expected material effect companys consolidated financial statements march fasb issued sfas accounting servicing financial assets amendment fasb statement pronouncement relates accounting separately recognized servicing assets servicing liabilities statement effective fiscal years beginning september adoption accounting pronouncement expected material effect companys consolidated financial statements february fasb issued sfas accounting certain hybrid financial instruments amendment fasb statements pronouncement primarily resolves certain issues addressed implementation sfas accounting derivative instruments hedging activities concerning beneficial interests securitized financial assets statement effective financial instruments acquired issued subject remeasurement event occurring beginning fiscal year adoption accounting pronouncement expected material effect companys consolidated financial statements may fasb issued sfas accounting changes error corrections replaces apb opinion accounting changes sfas reporting accounting changes interim financial statements pronouncement applies voluntary changes accounting principle revises requirements accounting reporting change accounting principle sfas requires retrospective application prior periods ' financial statements voluntary change accounting principle unless impracticable pronouncement also requires change method depreciation amortization depletion longlived nonfinancial assets accounted change accounting estimate affected change accounting principle sfas effective accounting changes corrections errors made fiscal years beginning december statement change transition provisions existing accounting pronouncements including transition phase effective date sfas adoption accounting pronouncement material effect companys consolidated financial statements march fasb issued fin accounting conditional asset retirement obligations fin clarifies entity must record liability conditional asset retirement obligation fair value obligation reasonably estimated asset retirement obligations covered fin entity legal obligation perform asset retirement activity even timing method settling obligation conditional future event may may within control entity fin also clarifies entity would sufficient information reasonably estimate fair value asset retirement obligation adoption accounting pronouncement material effect companys consolidated financial statements december fasb issued fsp application sfas accounting income taxes tax deduction qualified production activities provided american jobs creation act fsp provides deduction qualified production activities treated special deduction described sfas accounting income taxes accordingly tax effect deduction reported component companys tax provision effect deferred tax assets liabilities may irs issued final tax regulations ftr respect deduction qualified production activities section internal revenue code final regulations effective taxable years beginning june adoption ftr fsp material impact companys consolidated financial statements bristolmyers squibb december fasb issued sfas exchanges nonmonetary assets provisions statement effective nonmonetary asset exchanges occurring fiscal periods beginning june provisions statement applied prospectively eliminates exception fair value measurement nonmonetary exchanges similar productive assets paragraph b apb accounting nonmonetary transactions replaces exception exchanges commercial substance adoption accounting pronouncement material effect companys consolidated financial statements november fasb issued sfas inventory costs amendment arb chapter pronouncement requires abnormal amounts idle facility related expenses recognized current period charges also requires allocation fixed production overheads costs conversion based normal capacity production facilities sfas effective inventory costs incurred fiscal years beginning june adoption accounting pronouncement material effect companys consolidated financial statements critical accounting policies company prepares financial statements conformity accounting principles generally accepted us preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period companys critical accounting policies important companys financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates company believes following discussion represents critical accounting policies management discussed companys critical accounting policies audit committee board directors revenue recognition company recognizes revenue accordance sab revenue recognition financial statements amended sab revenue recognition companys accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management company recognizes revenue substantially risks rewards ownership transferred customer generally occurs date shipment exceptions described previous years certain transactions companys us pharmaceutical wholesalers accounted using consignment model case sales made wholesalers result incentives excess wholesalers ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesalers cost carrying inventory excess wholesalers ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesalers records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company recognizes revenue net grosstonet sales adjustments discussed involve significant estimates judgments consignment inventory longer subject incentive arrangements later inventory sold wholesalers customers firstin firstout basis fifo case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns discussions revenue recognition see note accounting policiesrevenue recognition sales rebate return accruals annual report grosstonet sales adjustments company following significant categories grosstonet sales adjustments prime vendor chargebacks wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments involve significant estimates judgments require company use information external sources company accounts grosstonet sales adjustments accordance emerging issues task force issue accounting consideration given vendor customer including reseller vendors products sfas revenue recognition right return exists applicable see net sales section reconciliation companys gross sales net sales significant category grosstonet sales adjustment prime vendor chargebacks companys us businesses participate prime vendor programs government entities significant us department defense us department veterans affairs parties whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower prime vendor price wholesalers charge difference acquisition cost lower prime vendor price back company company accounts prime vendor chargebacks reducing accounts receivable amount equal companys estimate chargeback claims attributable sale company determines estimate prime vendor charge backs primarily based historical experience regarding prime vendor chargebacks current contract prices prime vendor programs company considers prime vendor payments levels inventory distribution channel companys claim processing time lag adjusts reduction accounts receivable periodically throughout quarter reflect actual experience wic rebates companys us nutritionals business participates competitive bidding basis nutrition programs sponsored states tribal governments commonwealth puerto rico us territories wic programs company reimburses entities difference wholesaler list price contract price eligible products company accounts wic rebates establishing accrual amount equal companys estimate wic rebate claims attributable sale company determines estimate wic rebate accrual primarily based historical experience regarding wic rebates current contract prices wic programs company considers levels inventory distribution channel new wic contracts terminated wic contracts changes existing wic contracts wic participation adjusts accrual periodically throughout quarter reflect actual experience managed health care rebates contract discounts company offers rebates discounts managed health care organizations us manage prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well globally contract counterparties hospitals group purchasing organizations company accounts managed health care rebates contract discounts establishing accrual amount equal companys estimate managed health care rebates contract discounts attributable sale company determines estimate managed health care rebates contract discounts accrual primarily based historical experience regarding rebates discounts current contract prices company considers sales performance products subject managed health care rebates contract discounts levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience medicaid rebates companys us businesses participate state governmentmanaged medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities discounts rebates provided latter programs included companys medicaid rebate accrual considered medicaid rebates purposes discussion company accounts medicaid rebates establishing accrual amount equal companys estimate medicaid rebate claims attributable sale company determines estimate medicaid rebates accrual primarily based historical experience regarding medicaid rebates well expansion prospective basis participation nonmandatory aspects qualifying federal state government programs legal interpretations applicable laws related medicaid qualifying federal state government programs new information regarding changes medicaid programs regulations guidelines would impact amount rebates company considers outstanding medicaid claims medicaid payments levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience bristolmyers squibb cash discounts us certain countries company offers cash discounts approximating sales price incentive prompt payment company accounts cash discounts reducing accounts receivable full amount discounts company considers payment performance adjusts accrual reflect actual experience sales returns company accounts sales returns accordance sfas revenue recognition right return exists establishing accrual amount equal companys estimate sales recorded related products expected returned provision sales returns million million million respectively gross sales three years returns established products company determines estimate sales return accrual primarily based historical experience regarding sales returns also considers factors could impact sales returns factors include levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products company considers factors adjusts accrual periodically throughout quarter reflect actual experience company considers level inventory distribution channel determines whether believes adjustment sales return accrual appropriate company adjusts sales return accrual based historical experience companys returned goods policy shelf life companys products life cycle product levels inventory distribution channel company considers introductions generic products factors impact sales returns calculation based historical experience companys returned goods policy event product recall product discontinuance company considers reasons impact actions adjusts sales return accrual appropriate taking account historical experience estimated levels inventory distribution channel product discontinuances estimates continuing demand sales returns accruals new products estimated primarily based historical sales returns experience similar products within line product within similar therapeutic category limited circumstances new product extension existing line product company historical experience products similar therapeutic category company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns company also considers shelf life new products determines whether believes adjustment sales return accrual appropriate shelf life connection new products tends shorter shelf life established products company may still developing optimal manufacturing process new product would lengthen shelf life addition higher launch quantities may manufactured advance launch date ensure sufficient supply exists satisfy market demand cases company assesses reduced shelf life together estimated levels inventory distribution channel projected demand determines whether believes adjustment sales return accrual appropriate adjustments addition grosstonet sales adjustments described company makes grosstonet sales adjustments example company offers sales discounts significantly nonus businesses also offers consumer coupons rebates significantly us nutritionals pharmaceuticals business addition number countries outside us including major european countries company provides rebates government entities company generally accounts grosstonet adjustments establishing accrual amount equal companys estimate adjustments attributable sale company generally determines estimates accruals grosstonet sales adjustments primarily based historical experience performance commitments government entities relevant factors including estimated levels inventory distribution channel adjusts accruals periodically throughout quarter reflect actual experience annual report use information external sources company uses information external sources estimate grosstonet sales adjustments companys estimates inventory wholesalers deferred revenue consigned inventory based projected prescription demandbased sales products historical inventory experience well companys analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data companys internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals company receives information ims supplier market research pharmaceutical industry uses project prescription demandbased sales many us pharmaceuticals products company historically reported estimated total us prescription growth estimated therapeutic category share based npa data ims made available public subscription basis simple average estimated number prescriptions retail mail order channels third quarter company began disclosing estimated total us prescription growth estimated therapeutic category share based npa ngps version data ngps version data collected ims new revised methodology released ims limited basis pilot program ims announced ngps version data available public subscription basis starting january legacy npa ngps version discontinued company believes ngps data provided ims provides superior estimate prescription data companys products retail mail order channels company calculated estimated total us prescription growth estimated therapeutic category share based ngps data weighted average basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions company believes calculation estimated total us prescription growth estimated therapeutic category share based ngps data weighted average approach respect retail mail order channels provide superior estimate total prescription demand company uses methodology internal demand forecasts company also uses information external sources identify prescription trends patient demand average selling prices companys estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date company receives thirdparty information retirement benefits companys pension plans postretirement benefit plans accounted using actuarial valuations required sfas employers accounting pensions sfas employers accounting postretirement benefits pensions company considers accounting retirement plans critical management required make significant subjective judgments number actuarial assumptions including discount rates salary growth longterm return plan assets retirement turnover health care cost trend rates mortality rates depending assumptions estimates used pension postretirement benefit expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding company adopted sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated comprehensive income stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows plan description company certain subsidiaries defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan principal defined contribution plan bristolmyers squibb savings investment program approximately total company defined benefit pension plan assets liabilities held us plans assets us plans held single trust common asset allocation unless specified otherwise references section total company plans ie us plans together international plans benefits companys defined benefit pension plans based primarily years credited service participants compensation assets companys defined benefit plans consist primarily equity fixedincome securities december fair market value plan assets companys defined benefit plans increased million million december us plans assets allocated equity securities compared end fixed income securities compared end private equity investments compared end bristolmyers squibb common stock represented less assets us plans end bristolmyers squibb company provides comprehensive medical group life benefits substantially us retirees elect participate companys comprehensive medical group life plans asset allocation postretirement plans identical asset allocation described us defined benefit pension plans accrual accounting significant assumptions consistent requirements sfas company accounts pension benefits using accrual method recognizing pension expense payment benefits retirees accrual method accounting pension benefits necessarily requires actuarial assumptions concerning future events determine amount timing benefit payments companys key assumptions used calculating cost pension benefits discount rate rate compensation increase expected longterm rate return plan assets company consultation actuaries evaluates key actuarial assumptions assumptions used calculating cost pension benefits retirement turnover mortality rates based expectations actual experience appropriate determines assumptions december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding actual results given year may differ estimated economic factors determining discount rate company uses yield high quality corporate bonds coincides cash flows plans estimated payouts citigroup median yield curve used determining discount rate us plans assumed rate compensation increase used company determining future pension obligations reflects estimate change actual future compensation levels due general price levels productivity seniority factors net pension expense companys defined benefit pension plans included earnings minority interest income taxes million compared million us plans pension expense determined using assumed discount rate assumed rate compensation increase present value benefit obligations december us plans determined using assumed discount rate assumed rate compensation increase assumed discount rate used determining us plans pension expense reduced expense would increased approximately million assumed rate compensation increase used determining us plans pension expense reduced expense would decreased approximately million assumed discount rate used determining accumulated benefit obligation december reduced accumulated benefit obligation would increased million us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million actual rates return earned us plan assets last years follows year return year return december company increased assumed discount rate us plans maintained assumed rate compensation increase compensation assumed increase scale different rates different ages rate disclosed december single rate used age would produce present value benefit obligations company maintained expected rate return us plan assets company expects net pension expense defined benefit pension plans included earnings minority interest income taxes approximately million lower million reflecting primarily positive delayed impact favorable investment returns annual report company used assumed discount rates expected longterm rates return plan assets calculating cost pension benefits cost postretirement benefits us plans except case discount rates december rates respectively used pension benefits versus respectively postretirement benefits reflect shorter duration postretirement liabilities december respectively us health care costs retiree population assumed increase trend expected increase per year actual costs higher assumed likely put significant upward pressure companys expense retiree health care effects medicare prescription drug improvement modernization act reflected net periodic postretirement benefit cost reduction million accumulated postretirement benefit obligation january reduction million recognition actuarial gains losses sfas requires recognition actuarial gains losses component stockholders equity accumulated comprehensive income sfas provides delayed recognition years prior amounts arise changes estimated plan benefit obligations due changes assumed discount rate differences actual expected returns plan assets assumption changes net actuarial gain loss determined based marketrelated value plan assets differs fair market value calculated value recognizes changes fair value systematic rational manner five years amortized pension income expense year extent unrecognized net actuarial loss gain exceeds greater projected benefit obligation market related value plan assets beginning year net gains losses recognized pension income expense prospectively period approximates average remaining service period active employees expected receive benefits plans approximately years extent offset losses gains subsequent years unrecognized net actuarial loss reflects large part steady reduction weightedaverage discount rate years unless offset future unrecognized gains higher discount rates higher expected returns plan assets amortization unrecognized loss expected increase pension expense million progressively lower amounts following nine years plan funding companys funding policy defined benefit plans contribute amounts provide current service fund past service liability company contributed million million defined benefit plans respectively discussions retirement benefits see note pension postretirement benefit plans acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants assets acquired business combination used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weighted average cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred discussions acquired inprocess research development see note accounting policiesacquired inprocess research development bristolmyers squibb impairment longlived assets accordance sfas accounting impairment disposal longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced long lived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value accordance sfas goodwill intangible assets goodwill tested least annually impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds estimated fair value intangible assets evaluated impairment accordance sfas described estimates future cash flows based reasonable supportable assumptions projections require managements judgment changes key assumptions companys businesses prospects changes market conditions could result impairment charge discussions impairment longlived assets see note accounting policiesimpairment longlived assets goodwill intangible assets equity investments company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers apb opinion equity method accounting investments common stock related interpretations set forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment companys investment imclone subject accounting discussion companys investment imclone see note alliances investments discussions equity investments see note accounting policiesinvestments note alliances investments restructuring streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results could vary estimates adjustments million million million recorded respectively reflect changes estimates restructuring actions taken prior periods discussions restructuring see note accounting policiesrestructuring note restructuring items contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability tax matters accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated discussions contingencies see note accounting policiesincome taxes contingencies note income taxes note legal proceedings contingencies annual report income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made december company net deferred tax assets million million respectively net valuation allowances million million respectively increase net deferred tax assets primarily resulted adoption sfas see note income taxes note pension postretirement benefit plans company recorded significant deferred tax assets related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit carryforwards amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets discussion plavix related matters see note legal proceedings contingencies company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided discussions income taxes see note accounting policiesincome taxes note income taxes stockbased compensation expense company adopted sfas r sharebased payment requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values company uses modified prospective transition method requires application accounting standard january elected alternative method provided fsp r determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity comparatively pro forma basis stockbased compensation expense million million million million net tax respectively recognized years ended december respectively apb additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r company estimates fair value stockbased payment awards date grant using optionpricing model value portion award ultimately expected vest recognized expense requisite service periods companys consolidated statement earnings prior adoption sfas r company accounted stockbased bristolmyers squibb awards employees directors using intrinsic value method related stock options accordance apb allowed sfas accounting stockbased compensation intrinsic value method stockbased compensation expense recognized companys consolidated statement earnings exercise price companys stock options granted employees directors equaled fair market value underlying stock date grant stockbased compensation expense recognized period based value portion stockbased payment awards ultimately expected vest period stockbased compensation expense recognized companys consolidated statement earnings year ended december included compensation expense stockbased payment awards granted prior yet vested january based grant date fair value estimated accordance pro forma provisions sfas r compensation expense stockbased payment awards granted subsequent january based grant date fair value estimated accordance provisions sfas r conjunction adoption sfas r company changed method attributing value stockbased compensation expense accelerated multipleoption approach straightline single option method compensation expense stockbased payment awards granted prior continue recognized using accelerated multipleoption approach compensation expense stockbased payment awards service condition granted subsequent january recognized using straightline singleoption method stockbased payment awards granted subsequent january service market condition recognized using accelerated multipleoption approach required sfas r prior company applied apb opinion recognize compensation expense stock options granted plans exercise price option date grant equal fair market value date however grants restricted stock company recognized compensation expense straightline basis period restrictions expire fair value options granted estimated per common share per common share per common share respectively date grant using blackscholes optionpricing model assumptions used blackscholes optionpricing model follows expected volatility riskfree interest rate dividend yield expected life yrs yrs yrs company determines fair value certain stockbased payment awards date grant using optionpricing model model affected companys stock price well assumptions regarding number highly complex subjective variables variables include limited companys expected stock price volatility term awards actual projected employee stock option exercise behaviors respect accounting treatment retirement eligibility provisions employee stockbased compensation awards company historically followed nominal vesting period approach upon adoption sfas r company follows nonsubstantive vesting period approach recognizes compensation cost oneyear period awards granted retirement eligible employees period grant date date retirement eligibility achieved one year less vesting period impact applying nonsubstantive vesting period approach material companys consolidated financial statements stockbased compensation expense recognized consolidated statement earnings year ended december based awards ultimately expected vest reduced estimated forfeitures company estimates forfeitures time grant revised necessary subsequent periods actual forfeitures differ estimates companys pro forma information required sfas periods prior company accounted forfeitures occurred annual report special note regarding forwardlooking statements annual report written oral statements company makes time time contain certain forward looking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things companys goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years company included important factors cautionary statements included annual report company believes could cause actual results differ materially forwardlooking statement although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise bristolmyers squibb quantitative qualitative disclosures market risk company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used speculative purposes gains losses hedging transactions offset gains losses underlying exposures hedged ineffective portion hedges reported earnings occurs companys primary net foreign currency translation exposures euro japanese yen mexican peso chinese renminbi canadian dollar company utilizes foreign currency contracts hedge anticipated transactions primarily intercompany transactions certain foreign currencies designates derivative instruments foreign currency cash flow hedges appropriate fair value foreign exchange forward contracts based yearend currency rates fair value foreign exchange forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates companys outstanding foreign exchange forward contracts december follows weightedaverage fair value dollars millions except currency rates strike price notional amount assetliability maturity foreign exchange forwards australian dollar british pound canadian dollar euro japanese yen mexican peso swedish krona swiss franc total contracts december company held foreign exchange forward contracts maturity dates december company hold foreign exchange option contracts notional amounts fair values foreign exchange forward contract maturity dates follows year maturity notional amount fair value dollars millions december fair value companys foreign exchange forward contracts net liability million million recorded noncurrent asset million recorded current liability company estimates appreciation depreciation underlying currencies hedged levels dollar december variables held constant would decrease increase respectively million fair value foreign exchange forward contracts held december company obligated settle foreign exchange forward contracts based specified contract rates december balance deferred net aftertax losses foreign exchange forward contracts included accumulated comprehensive income million net aftertax loss million estimated reclassified earnings within next months december company held foreign exchange forward contracts aggregate notional amount million fair value foreign exchange forward contracts net asset million million recorded noncurrent asset million recorded current liability contracts primarily related exposures euro canadian dollar australian dollar company estimates appreciation depreciation underlying currencies hedged levels dollar december variables held constant would decrease increase respectively million fair value foreign exchange forward contracts held december annual report years ended december impact hedge ineffectiveness earnings significant additionally years ended december impact discontinued hedges loss million gain million gain million respectively furthermore company uses foreign exchange forward contracts offset exposure certain currency assets liabilities foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings occur amounts recognized earnings related foreign exchange forward contracts qualify hedge accounting treatment significant company also uses foreign exchange forward contracts hedge foreign currency denominated monetary assets liabilities primary objective foreign exchange forward contracts protect us dollar value foreign currency denominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated euro foreign exchange forward contracts designated hedges marked market incomeexpense notional fair value amounts purchased foreign exchange forward contracts million million asset respectively december million million liability respectively december notional fair value amounts sold foreign exchange forward contracts million million liability respectively december million million asset respectively december addition foreign exchange forward contracts noted company uses non us dollar borrowings lesser extent foreign exchange forward contracts hedge foreign currency exposures companys net investment certain foreign affiliates non us dollar borrowings foreign exchange forward contracts designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component comprehensive income december million aftertax losses million aftertax gains respectively recorded foreign currency translation component accumulated comprehensive income company uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment november connection funding retirement fixed rate debt company executed several fixed floating interest rate swaps convert billion billion euro billion companys newly issued fixed rate debt paid variable rate debt company executed several fixed floating interest rate swaps convert million companys fixed rate debt paid variable rate debt total notional amount outstanding interest rate swaps billion billion euro billion december billion december respectively accordance sfas accounting derivative instruments hedging activities company recognized net increase interest expense million net reduction interest expense million million respectively impact interest rate swaps bristolmyers squibb sfas requires revaluation fair value swap contracts well underlying debt hedged swap contracts underlying debt revalued resulting increase noncurrent assets million current liabilities million reduction longterm debt million december increase noncurrent assets million current liabilities million reduction longterm debt million december swap contracts generally held maturity intended create appropriate balance fixed floating rate debt company swap contracts qualify fair value hedges terminated prior maturity dates reported part carrying value underlying debt amortized earnings remaining life debt swap contracts qualify cash flow hedges terminated reported accumulated comprehensive income amortized earnings remaining life debt interest rate swaps outstanding december terminated interest rate swaps follows notional amount underlying variable rate year fair interest rate contracts debt received transaction maturity value dollars millions swaps associated notes due month us libor notes due month us libor million eur notes due month eur euribor million eur notes due month eur euribor notes due month us libor notes due month us libor terminated swap contracts total pretax pretax pretax year notional amount deferred incomeexpense incomeexpense interest rate contracts termination underlying debt gainloss recognized recognized dollars millions interest rate swap lock associated notes due interest rate swap lock associated notes due swaps associated notes due swaps associated notes due swaps associated notes due swaps associated notes due underlying notes extinguished respectively december company held interest rate swap contracts notional value billion billion euro billion fair value net liability million estimated increase decrease basis points shortterm longterm interest rates would material impact companys consolidated financial position results operations cash flows company million million longterm debt outstanding december respectively additional information see note shortterm borrowings longterm debt see note financial instruments company maintains cash cash equivalents marketable securities various financial institutions order limit exposure one financial institution financial institutions headquartered primarily north america europe annual report consolidated statements earnings dollars shares millions except per share data year ended december earnings net sales costs products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring net litigation charges net gain sale product asset businesses equity net income affiliates expense net total expenses earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations discontinued operations earningsloss net taxes gain disposal net taxes net earnings earnings per common share basic earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings per common share diluted earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings per common share average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements bristolmyers squibb consolidated statements comprehensive income retained earnings dollars millions year ended december comprehensive income net earnings comprehensive incomeloss foreign currency translation tax effect net tax liability tax benefit deferred gainslosses derivatives qualifying hedges net tax benefit net tax liability minimum pension liability adjustment net tax liability net tax benefit available sale securities net tax liability net tax benefit tax effect total comprehensive incomeloss comprehensive income retained earnings retained earnings january net earnings cash dividends declared retained earnings december accompanying notes integral part financial statements annual report consolidated balance sheets dollars millions except per share data december assets current assets cash cash equivalents marketable securities receivables net allowances inventories net deferred income taxes net valuation allowances prepaid expenses total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances prepaid pension assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses accrued rebates returns deferred income us foreign income taxes payable dividends payable accrued litigation liabilities total current liabilities pension postretirement liabilities deferred income liabilities longterm debt total liabilities commitments contingencies note stockholders equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements bristolmyers squibb consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization deferred income tax benefitsexpense litigation settlement expense net recoveries stockbased compensation expense provision restructuring gain sale product asset businesses deferred income recognized acquired inprocess research development impairment charges asset writeoffs loss disposal property plant equipment investment companies deferred expenses extinguishment longterm debt underover distribution earnings affiliates unfunded pension expense changes operating assets liabilities receivables inventories prepaid expenses assets litigation settlement payments net insurance recoveries accounts payable accrued expenses deferred income product liability us foreign income taxes payable liabilities net cash provided operating activities cash flows investing activities purchases proceeds marketable securities net additions property plant equipment capitalized software proceeds disposal property plant equipment investment companies proceeds sale product assets businesses proceeds sale leaseback properties upfront milestone payments purchase acordis speciality fibres purchases trademarks patents licenses businesses investments companies divestiture acquisition costs net cash provided byused investing activities cash flows financing activities shortterm borrowingsrepayments longterm debt borrowings longterm debt repayments charges extinguishment longterm debt issuances common stock stock plans excess tax benefits sharebased payment arrangements dividends paid net cash used financing activities effect exchange rates cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period accompanying notes integral part financial statements annual report note accounting policies basis consolidation consolidated financial statements include accounts bristolmyers squibb company bms company bristol myers squibb controlled majorityowned subsidiaries intercompany balances transactions eliminated certain prior year amounts reclassified conform current year presentation use estimates preparation financial statements conformity united states us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities well estimates used applying revenue recognition policy accounting stockbased compensation costs retirement postretirement benefits including actuarial assumptions actual results may may differ estimated results revenue recognition company recognizes revenue accordance staff accounting bulletin sab revenue recognition financial statements amended sab revenue recognition substantially risks rewards ownership transferred customer generally revenue recognized time shipment however case certain sales made nutritionals health care segments certain nonus businesses within pharmaceuticals segment revenue recognized date receipt purchaser revenues reduced time recognition reflect expected returns estimated based historical experience business trends additionally provisions made time revenue recognition discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provisions recorded reduction revenue case sales made wholesalers result incentives excess wholesalers ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesalers cost carrying inventory excess wholesalers ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company recognizes revenue consignment inventory longer subject incentive arrangements later inventory sold wholesalers customers firstin firstout basis fifo case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns sales rebate return accruals medicaid rebate accruals million million december respectively women infants children wic rebate accruals million million december respectively sales return accruals million million december respectively managed health care rebate contractual discount accruals million million december respectively rebate accruals established period related revenue recognized resulting reduction sales establishment liability included accrued liabilities accrual recorded based estimate proportion recorded revenue result rebate return prime vendor chargeback accruals established similar manner recorded reduction accounts receivable million million december respectively bristolmyers squibb income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made december company net deferred tax assets million million respectively net valuation allowances million million respectively company recorded significant deferred tax assets related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit carryforwards amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets discussion plavix related matters see note legal proceedings contingencies december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known cash cash equivalents cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value marketable securities company accounts marketable securities accordance statement financial accounting standard sfas accounting certain investments debt equity securities company determined appropriate classification marketable securities availableforsale time purchase december companys investments marketable securities reported fair value unrealized gains losses reported component accumulated comprehensive income loss stockholders equity company follows investment managers method determining cost basis computing realized gains losses sale availableforsale securities average cost method realized gains losses included income expense inventory valuation inventories generally stated average cost excess market annual report capital assets depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straight line method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying value depreciable assets may recoverable impairment longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges years costs obtain software projects significant expensed incurred capitalized software net accumulated amortization included intangible assets million million december respectively amortization expense million million million years ended december respectively investments company accounts less owned companies ability exercise significant influence using equity method accounting otherwise cost method used companys share net income losses equity investments included equity net income affiliates consolidated statement earnings losses recognized income expense decline market value deemed temporary company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers accounting principles board apb opinion equity method accounting investments common stock related interpretations set forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment goodwill intangible assets goodwill tested impairment annually using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value company completed goodwill impairment assessment indicated impairment goodwill intangible assets consisting patents trademarks technology licenses capitalized software amortized straightline basis useful lives ranging years indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net carrying value exceeds estimated fair value intangible assets evaluated impairment described impairment longlived assets restructuring streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results may may vary estimates product liability accruals product liability including associated legal costs recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recorded undiscounted basis probable recovery realized classified reduction litigation charges consolidated statement earnings bristolmyers squibb contingencies normal course business company subject loss contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability tax matters accordance sfas accounting contingencies company records accruals loss contingencies probable liability incurred amount loss reasonably estimated company accordance sfas recognize gain contingencies realized discussion contingencies see note income taxes note legal proceedings contingencies derivative financial instruments derivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments speculative purposes company records derivative instruments balance sheet fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized consolidated statement earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded comprehensive income loss subsequently recognized consolidated statement earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earnings company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company immediately recognizes gain loss designated hedging financial instruments consolidated statement earnings shipping handling costs company typically charge customers shipping handling costs therefore shipping handling costs included marketing selling administrative expenses million million advertising costs advertising costs expensed incurred advertising expense million million million respectively research development research development costs expensed incurred company time time enter strategic alliances third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties result alliances company may obligated make payments alliance partners connection research development contingent upon achievement certain predetermined criteria milestones achieved prior regulatory approval product payments expensed research development milestone payments made connection regulatory approvals including nonus regulatory approvals additional indications capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability periodically whenever events changes circumstances indicate carrying amounts may recoverable acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weighted average cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred annual report earnings per share basic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options restricted stock convertible instruments foreign currency translation statements earnings company 's foreign subsidiaries translated us dollars using average exchange rates net assets companys foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation adjustment account included accumulated comprehensive income oci recently issued accounting standards company adopted sfas revised sharebased payment sfas r requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb accounting stock issued employees periods beginning january march us securities exchange commission sec issued sab sharebased payment relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fasb staff position fsp r transition election related accounting tax effects sharebased payment awards determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stock based compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r february financial accounting standards board fasb issued sfas fair value option financial assets financial liabilities permits entity measure certain financial assets financial liabilities fair value objective sfas improve financial reporting allowing entities mitigate volatility reported earnings caused measurement related assets liabilities using different attributes without apply complex hedge accounting provisions sfas entities elect fair value option instrument report unrealized gains losses earnings subsequent reporting date fair value option election irrevocable unless new election date occurs sfas establishes presentation disclosure requirements help financial statement users understand effect entity 's election earnings eliminate disclosure requirements accounting standards assets liabilities measured fair value must displayed face balance sheet statement effective fiscal years beginning november company evaluating potential impact pronouncement september fasb issued statement sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r pronouncement requires employer recognize overfunded underfunded status defined benefit postretirement plan multiemployer plan asset liability statement financial position recognize changes funded status year changes occur comprehensive income business entity pronouncement also requires employer measure funded status plan date yearend statement financial position limited exceptions pronouncement require prior periods restated reflect impact sfas company adopted sfas fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows september fasb issued sfas fair value measurements pronouncement defines fair value establishes framework measuring fair value expands disclosures fair value measurements statement effective fiscal years beginning november adoption accounting pronouncement expected material effect companys consolidated financial statements bristolmyers squibb september sec issued sab considering effects prior year misstatements quantifying misstatements current year financial statements expresses staff 's views regarding process quantifying financial statement misstatements bulletin effective interim period first fiscal year ending november sab requires companies utilize dual approach assess quantitative effects financial statement misstatements dual approach includes income statement focus balance sheet focus assessment adoption bulletin effect companys consolidated financial statements july fasb issued fasb interpretation number fin accounting uncertainty income taxes interpretation fasb statement case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end annual reporting period including tabular reconciliation unrecognized tax benefits accordance fin company report difference net amount assets liabilities recognized statement financial position prior application fin cumulative effect adjustment opening balance retained earnings adoption accounting pronouncement expected material effect companys consolidated financial statements march fasb issued sfas accounting servicing financial assets amendment fasb statement pronouncement relates accounting separately recognized servicing assets servicing liabilities statement effective fiscal years beginning september adoption accounting pronouncement expected material effect companys consolidated financial statements february fasb issued sfas accounting certain hybrid financial instruments amendment fasb statements pronouncement primarily resolves certain issues addressed implementation sfas accounting derivative instruments hedging activities concerning beneficial interests securitized financial assets statement effective financial instruments acquired issued subject remeasurement event occurring beginning fiscal year adoption accounting pronouncement expected material effect companys consolidated financial statements may fasb issued sfas accounting changes error corrections replaces apb opinion accounting changes sfas reporting accounting changes interim financial statements pronouncement applies voluntary changes accounting principle revises requirements accounting reporting change accounting principle sfas requires retrospective application prior periods ' financial statements voluntary change accounting principle unless impracticable pronouncement also requires change method depreciation amortization depletion longlived nonfinancial assets accounted change accounting estimate affected change accounting principle sfas effective accounting changes corrections errors made fiscal years beginning december statement change transition provisions existing accounting pronouncements including transition phase effective date sfas adoption accounting pronouncement material effect companys consolidated financial statements march fasb issued fin accounting conditional asset retirement obligations fin clarifies entity must record liability conditional asset retirement obligation fair value obligation reasonably estimated asset retirement obligations covered fin entity legal obligation perform asset retirement activity even timing method settling obligation conditional future event may may within control entity fin also clarifies entity would sufficient information reasonably estimate fair value asset retirement obligation company adopted provisions fin fiscal year ended december adoption accounting pronouncement material effect companys consolidated financial statements december fasb issued fsp application sfas accounting income taxes tax deduction qualified production activities provided american jobs creation act fsp provides deduction qualified production activities treated special deduction described sfas accounting income taxes accordingly tax effect deduction reported component companys tax provision effect deferred tax assets liabilities may internal revenue service irs issued final tax regulations ftr respect deduction qualified production activities section internal revenue code final regulations effective taxable years beginning june taxable years beginning prior annual report effective date final regulations taxpayer may apply either final regulations provided taxpayer applies provisions final regulations subject certain limitations rules provided notice well proposed regulations issuance ftr adoption fsp material impact companys consolidated financial statements december fasb issued sfas exchanges nonmonetary assets provisions statement effective nonmonetary asset exchanges occurring fiscal periods beginning june provisions statement applied prospectively eliminates exception fair value measurement nonmonetary exchanges similar productive assets paragraph b apb accounting nonmonetary transactions replaces exception exchanges commercial substance adoption accounting pronouncement material effect companys consolidated financial statements november fasb issued sfas inventory costs amendment arb chapter standard requires abnormal amounts idle facility related expenses recognized current period charges also requires allocation fixed production overheads costs conversion based normal capacity production facilities sfas effective inventory costs incurred fiscal years beginning june adoption accounting pronouncement material effect companys consolidated financial statements note alliances investments sanofiaventis company agreements sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy plavix clopidogrel bisulfate platelet aggregation inhibitor worldwide alliance operates framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia accordingly two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place agreements expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory company acts operating partner territory covering americas australia owns majority controlling interest territory sanofis ownership interest territory company consolidates country partnership results territory records sanofis share results minority interest net taxes million million million company recorded sales territory comarketing countries outside territory germany italy spain greece million million million cash flows operating activities partnerships territory covering americas australia recorded operating activities within companys consolidated statement cash flows distributions partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis also recorded within operating activities companys consolidated statement cash flows sanofi acts operating partner territory covering europe asia owns majority financial controlling interest within territory companys ownership interest partnerships within territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statement earnings companys share net income partnership entities taxes million million million company routinely receives distributions profits provides funding ongoing operations partnerships territory covering europe asia transactions recorded operating activities within companys consolidated statement cash flows company sanofi companies formed alliance copromotion irbesartan part company contributed irbesartan distribution rights us sanofi paid company total million two years ended december company accounted transaction sale interest license deferred amortizing million income expected useful life license approximately years bristolmyers squibb formation irbesartan copromotion alliance company recognized income million million million respectively unamortized portion deferred income recorded liabilities section consolidated balance sheet million million december respectively otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia related psychiatric disorders except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt product currently copromoted otsuka united kingdom uk germany france spain us germany spain product sold otsuka affiliate distributor company records alliance revenue contractual share otsukas net sales records expenses related product company recognizes alliance revenue abilify shipped risks rewards ownership transferred otsuka 's customers uk france italy company presently exclusive distributor product company records net sales related cost products sold expenses company also exclusive right sell abilify countries europe americas number countries asia countries company records net sales related cost products sold terms agreement company purchases product otsuka performs finish manufacturing sale company customers agreement expires november us puerto rico entire european union eu agreement expires june country company exclusive right sell abilify agreement expires later tenth anniversary first commercial sale country expiration applicable patent country company recorded total revenue abilify million million million total milestone payments made otsuka agreement december million million expensed acquired inprocess research development remaining million capitalized intangible assets amortized cost products sold remaining life agreement us ranging years company amortized cost products sold million million million unamortized capitalized payment balance million million december respectively imclone company commercialization agreement expiring september imclone systems incorporated imclone biopharmaceutical company focused developing targeted cancer treatments codevelopment copromotion erbitux us us food drug administration fda approved biologics license application bla erbitux use combination irinotecan treatment patients epidermal growth factor receptor egfrexpressing metastatic colorectal cancer refractory irinotecanbased chemotherapy use single agent treatment patients egfrexpressing metastatic colorectal cancer intolerant irinotecanbased chemotherapy also fda approved imclones chemistry manufacturing controls supplemental bla licensure bb manufacturing facility march fda approved erbitux use treatment squamous cell carcinoma head neck combination radiation monotherapy company paid million milestone payment imclone fda approvals agreement imclone receives distribution fee based flat rate net sales north america addition company coexclusive right commercialize erbitux japan imclone previously granted co exclusive right merck kgaa japan december company japanese affiliate bmkk merck kgaa merck ltd imclone executed joint development agreement erbitux japan erbitux yet marketed japan although application submitted japanese pharmaceuticals medical devices agency use erbitux treating patients advanced colorectal cancer company accounts million approval milestones paid license acquisitions capitalized amortized cost products sold remaining term agreement ends company amortized cost products sold million million million respectively unamortized portion approval payments recorded intangible assets million million december respectively company accounts investment imclone equity method records share results equity net income affiliates consolidated statement earnings companys recorded investment market value holdings imclone common stock million approximately million december respectively million approximately million december respectively company holds million shares imclone stock representing approximately imclones shares outstanding december per share basis annual report carrying value imclone investment closing market price imclone shares december respectively compared respectively december company determines equity share imclones net income loss eliminating imclones results milestone revenue imclone recognizes million preapproval milestone payments made company company recorded million preapproval milestone payments equity investment expensed remaining million acquired inprocess research development period milestone revenue recognized imclone excess million eliminated company determining equity share imclone 's results share imclones results operations company recorded net income million net loss million net income million company recorded net sales erbitux million million million gilead company gilead sciences inc gilead entered joint venture develop commercialize fixed dose combination company 's sustiva efavirenz gilead 's truvada emtricitabine tenofovir disoproxil fumarate us canada july fda granted approval atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg treatment human immunodeficiency virus hiv infection adults atripla firstever oncedaily single tablet regimen hiv intended standalone therapy combination antiretrovirals gilead records atripla revenues consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product gilead joint venture third party customers company 's revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand company recorded efavirenz revenues million related atripla sales company accounts participation joint venture equity method accounting records share joint venture results equity net income affiliates consolidated statement earnings company recorded equity loss joint venture gilead million million year ended december respectively summary financial information summarized financial information companys equity investments joint venture sanofi europe asia follows dollars millions revenues gross profit net income current assets current liabilities note restructuring activities company recorded pretax charges million related termination benefits related costs workforce reductions approximately selling operating administrative personnel charges decreased million adjustments reflecting changes estimates restructuring actions taken prior periods following table presents detail charges segment type company expects substantially complete activities termination dollars millions benefits exit costs total pharmaceuticals nutritionals health care subtotal changes estimates restructuring reflected statement earnings bristolmyers squibb activities company recorded pretax charges million related termination benefits related costs workforce reductions streamlining worldwide operations charges million related employee termination benefits related expenses approximately selling administrative personnel includes restructuring us cardiovascularmetabolics primary care sales organization workforce headcount reduction million related retention bonuses million related asset impairments charges decreased million adjustments reflecting changes estimates restructuring actions taken prior periods following table presents detail charges segment type company substantially completed restructuring activities late termination relocation asset write dollars millions benefits exit costs retention downs total pharmaceuticals nutritionals health care subtotal changes estimates restructuring reflected statement earnings activities company recorded pretax charges million relating termination benefits related costs workforce reduction streamlining worldwide operations charges million primarily related employee termination benefits related expenses approximately selling administrative manufacturing personnel million related primarily asset impairments million related consolidation certain research facilities million retention bonuses charges partially offset million adjustments reflecting changes estimates restructuring actions taken prior periods million gain sale research facility previously written restructuring following table presents detail charges segment type company substantially completed restructuring activities termination relocation asset write dollars millions benefits exit costs retention downs total pharmaceuticals health care corporateother subtotal changes estimates gain sale research facility restructuring reflected statement earnings rollforward restructuring charges spending liabilities associated prior current actions follows employee termination exit cost dollars millions liability liability total balance january charges spending changes estimate balance december charges spending changes estimate balance december charges spending changes estimate balance december annual report liabilities million million december respectively included accrued expenses consolidated balance sheet longterm liability million included liabilities december note acquisitions divestitures january company completed sale inventory trademark patent intellectual property rights us related dovonex treatment psoriasis warner chilcott company inc million cash addition company receive royalty based net sales dovonex end result transaction company recognized pretax gain million million net tax first quarter third quarter company completed sale us canadian consumer medicines consumer medicines business related assets novartis ag novartis terms agreement novartis acquired trademarks patents intellectual property rights consumer medicines million cash including impact working capital adjustment million attributable postclosing supply arrangement company novartis related assets include rights us consumer medicines brands latin america europe middle east africa results operations consumer medicines included companys consolidated statement earnings date disposal result transaction company recorded pretax gain million million net tax third quarter april company completed acquisition acordis speciality fibres acordis company purchased stock acordis million incurred million acquisition costs connection transaction december company accrued million liability based achievement production volumes recorded additional goodwill purchase price acquisition allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date million million allocated inprocess research development immediately expensed million assigned identifiable intangible assets predominantly patents excess purchase price estimated fair values net assets acquired recorded goodwill acquisition accounted purchase method accordingly results operations included accompanying consolidated financial statements date acquisition february company completed divestiture adult nutritional business novartis million including million contingent achievement contractual requirements satisfied million upfront payment supply agreement company recorded total pretax gain million million net tax included million contingent payment million reduction company goodwill associated mead johnson product lines note discontinued operations may company completed sale oncology therapeutics network otn one equity partners llc cash proceeds million including impact preliminary working capital adjustment company recorded pretax gain million million net tax presented gain sale discontinued operations consolidated statement earnings otn previously presented separate segment following amounts related otn business segregated continuing operations reported discontinued operations date disposition reflect costs certain services provided otn company costs allocated company otn services included legal counsel insurance external audit fees payroll processing certain human resource services information technology systems support year ended december dollars millions net sales lossearnings incomes taxes net lossearnings discontinued operations consolidated statement cash flows includes otn business date disposition company uses centralized approach cash management financing operations accordingly debt allocated business cash flows operating activities discontinued operations consist outflows million year ended december cash inflows million year ended december cash flows used investing activities discontinued bristolmyers squibb operations million year ended december investing activities year ended december note earnings per share numerator basic earnings per share net earnings available common stockholders numerator diluted earnings per share net earnings available common stockholders interest expense added back assumed conversion convertible debt common stock denominator basic earnings per share weighted average number common stock outstanding period denominator diluted earnings per share weighted average shares outstanding adjusted effect dilutive stock options assumed conversion convertible debt common stock computations basic diluted earnings per common share follows year ended december amounts millions except per share data basic earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings basic earnings per share average common shares outstanding earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings per common share diluted earnings continuing operations interest expense conversion convertible debt net taxes discontinued operations loss net taxes gain disposal net taxes net earnings diluted earnings per share average common shares outstanding conversion convertible debt incremental shares outstanding assuming exercisevesting dilutive stock optionsrestricted stock earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings per common share weightedaverage shares issuable upon exercise stock options included diluted earnings per share calculation dilutive million million million respectively million weightedaverage shares issuable well million interest expense net tax assumed conversion convertible debt included diluted earnings per share calculation dilutive annual report note expense net components expense net follows year ended december dollars millions interest expense interest income foreign exchange transaction losses net expense net interest expense increased net interest swap losses million interest expense reduced net interest swap gains million million respectively interest income relates primarily cash cash equivalents investments marketable securities net includes income thirdparty contract manufacturing royalty income expenses debt retirement costs certain litigation matters gains losses disposal property plant equipment gains losses sale marketable securities deferred income recognized change net compared primarily due debt retirement costs deferred income recognized note income taxes components earnings loss continuing operations minority interest income taxes follows year ended december dollars millions us nonus amounts categorized based location taxing authorities provisionbenefit income taxes attributable continuing operations consisted year ended december dollars millions current us nonus deferred us nonus bristolmyers squibb effective tax rate companys provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations minority interest income taxes result following earnings minority interest income taxes dollars millions earnings continuing operations minority interest income taxes us statutory rate foreign tax effect operations ireland puerto rico switzerland state local taxes net valuation allowance us federal foreign contingent tax matters dividend repatriation ajca us federal research tax credit us federal foreign valuation allowance foreign effective income tax rate earnings continuing operations minority interest income taxes compared increase effective tax rate compared resulted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible tax benefits associated settlement irs examination favorable adjustment taxes special dividends american jobs creation act ajca partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions decrease effective tax rate due primarily charge approximately million taxes special dividends ajca charge related establishment valuation allowance certain charitable contributions tax benefits discussed partially offset lower estimated foreign tax credits annual report deferred taxes valuation allowance components current noncurrent deferred income tax assets liabilities follows december dollars millions acquired inprocess research development intercompany profit inventory items us federal foreign tax credit carryforward deferred income us federal research development tax credit carryforward us federal charitable contribution carryforward state net operating loss carryforwards foreign net operating loss carryforwards foreign deferred tax assets pension postretirement benefits depreciation share based compensation legal settlements net valuation allowance deferred tax assets net recognized deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable liabilities noncurrent total includes impact million increase deferred tax benefits adoption sfas see note pension postretirement benefit plans valuation allowance million december relates million state deferred tax assets million foreign net operating loss tax credit carryforwards million state net operating loss tax credit carryforwards company currently believes likely realized company recorded significant deferred tax assets related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit carryforwards amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets discussion plavix related matters see note legal proceedings contingencies income taxes paid year million million million respectively current tax benefit realized upon exercise stock options charged capital excess par value stock amounted million million million respectively december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided bristolmyers squibb company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation company recognized income tax benefit approximately million due settlement companys us federal income tax returns years companys us federal income tax returns currently examination irs irs proposed significant disallowance certain litigation settlement expenses significant reduction us foreign tax credits claimed following companys previously disclosed international restructuring irs position latter matter also affects us foreign tax credits claimed company although year currently examination company believes strong positions respect issues intends contest irs positions possible predict outcome issues company established tax contingency reserves reflect best estimate probable tax liability matters company prevail final nonappealable determination matters amount loss excess established reserves could material adverse effect companys results operations however company believe determination would material adverse effect cash flows note receivables major categories receivables follows december dollars millions trade receivables miscellaneous receivables less allowances receivables net miscellaneous receivables includes million net allowances million million net allowances million respectively related receivables alliance partners additional information company 's alliance partners see note alliances investments note inventories major categories inventories follows december dollars millions finished goods work process raw packaging materials inventories net annual report note property plant equipment major categories property plant equipment follows december dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation property plant equipment net capitalized interest million million million years ended december respectively included categories property plant equipment shown note goodwill changes carrying amount goodwill years ended december follows pharmaceuticals nutritionals health care discontinued dollars millions segment segment segment operations total balance january adjustments reduction due sale otn reduction due sale consumer medicines purchase price allocation adjustment balance december adjustments reduction due sale business purchase price allocation adjustments balance december note intangible assets december intangible assets consisted following december dollars millions patentstrademarks less accumulated amortization patentstrademarks net licenses less accumulated amortization licenses net technology less accumulated amortization technology net capitalized software less accumulated amortization capitalized software net total intangible assets net bristolmyers squibb first quarter year company recorded impairment charges licenses million million respectively resulting actual estimated future sales declines tequin charges recorded cost products sold companys consolidated statement earnings march result fda approval erbitux use treatment head neck cancer company made million milestone payment imclone capitalized licenses third quarter company recorded impairment charge licenses million resulting lower expected sales emsam charge recorded cost products sold companys consolidated statement earnings amortization expense intangible assets years ended december million million million respectively expected amortization expense related current net carrying amount intangible assets follows years ending december dollars millions later years note shortterm borrowings longterm debt shortterm borrowings end million million respectively longterm debt billion december compared billion december fourth quarter company restructured longterm debt retiring outstanding billion notes due cash tender offer subsequent redemption issuing million million aggregate principal amount notes due million million aggregate principal amount notes due well billion aggregate principal amount notes due resulted million pretax expense comprised items discussed premium paid debt tender make whole million million respectively addition company recognized earnings million unamortized discount debt issuance costs associated debt incurred pretax loss million related termination remaining billion notional amount fixedtofloating interest rate swap agreements recognized earnings pretax unamortized portion million aforementioned loss incurred termination million notional amount fixedtofloating interest rate swaps occurred june furthermore november company recognized earnings accumulated comprehensive income pretax unamortized portion million loss incurred settlement interest rate lock contracts used manage exposure changes interest rates anticipated issuance longterm fixed rate debt december company replaced prior billion revolving credit facility new billion fiveyear revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions substantially similar prior facility including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december company unused shortterm lines credit available trade finance facilities foreign banks million million december respectively august whollyowned subsidiary company entered billion term facility syndicate bank lenders borrowings facility guaranteed company subsidiaries borrower certain european subsidiaries company facility contained fiveyear tranche billion twoyear tranche million fully drawn december interest paid periodic basis agreed lenders annual rate equal applicable london interbank offered rate libor plus company subject substantially covenants included december revolving credit facility company also subject restrictions including certain financial covenants prior borrowing proceeds facility company obtained waiver lenders covenant default facility due onetime intercompany distribution december annual report company fully repaid twoyear tranche billion outstanding fiveyear tranche full compliance covenants second quarter company retired outstanding billion notes due incurred aggregate pretax expense approximately million connection early redemption notes termination related interest rate swaps components longterm debt follows december dollars millions notes due floating rate bank term facility due notes due floating rate convertible debentures due euro notes due euro notes due notes due floating rate bank term facility due notes due debentures due debentures due debentures due yen notes due industrial revenue bonds due yen notes due yen notes due variable rate industrial revenue bonds due companys outstanding billion convertible debentures pay interest quarterly annual rate equal month libor reset quarterly minus yield never less zero final maturity september debentures callable par time september issuer holders also redeem debentures par september fundamental change ownership company occurs bond initial conversion price conversion rate shares adjustable depending average closing prices applicable period maximum conversion rate shares company entered fixed floating interest rate swaps billion longterm debt conjunction new issuance billion notes due billion euro notes billion company executed several fixed floating interest rate swaps convert new fixed rate debt paid variable rate debt company executed several fixed floating interest rate swaps convert million companys fixed rate debt paid variable rate debt year ended december company realized net increase interest expense million result higher floating rates obtained swap agreements year ended december company recognized net reduction interest expense million reflects benefit lower floating rates obtained swap agreements november connection early retirement outstanding billion notes due company terminated remaining billion notional amount fixed floating interest rate swap agreements incurred pre tax loss million april connection early redemption billion notes due company terminated billion notional amount fixedtofloating interest rate swap agreements incurred pretax loss million june company terminated million notional amount fixedtofloating interest rate swap agreements related billion notes due incurred pretax loss million loss amortized interest expense million million recognized respectively remaining loss million together million loss incurred unwind billion swap fully recognized september company terminated million notional amount fixedtofloating interest rate swap agreements related million debentures due gain million gain recognized interest expense remaining life debentures due approximately million recognized bristolmyers squibb cash payments interest including payments due interest rate swaps million million million respectively companys cash receipts interest rate swaps million million million respectively excluded cash payments interest payments due period dollars millions total later years longterm debt obligations included shortterm borrowings companys consolidated balance sheet december balances approximate outstanding nominal longterm debt values companys convertible debenture included due payment contains put call feature described december company provided total million financial guarantees form standby letters credit performance bonds standby letters credit insurance companies support thirdparty liability programs performance bonds issued support range ongoing operating activities including sale company products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority companys outstanding financial guarantees expire within year expected funded note stockholders equity changes common shares treasury stock capital excess par value stock restricted stock follows capital excess common shares treasury cost treasury par value restricted dollars shares millions issued shares stock stock stock balance january issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december share companys preferred stock convertible shares common stock callable companys option reductions number issued shares preferred stock due conversions shares common stock dividends declared per common share annual report accumulated balances related component comprehensive incomeloss net taxes follows deferred charges minimum pension deferred pension accumulated foreign currency incomeloss liability postretirement available sale comprehensive dollars millions translation effective hedges adjustment benefits securities incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss adjustments adoption sfas balance december note employee stock benefit plans employee stock plans companys stock incentive plan executive officers key employees may granted options purchase companys common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years generally company issues shares stock option exercise treasury stock additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price terms stock incentive plan authorized shares include outstanding shares per year well number shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise shares available grant prior year granted year shares cancelled forfeited expired also available future grant stock incentive plan provides granting common stock key employees subject restrictions continuous employment restrictions generally expire fouryear period date grant compensation expense recognized restricted period december million million shares restricted stock restricted stock units outstanding plan respectively years ended december approximately million million million shares respectively restricted stock restricted stock units granted weighted average fair value per common share respectively stock incentive plan also incorporates company 's longterm performance awards awards delivered form target number performance shares threeyear cycle awards based cumulative earnings per share cumulative sales ultimate payout modified companys total stockholder return versus companies proxy peer group threshold targets met performance period payment made longterm performance award plan maximum performance three measures result maximum payout target december million million performance shares outstanding plan respectively million million million performance shares granted respectively fair value per common share respectively teamshare stock option plan terminated january fulltime employees excluding key executives granted options purchase companys common stock market price date options granted company authorized million shares issuance plan individual grants generally became exercisable evenly third fourth fifth anniversary grant date maximum term years options million shares exercised plan december bristolmyers squibb companys results operations year ended december reflect impact sfas r includes impact expensing stock options company elected alternative method provided fsp r determining companys pool excess tax benefits results operations years ended december restated reflect impact expensing stock options prepared accordance apb following table summarizes stockbased compensation expense net tax related employee stock options restricted stock longterm performance awards years ended december years ended december dollars millions cost products sold marketing selling administrative research development total stockbased compensation expense deferred tax benefit stockbased compensation net tax table reflects pro forma net income diluted net income per share years ended december year ended december dollars millions except per share data net earnings reported total stockbased employee compensation expense included reported net earnings net related tax effects total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma basic earnings per share reported pro forma diluted earnings per share reported pro forma costs related stockbased compensation capitalized period summary option activities follows shares common stock available issued weightedaverage shares millions option award plan exercise price shares balance january authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december annual report weightedaverage grantdate fair value options granted company twelve months ended december respectively total intrinsic value options exercised twelve month periods ended december million million million respectively twelve months ended december company received million million million cash proceeds exercise stock options december million total unrecognized compensation cost related stock options expected recognized weightedaverage period years following tables summarize information concerning companys stock compensation plans currently outstanding exercisable options number securities remaining available future number securities issued weightedaverage exercise issuance equity compensation upon exercise outstanding price outstanding plans excluding securities reflected options rights options rights column shares millions b c plan category equity compensation plans approved security holders equity compensation plans approved security holders shares plan longer issued following table summarizes significant ranges outstanding exercisable options december shares millions options outstanding options exercisable weighted weighted average weighted aggregate average weighted aggregate remaining average intrinsic remaining average intrinsic range number contractual exercise price value number contractual exercise price value exercise prices outstanding life years per share millions exercisable life years per share millions aggregate intrinsic value preceding table represents total pretax intrinsic value based companys average stock price december would received option holders option holders exercised options date total number inthemoney options exercisable december million december million outstanding options exercisable weightedaverage exercise price december million shares common stock reserved issuance pursuant stock plans options conversions preferred stock bristolmyers squibb stock option valuation fair value employee stock options granted estimated date grant prior january estimated using weightedaverage estimated per option value granted using blackscholes option pricing model following assumptions expected volatility riskfree interest rate dividend yield expected life yrs yrs yrs company derived expected volatility assumption required blackscholes model calculating year historical volatility weighting equally derived implied volatility consistent sfas r sab prior company used historical stock price volatility accordance sfas purposes pro forma information selection blended historical implied volatility approach based companys assessment calculation expected volatility representative future stock price trends using historical volatility riskfree interest rate assumption based upon us treasury yield curve effect time grant dividend yield assumption based companys history expectation dividend payouts expected life employee stock options represents weightedaverage period stock options expected remain outstanding derived output latticebinomial model expected life employee stock options impacted underlying assumptions calibration companys model latticebinomial model assumes employees exercise behavior function options remaining vested life extent option inthemoney latticebinomial model estimates probability exercise function two variables based entire history exercises cancellations past option grants made company prior company used optionpricing model indirectly estimate expected life stock options expected life expected volatility stock options based upon historical economic data trended future forfeitures employee stock options accounted asincurred basis stockbased compensation expense recognized consolidated statement earnings twelve months ended december based awards ultimately expected vest reduced estimated forfeitures sfas r requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates forfeitures estimated based historical experience companys pro forma information required sfas periods prior company accounted forfeitures occurred annual report restricted stock fair value nonvested shares companys common stock determined based average trading price companys common stock grant date restricted share activities follows weighted average grantdate shares thousands number shares fair value nonvested shares january granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december december million million respectively total unrecognized compensation cost related nonvested restricted stock restricted stock units cost expected recognized weightedaverage period years balance december years balance december total fair value shares share units vested twelve months ended december million million million respectively longterm performance awards prior adoption sfas r compensation expense related longterm performance awards determined based market price companys stock time award applied expected number shares contingently issuable amortized threeyear performance cycle upon adoption sfas r fair value longterm performance award estimated date grant using monte carlo simulation model instead grant date market price used previously company changed valuation technique based clarification provided sfas r fact longterm performance awards contain market condition performance conditions affect factors vesting ie variable number shares awarded reflected grant date fair value award monte carlo simulation model utilizes multiple input variables determine probability satisfying market condition stipulated award grant calculates fair market value longterm performance awards valuation model used following assumptions weightedaverage expected expected dividend risk free grant year grant date volatility yield interest rate weightedaverage expected volatility based three year historical volatility levels companys common stock expected dividend yield based historical dividend payments risk free interest rate reflects yield year zero coupon us treasury bonds based performance shares contractual term fair value longterm performance awards amortized performance period award longterm performance shares thousands shares outstanding performance cycle weightedaverage grant date measurement date grant date fair value december bristolmyers squibb december million million respectively total unrecognized compensation cost related performance share plan expected recognized weightedaverage period years years respectively accuracy fair value estimates companys determination fair value stockbased payment awards date grant using optionpricing model affected companys stock price well assumptions regarding number highly complex subjective variables variables include limited companys expected stock price volatility term awards actual projected employee stock option exercise behaviors optionpricing models developed use estimating value traded options vesting hedging restrictions fully transferable companys employee stock options certain characteristics significantly different traded options changes subjective assumptions materially affect estimated value managements opinion existing valuation models may provide accurate measure fair value companys employee stock options although fair value employee stock options determined accordance sfas r sab using optionpricing model value may indicative fair value observed willing buyerwilling seller market transaction company adopted sfas r requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb periods beginning january march sec issued sab relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fsp r determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stock based compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r note financial instruments company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used speculative purposes companys primary net foreign currency translation exposures euro japanese yen mexican peso chinese renminbi canadian dollar company utilizes foreign currency contracts hedge anticipated transactions primarily intercompany transactions certain foreign currencies designates derivative instruments foreign currency cash flow hedges appropriate notional amounts companys foreign exchange derivative contracts december million million respectively derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings company reclassified deferred losses million million million respectively accumulated oci earnings majority classified cost products sold december balance deferred net aftertax losses foreign exchange forward contracts included accumulated oci million net aftertax loss million estimated reclassified earnings within next months sfas requires company perform periodic assessments hedge effectiveness assessments determine whether derivatives designated qualifying hedges continue highly effective offsetting changes cash flows hedged items ineffective portion fair value longer deferred accumulated oci included current period earnings years ended december impact hedge ineffectiveness earnings significant additionally years ended december impact discontinued hedges loss million gain million respectively furthermore company uses foreign exchange forward contracts offset exposure certain currency annual report assets liabilities foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings occur amounts recognized earnings related foreign exchange forward contracts qualify hedge accounting treatment significant fair value forward contracts net liability million december million recorded noncurrent asset million recorded current liability fair value forward contracts net asset million december million recorded noncurrent asset million recorded current liability fair value foreign exchange contracts based yearend currency rates blackscholes model case option contracts company exposures net foreign currency denominated assets liabilities approximately billion billion december respectively primarily mexico japan uk china australia canada reduction net exposure primarily due issuance billion euro billion notes additional information see note shortterm borrowings longterm debt addition foreign exchange hedge contracts noted company utilizes forward contracts hedge foreign currency denominated monetary assets liabilities primary objective forward contracts protect us dollar value foreign currency denominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated euro forward contracts designated hedges marked market incomeexpense notional fair value amount purchased foreign exchange forward contracts million million asset respectively december million million liability respectively december notional fair value amount sold foreign exchange forward contracts million million liability respectively december million million asset respectively december company also uses non us dollar borrowings lesser extent forward contracts hedge foreign currency exposures companys net investment certain foreign affiliates non us dollar borrowings forward contracts designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component oci december million tax losses million tax gains respectively recorded foreign currency translation component oci company uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment november connection funding retirement fixed rate debt company executed several fixed floating interest rate swaps convert billion billion euro billion companys newly issued fixed rate debt paid variable rate debt company executed several fixed floating interest rate swaps convert million companys fixed rate debt paid variable rate debt total notional amount outstanding interest rate swaps billion billion euro billion december billion december accordance sfas accounting derivative instruments hedging activities company recognized net increase interest expense million net reduction interest expense million million respectively impact interest rate swaps bristolmyers squibb swap contracts well underlying debt hedged recorded fair value resulted increase non current assets million current liabilities million reduction longterm debt million december increase noncurrent assets million current liabilities million reduction longterm debt million december swap contracts generally held maturity intended create appropriate balance fixed floating rate debt company swap contracts qualify fair value hedges terminated prior maturity dates reported part carrying value underlying debt amortized earnings remaining life debt swap contracts qualify cash flow hedges terminated reported accumulated oci amortized earnings remaining life debt following tables summarize new terminated interest rate swaps notional amount dollarseuro millions year transaction underlying debt interest rate contracts swaps associated eur notes due swaps associated eur notes due swaps associated notes due terminated swap contracts total pretax pretax pretax year notional amount deferred incomeexpense incomeexpense interest rate contracts termination underlying debt gainloss recognized recognized dollars millions interest rate swap lock associated notes due interest rate swap lock associated notes due swaps associated notes due swaps associated notes due swaps associated notes due swaps associated notes due underlying notes extinguished respectively carrying amount companys financial instruments includes cash cash equivalents marketable securities accounts receivable accounts payable approximates fair value december longterm debt difference fair value carrying value material note segment information company organized three reportable segmentspharmaceuticals nutritionals health care pharmaceuticals segment comprised global pharmaceutical international consumer medicines businesses nutritionals segment consists mead johnson primarily infant formula business childrens nutritional business health care segment consists convatec medical imaging consumer medicines businesses third quarter company completed sale consumer medicines business additional information sale consumer medicines see note acquisitions divestitures annual report companys products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals clinics government agencies medical profession three wholesalers accounted approximately respectively companys total net sales sales wholesalers accounted respectively companys total net sales three wholesalers accounted approximately respectively companys total net sales sales concentrated pharmaceuticals segment earnings minority interest net sales income taxes yearend assets dollars millions pharmaceuticals nutritionals health care health care group total segments corporateother total corporateother consists principally interest income interest expense certain administrative expenses allocations business segments certain corporate programs litigation expense debt retirement costs gain sale businesses product asset deferred income recognized collaboration agreement restructuring charges corporateother assets include cash cash equivalents marketable securities goodwill assets otn held available sale december sold certain assets capital expenditures depreciation dollars millions pharmaceuticals nutritionals health care health care group total segments corporateother total geographic areas net sales yearend assets dollars millions united states europe middle east africa western hemisphere pacific total change yearend assets us primarily due decrease cash cash equivalents marketable securities resulting reinvestment foreign dividends received pursuant repatriation earnings us ajca bristolmyers squibb note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december follows years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense net sublease rental income million million million million million million december company completed sale leaseback several administrative facilities new jersey million resulting pretax gain transaction million deferred reduce future lease rental costs lease periods ranging years note pension postretirement benefit plans company certain subsidiaries defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal pension plan bristolmyers squibb retirement income plan us funding policy contribute amounts provide current service fund past service liability plan benefits based primarily participants years credited service compensation plan assets consist principally equity fixed income securities company also provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us company adopted sfas fiscal year ended december resulting million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities impact adoption summarized follows sfas adjustments dollars millions pre sfas pretax tax net post sfas current assets deferred income taxes noncurrent assets deferred income taxes prepaid pension assets current liabilities accrued expenses us foreign income taxes payable noncurrent liabilities liabilities stockholders equity accumulated comprehensive loss annual report cost companys deferred benefits postretirement benefit plans included following components pension benefits benefitsa dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets net amortization deferral net periodic benefit cost curtailments settlements total net periodic benefit cost company recognized impact medicare prescription drug improvement modernization act accordance fsp recorded million million million respectively reduction net periodic benefit costs estimated net actuarial loss prior service cost amortized accumulated oci net periodic benefit cost dollars millions pension benefits benefits amortization net actuarial loss amortization prior service cost changes benefit obligations plan assets funded status amounts recognized balance sheet years ended december companys defined benefit postretirement benefit plans follows pension benefits benefits dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected benefit obligation plan participants contributions curtailments settlements actuarial lossesgains plan amendments retiree drug subsidy received benefits paid exchange rate gainslosses benefit obligation end year fair value plan assets beginning year actual return plan assets employer contribution plan participants contributions settlements retiree drug subsidy received benefits paid exchange rate lossesgains fair value plan assets end year funded status unamortized net obligation adoption unrecognized prior service cost unrecognized net actuarial loss net amount recognized bristolmyers squibb pension benefits benefits dollars millions amounts recognized balance sheet consist prepaid pension prepaid benefit cost assets accrued expenses pension postretirement liabilities accrued benefit cost accumulated comprehensive loss net amount recognized amounts recognized accumulated comprehensive loss net actuarial loss net obligation adoption prior service cost several plans underfunded accrued benefit obligations exceeded accrued benefit liabilities december additional minimum liabilities established increase accrued benefit liabilities values underfunded accrued benefit obligations additional minimum liabilities totaled million december prior adoption sfas us unfunded benefit equalization plan several international plans liabilities reversed upon adoption sfas additional minimum liabilities totaled million december offset intangible assets million charges accumulated oci included stockholders equity million accumulated benefit obligation defined benefit pension plans million million december respectively information pension plans accumulated benefit obligations excess plan assets follows december dollars millions projected benefit obligation accumulated benefit obligation fair value plan assets attributable primarily unfunded us benefit equalization plan several plans international markets unfunded us benefit equalization plan provides pension benefits employees compensation irs limits funded taxadvantaged manner additional information pertaining companys pension postretirement plans follows pension benefits benefits dollars millions decreaseincrease minimum liability including impact foreign currency fluctuations included comprehensive income weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase annual report weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase december companys expected longterm rate return us pension plan assets target asset allocation public equity us international private equity fixed income approximated applying expected returns public equity private equity fixed income target allocation actual historical returns also relevant annualized returns periods ended december years years years us pension plan assets represented approximately total company pension plan assets december disclosed total company expected return assets us pension plans due impact international pension plans typically employ less aggressive asset allocation expected return disclosed benefits relevant assets invested manner us pension plan assets international plan assets assumed health care cost trend rates december follows health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed health care cost trend rates effect amounts reported health care plans onepercentagepoint change assumed health care cost trend rates would following effects percentage percentagepoint dollars millions point increase decrease effect total service interest cost effect postretirement benefit obligation companys asset allocation pension postretirement benefits december follows pension benefits benefits public equity securities debt securities including cash private equity total companys investment strategy emphasizes equities order achieve high expected returns long run low expense low required cash contributions us pension plans target asset allocation public equity us international private equity fixed income maintained cash flow ie cash contributions benefit payments used rebalance back targets necessary investments well diversified within three major asset categories us equity passively managed otherwise investments actively managed investment strategies international pension plans typically similar although asset allocations usually conservative bristolmyers squibb company common stock represents less plan assets december bristolmyers squibb assets postretirement benefits commingled us pension plan assets therefore investment strategy identical described us pension plans contributions although minimum contributions required company made cash contributions us pension plans million million million respectively company also plans make cash contribution us pension plans contributions made us pension plans company may make taxdeductible contributions h account retiree medical benefits equal portion pension normal cost contributions international pension plans million million million respectively contributions international plans expected million estimated future benefit payments following benefit payments mainly us pension plans reflect expected future service appropriate expected paid benefits medicare dollars millions pension benefits gross subsidy net years savings plan principal defined contribution plan bristolmyers squibb savings investment program companys contribution based employee contributions level company match companys contributions plan million million million termination indemnity plans company operates certain jurisdictions primarily europe require recording statutory termination obligations obligations assessed accordance emerging issues task force issue determination vested benefit obligation defined benefit pension plan total pension liability recorded obligations million december million december note legal proceedings contingencies various lawsuits claims proceedings investigations pending involving company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated matters involve antitrust securities patent infringement pricing sales marketing practices environmental health safety matters consumer fraud product liability insurance coverage significant matters described assurance increase scope matters future lawsuits claims proceedings investigations material management continues believe previously disclosed next years aggregate impact beyond current reserves legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity annual report intellectual property plavix litigation plavix currently companys largest product ranked net sales net sales plavix approximately billion year ended december billion year ended december billion us net sales plavix billion billion billion plavix patents subject number challenges us less significant markets product possible reasonably estimate impact lawsuits company however loss market exclusivity plavix sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity company sanofi companies intend vigorously pursue enforcement patent rights plavix plavix litigation united states patent infringement litigation companys us territory partnership alliance sanofi plaintiff pending patent infringement lawsuit instituted us district court southern district new york entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex inc apotex corp apotex suit filed march based us patent patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel medicine made available us companies plavix plaintiffs infringement position based defendants filing abbreviated new drug applications anda fda seeking approval sell generic clopidogrel bisulfate prior expiration composition matter patent defendants responded alleging patent invalid andor unenforceable march companies announced executed proposed settlement agreement march agreement apotex settle patent infringement lawsuit pending parties us district court southern district new york response concerns expressed federal trade commission state attorneys general parties modified march agreement modified agreement july companies announced modified agreement failed receive required antitrust clearance state attorneys general august apotex launched generic version clopidogrel bisulfate august companies filed motion preliminary injunction august trial court issued preliminary injunction ordered apotex halt sales generic clopidogrel bisulfate court order apotex recall product customers companies also required post bond amount million provide security apotex court conclude end patent litigation injunction wrongly imposed september companies posted million bond satisfy requirement company pledged issuer bond collateral million bond consisting shortterm high quality securities collateral reported marketable securities consolidated balance sheet december terms pledge agreement company entitled receive income generated marketable securities make certain investment decisions restricted using million pledged securities purpose time bond cancelled september court denied apotexs motion stay preliminary injunction apotex filed appeal preliminary injunction us court appeals federal circuit september filed motion stay injunction pending appeal september federal circuit denied september december federal circuit affirmed trial courts issuance injunction apotex subsequently filed motion reconsideration andor rehearing denied january september apotex filed motion supplement answer counterclaims add claims breach contract antitrust counterclaims additional equitable defenses trial court permitted apotex add additional antitrust counterclaims stayed pending outcome trial court permit apotex add breach contract claim trial commenced january ended february court ordered posttrial briefing expected rule thereafter companys us territory partnership alliance sanofi also plaintiff three additional pending patent infringement lawsuits instituted us district court southern district new york dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt related patent trial date action dr reddy 's set patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex although teva cobalt appeal outcome litigation dr reddys teva filed anda fda exclusivity periods statutory stay periods hatch waxman act expired exception month stay applies teva expires february accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages bristolmyers squibb companys us territory partnership alliance sanofi plaintiff another pending patent infringement lawsuit instituted us district court district new jersey entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v watson pharmaceuticals inc watson laboratories inc suit filed october based us patent discloses claims particular crystalline polymorph form hydrogen sulfate salt clopidogrel marketed plavix case discovery phase december court permitted watson pursue declaratory judgment counterclaim respect us patent january court approved parties stipulation stay case pending outcome trial apotex matter possible time reasonably assess patent litigation apotex plavix patent litigation timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies however apotex prevail patent litigation company would expect face renewed generic competition plavix apotex promptly thereafter noted loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity full impact apotexs launch generic clopidogrel bisulfate product company reasonably estimated time depend number factors including among others amount generic product sold apotex whether companies prevail underlying patent litigation even companies prevail pending patent case extent launch apotex permanently adversely impact pricing prescription demand plavix amount damages would sought andor recovered companies apotexs ability pay damages loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity launch generic clopidogrel bisulfate product apotex august significant adverse effect sales company estimates range billion billion particular launch adverse impact sales third fourth quarters company estimates range million million third quarter million fourth quarter first second third fourth quarters us net sales plavix million million million million respectively sales generic clopidogrel bisulfate expected residual impact plavix sales company certainty estimate impact point time also previously disclosed antitrust division us department justice doj conducting criminal investigation regarding proposed settlement company cooperating fully investigation possible time reasonably assess outcome investigation impact company previously disclosed company entered deferred prosecution agreement dpa us attorneys office district new jersey usao june pursuant dpa usao filed criminal complaint company alleging conspiracy commit securities fraud deferred prosecution company dismiss complaint two years company satisfies requirements dpa terms dpa usao discretion may prosecute company matters subject criminal complaint filed usao company connection dpa usao make determination company committed criminal conduct dpa criminal conduct defined crime related companys business activities committed one executive officers directors securities fraud accounting fraud financial fraud business fraud materially affecting books records publicly filed reports company obstruction justice possible time reasonably assess impact pending criminal investigation doj may companys compliance dpa additional information respect dpa included item managements discussion analysissec consent order deferred prosecution agreement annual report september board directors board announced companys current chief executive officer ceo general counsel would leaving respective positions effective immediately announcement took place board received considered reports companys outside counsel issues relating plavix patent litigation apotex preliminary recommendation monitor dpa monitor terminate employment individuals monitors recommendation followed investigation initiated usao conducted monitor usao corporate governance issues relating companys negotiations proposed settlement apotex company advised monitor usao investigation involve matters subject ongoing investigation antitrust division doj plavix settlement agreement time monitor made preliminary recommendation monitor usao also advised company found violation dpa unlawful conduct company employees investigation included review whether violation federal securities laws connection proposed settlement apotex terms sec consent monitor completed investigation submitted report investigation usao monitors report find violation sec consent federal securities laws connection proposed settlement monitor concluded company violated certain paragraphs dpa related governance matters violations cited monitor report relate among things communication failures including insufficient communications companys former ceo former general counsel board members senior management well failure comply certain internal company policies procedures monitor make findings respect whether company knowingly materially breached dpa make recommendations usao advised company believes matters cited monitors report fully remediated accordingly intend take action dpa respect monitors report antitrust litigation eighteen lawsuits comprised individual suits purported class actions filed company us district court southern district ohio western division various plaintiffs including pharmacy chains individually assignees whole part certain wholesalers various health welfare benefit plansfunds individual residents various states since announcement march agreement apotex march lawsuits allege among things apotex settlement violates sherman act related laws plaintiffs seeking among things permanent injunctive relief barring apotex settlement andor monetary damages class actions filed behalf direct purchasers consolidated caption plavix direct purchaser antitrust litigation class actions filed behalf indirect purchasers consolidated caption plavix indirect purchaser antitrust litigation amended complaints filed consolidated class actions individual actions since july announcement modified agreement failed receive required antitrust clearance state attorneys general amended complaints include allegations regarding criminal investigation antitrust division doj november companies filed motion transfer eighteen lawsuits us district court southern district new york apotex matter similar plavixrelated patent infringement cases pending motion pending court court also considering whether stay litigation pending outcome patent infringement litigation possible time reasonably assess outcome lawsuits impact company shareholder derivative lawsuits september certain members board current former officers company named derivative complaint steven w sampson v peter r dolan et al filed new york state supreme court also september certain members board current former officers company named derivative complaint americo marchese v peter r dolan et al filed us district court southern district new york complaints allege among things breaches fiduciary duty claims contribution indemnification relation negotiations apotex regarding plavix patent litigation among things complaints seek money damages injunctive remedies forms equitable relief possible time reasonably assess outcome lawsuits impact company plaintiff marchese voluntarily dismissed without prejudice named plaintiff sold bristolmyers squibb stock bristolmyers squibb consumer fraud november companies served purported class action complaint subsequently amended include various sanofi entities captioned skilstaf inc v bristolmyers squibb company et al cv filed us district court district new jersey complaint alleges defendants misrepresented safety effectiveness plavix alone combination aspirin thirdparty payors misled causing pay plavix prescriptions insureds compared lower cost alternatives plaintiffs assert among things violations new jersey consumer fraud act plaintiffs seek compensatory punitive damages possible time reasonably assess outcome lawsuit impact company plavix litigation international sanofisynthelabo sanofisynthelabo canada inc instituted prohibition action federal court canada apotex inc minister health response notice allegation noa apotex inc directed canadian patent patent covering clopidogrel bisulfate apotexs noa indicated filed abbreviated new drug submission ands clopidogrel bisulfate tablets sought approval notice compliance ands expiration patent scheduled august apotexs noa alleged patent invalid infringed march canadian federal court ottawa rejected apotexs challenge canadian plavix patent held asserted claims novel obvious infringed granted sanofis application order prohibition minister health apotex inc order prohibition precludes approval apotexs ands patent expires unless federal courts decision reversed appeal apotex filed appeal canadian federal court appeal heard december december federal court appeal dismissed apotexs appeal upheld federal courts issuance order prohibition february apotex filed leave appeal decision supreme court canada sanofi sanofisynthelabo canada instituted prohibition action federal court canada cobalt minister health response noa cobalt directed patent canadian patent patent cobalts noa indicated filed ands clopidogrel bisulfate tablets sought notice compliance ands expiration patents cobalt alleged patent invalid patent invalid infringed case stayed pending outcome apotex appeal june korean intellectual property tribunal invalidated claims sanofis korean patent including claims directed clopidogrel pharmaceutically acceptable salts clopidogrel bisulfate sanofi appealed sanofi also commenced infringement actions generic pharmaceutical companies several launched generic clopidogrel bisulfate product korea possible time reasonably assess outcome lawsuits impact company intellectual property litigation tequin injectable form company kyorin pharmaceuticals co ltd kyorin commenced patent infringement actions march apotex sicor pharmaceuticals inc sicor inc sicor pharmaceuticals sales inc teva teva pharmaceutical industries ltd us district court southern district new york relating injectable forms antibiotic gatifloxacin kyorin holds composition matter patent company sells tequin action related apotexs sicors filing andas generic versions injectable gatifloxacin piv certifications composition matter patent expires december granted patent term extension december invalid filing lawsuits placed stays approvals apotexs sicors generic products julyaugust unless court decision adverse company kyorin date sicor case consolidated proceeding stipulation approved us district court southern district new york august parties agreed apotex case stayed pending resolution teva sicor cases parties bound outcome litigation august court approved stipulation dismissal jointly submitted parties stipulation plaintiffs claims teva sicor dismissed without prejudice teva sicors counterclaims concerning claim us patent dismissed prejudice teva sicors remaining counterclaims dismissed without prejudice apotex case remains pending possible time reasonably assess outcome apotex lawsuit however result companys decision discontinue manufacture distribution sale tequin expected outcome apotex lawsuit material impact company annual report erbitux yeda litigation october yeda research development company ltd yeda filed suit imclone aventis pharmaceuticals inc federal court claiming three individuals associated yeda named inventors us patent patent covers therapeutic combination egfr specific monoclonal antibody antineoplastic agents chemotherapeutic agents use treatment cancer september following trial court issued opinion order held three researchers yeda sole inventors subject matter patent giving complete ownership patent yeda imclone appealed imclone also filed declaratory judgment action us district court southern district new york complaint alleges yeda researchers remain sole inventors patent patent invalid company party action unable predict outcome proceedings result courts decision yeda may seek damages infringement respect past erbitux sales royalties future erbitux sales yeda also right license patent others yedas license patent third parties could result product competition erbitux might otherwise occur early assess whether extent competitive impact occur quantify impact however yeda announced licensed patent amgen inc amgen amgen received fda approval market egfr product competes erbitux commercial agreement imclone company pays royalty imclone sales erbitux impacted courts decision agreement imclone company also includes provisions pursuant certain financial consequences company resulting decision would responsibility imclone addition company owns million shares imclone common stock company accounts equity method accounting carrying value per share december closing market price imclone common stock december assurance company able realize fully benefits contractual protections commercial agreement imclone financial consequences company result courts decision repligen litigation repligen corporation repligen massachusetts institute technology mit filed lawsuit us district court district massachusetts imclone claiming imclones manufacture sale erbitux infringes patent generally covers process protein production mammalian cells july court granted summary judgment favor repligen mit rejecting one imclones defenses relating patent exhaustion trial proceed issue patent infringement company party action possible time reasonably assess outcome lawsuit impact company abbott laboratories litigation february abbott laboratories filed suit imclone us district court district massachusetts case cvrgs complaint alleges imclones manufacture sale erbitux infringe us patent seeks damages alleged infringement company party action possible time reasonably assess outcome lawsuit impact company orencia january repligen regents university michigan filed complaint company us district court eastern district texas marshall division orencia launched february complaint alleges companys thenanticipated sales orencia infringe us patent repligen since amended complaint include ongoing future sales orencia august zymogenetics inc filed complaint company us district court district delaware complaint alleges companys manufacture sales orencia infringe us patents nos trial scheduled commence april possible time reasonably assess outcome lawsuits impact company bristolmyers squibb general commercial litigation clayworth litigation company together number pharmaceutical manufacturers named defendant action filed california state superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals agreeing charge drugs us charge outside us particularly canada asserting claims californias cartwright act unfair competition law plaintiffs sought trebled monetary damages injunctive relief relief december court granted company manufacturers motion summary judgment based passon defense judgment entered favor defendants january notice appeal respect judgment filed remains pending possible time reasonably assess outcome lawsuit impact company event plaintiffs successful appeal weisz stephenson litigations company named defendant along many pharmaceutical companies action originally brought utility consumers action network consumer advocacy organization focuses privacy issues lawsuit entitled utility consumers action network behalf privacy rights clearinghouse et al v bristolmyers squibb co et al filed california state superior court san diego county july another substantially similar lawsuit rowan klein representative action behalf similarly situated persons consuming public v walgreens et al filed february court retail pharmacies company pharmaceutical companies two complaints seek equitable relief monetary damages attorneys fees based upon allegedly unfair business practices untrue misleading advertising various california statutes including california confidentiality medical information act based allegations retail stores selling consumers confidential medical information companies using consumers medical information direct marketing designed increase sale targeted drugs january company pharmaceutical defendants sought dismiss utility consumers action network case grounds californias proposition requires plaintiff must injured party order standing bring suit utility consumers action network personally injured october court entered stay utility consumers action network klein cases pending california supreme courts decision review several intermediate appellate decisions discuss applicability proposition pending cases july california supreme court entered decisions two appeals held proposition applies pending cases complaints may amended add plaintiff standing court granted plaintiffs lawsuits leave amend amended complaints containing substantially similar allegations earlier complaints filed behalf new plaintiffs purports allege personal injury lawsuit filed utility consumers action network behalf privacy rights clearinghouse entitled kimberly weisz et al v bristolmyers squibb co et al lawsuit filed rowan klein entitled roseanna stephenson behalf others similarly situated v bristolmyers squibb co et al cases preliminary stage possible time reasonably assess outcome lawsuits impact company rxusa wholesale litigation july complaint filed drug wholesaler rxusa wholesale inc us district court eastern district new york company fifteen drug manufacturers five drug wholesalers two officers defendant mckesson wholesale distribution industry trade group rxusa wholesale inc v alcon labs inc et al complaint alleges violations federal new york antitrust laws well various laws plaintiff claims defendants allegedly engaged anticompetitive acts resulted exclusion plaintiff relevant market seeks million damages trebling relief company together manufacturer defendants filed motion dismiss case november motion pending court possible time reasonably estimate outcome lawsuit impact company securities litigation investigations sec investigation wholesaler inventory accounting matters august company entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters company agreed without admitting denying liability violate certain provisions securities laws company also established million fund distributed certain company shareholders plan distribution established sec settlement resolve ongoing investigation sec activities certain former members companys management connection wholesaler inventory issues accounting matters company continuing cooperate investigation annual report dk health care resources litigation november class action complaint filed us district court eastern district missouri company dk health care resources inc dk several current former dk directors officers complaint alleges company participated fraudulently inflating value dk stock allegedly engaging improper channel stuffing agreement dk june court granted companys motion dismiss complaint plaintiffs time appeal decision appeal lodged begin run litigation dk officers directors finally resolved possible time reasonably assess outcome lawsuit impact company starkman litigation september certain companys current former officers named purported class action starkman v bristolmyers squibb et al filed new york state supreme court alleging factual claims similar resolved federal class action us southern district new york related alleged violations federal securities laws regulations connection sales incentives wholesaler inventory levels asserting common law fraud breach fiduciary duty claims behalf certain companys stockholders october company removed case us district court southern district new york november plaintiff moved remand matter state court matter stayed supreme court march entered decision another case held holder class actions asserting securities fraud claims state law like starkman preempted federal law following oral argument court denied plaintiffs motion remand september november company plaintiff submitted stipulation dismissal without prejudice approved court pricing sales promotional practices litigation investigations company together number defendants defendant number private civil matters relating pricing practices addition company together number pharmaceutical manufacturers received subpoenas document requests various government agencies seeking records relating pricing sales marketing practices best price reporting investigations company us doj office us attorney district massachusetts reached agreement principle subject approval doj settle several investigations involving companys drug pricing sales marketing activities agreement principle provides civil resolution expected payment million agreement principle involves matters actively investigated discussed us doj us attorney district massachusetts number years including matters relating pricing certain products sold several years ago subsidiary reimbursed governmental health care programs financial relationships subsidiary noted certain customers entities certain consulting programs promotion abilify unapproved indications calculation certain medicaid rebates serzone nefazodone hydrochloride pricing certain companys products reimbursed governmental health care programs agreement contemplates states choose participate settlement would criminal charges company respect matters agreement principle also provides company enter corporate integrity agreement office inspector general us department health human services settlement contingent upon parties agreement terms final settlement agreement including terms corporate integrity agreement approval doj assurance settlement finalized states choose participate agreement principle covers matters outlined us doj us attorney district massachusetts states indicated may pursue matters outside scope expected settlement event matters could result assertion civil andor criminal claims result agreement principle company increased reserves related investigations million bringing aggregate reserves matters million increased reserve recorded fourth quarter accordance gaap aggregate reserves reflect companys estimate expected probable loss respect matters assuming settlement finalized settlement finalized andor certain states choose participate amount reserved may reflect eventual losses furthermore open investigations issues conducted various federal state agencies well certain congressional committees company producing documents actively cooperating investigations could result assertion civil andor criminal claims bristolmyers squibb possible time reasonably assess outcome investigations described additional matters us doj office us attorney district massachusetts may pursue potential impact company previously disclosed company undertook analysis methods processes calculating prices reporting governmental rebate pricing programs related us pharmaceuticals business analysis completed early based analysis company identified need revisions methodology processes used calculating reported pricing related rebate amounts implemented revised methodologies processes beginning reporting federal government agency primary responsibility rebate price reporting obligations centers medicare medicaid services cms first quarter addition using revised methodologies processes company also recalculated best price average manufacturers price required reported companys federal medicaid rebate agreement certain state agreements corresponding revised rebate liability amounts programs threeyear period upon completion analysis early company determined estimated rebate liability programs threeyear period actually less rebates paid company period accordingly fourth quarter company recorded reduction rebate liability amount estimated overpayment company submitted proposed revisions updated estimate cms review cms may take position revisions companys methodologies calculations required company believes however based current information recalculation period likely result material rebate liability however due uncertainty surrounding recoverability companys estimated overpayment arising review process described company recorded reserve amount equal estimated overpayment litigation respect private civil matters company together number pharmaceutical manufacturers defendant private class actions well suits brought attorneys general several states numerous new york counties city new york pending federal state courts actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps federal cases several state attorneys general actions suits new york counties city new york consolidated pretrial purposes us district court district massachusetts awp mdl court awp mdl certified three classes persons entities paid reimbursed seven companys physicianadministered drugs nonjury trial classes insurance companies health welfare funds massachusetts commenced november currently ongoing trial date claims class medicare part b beneficiaries nationwide yet set company company also one many defendants putative class action filed california allegedly behalf entities entitled discounted pricing pursuant section b public health services act requires prescription drug manufacturers offer discounts qualified medical providers generally disproportionately service poor people july order entered dismissing california case prejudice plaintiff appealed dismissal california action possible time reasonably assess outcome litigation matters described potential impact company product liability litigation company party various product liability lawsuits involve among things hormone replacement therapy hrt products companys serzone prescription drug addition lawsuits company also faces unfiled claims involving products companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result external factors availability insurance continues restrictive cost increased significantly company evaluated risks determined cost obtaining insurance product liability losses outweighs benefits coverage protection losses became selfinsured product liability losses effective july company continue evaluate risks benefits determine insurance needs future annual report serzone serzone antidepressant launched company may canada march us december company added black box warning serzone label warning potential risk severe hepatic events including possible liver failure need transplantation risk death within several months black box warning added package insert serzone number lawsuits including several class actions filed company plaintiffs masstort litigation allege among things company knew known hepatic risks posed serzone failed adequately warn physicians users risks addition cases filed us class actions filed canada without admitting wrongdoing liability october company entered settlement agreement respect claims us territories regarding serzone november district court conditionally certified temporary settlement class preliminarily approved settlement september court issued opinion granting final approval settlement august company agreed proceed settlement exercise backend optout right without admitting wrongdoing liability september company reached agreement principle respect claims canada regarding serzone pursuant terms proposed settlement claims dismissed litigation terminated defendants receive releases company committed paying least million funds class members may company announced following evaluation commercial potential product generic entry marketplace rapidly declining brand sales decided discontinue manufacture sale product us effective june hormone replacement therapy plaintiffs masstort litigation allege among things various hormone therapy products including hormone therapy products formerly manufactured company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clots cardiac injuries women defendants aware risks failed warn consumers december company defendant lawsuits filed behalf approximately plaintiffs federal state courts throughout us company expects dismissed many cases products never used initial trials hrt litigation involving primary defendant wyeth commenced federal court july pennsylvania november initial trials involve breast cancer claims company defendant cases companys hormone therapy products sold companies january august company maintains estrace anda continues manufacture products supply agreement possible time reasonably assess outcome lawsuits company party impact company environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency epa counterpart state agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable december company estimated share total future costs sites approximately million recorded liabilities represents sum best estimates simple estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties currently expected company paid less million excluding legal fees last five years investigation remediation matters including liabilities cercla onsite remedial obligations puerto rico air emissions civil litigation previously reported company one several defendants including many major us pharmaceutical companies purported class action suit filed superior court puerto rico february relating air emissions government owned operated wastewater treatment facility april company executed individual settlement plaintiffs amount subject certain conditions including court would decide certify case class action court deferred decision class certification pending review expert reports facilitys operations court considered expert reports hearing october thereafter facilitated settlement discussions parties claims discussions ongoing consequently class certification hearing scheduled december postponed may bristolmyers squibb passaic river nj remediation natural resource damages claims september new jersey department environmental protection njdep issued administrative enforcement directive notice new jersey spill compensation control act requiring company approximately companies perform assessment natural resource damages implement unspecified interim remedial measures restore conditions lower passaic river directive alleges company liable historically sent bulk waste former inland chemical company facility newark nj owned mckesson corp reprocessing releases hazardous substances facility migrated newark bay continue adverse impact lower passaic river watershed subsequently epa also issued notice letter cercla numerous partiesbut including companyseeking cooperation study conditions substantially portion passaic river subject njdeps directive group parties entered consent agreement epa finance portion study epa yet determined estimated cost study consent agreement private party group committed pay roughly half million estimate subject revision future negotiation study may also lead cleanup actions directed epa army corps engineers group actively negotiating epa successful negotiations result amended consent agreement anticipation agreement company reached agreement principle mckesson corp share costs anticipated agreed portion epa study tasks company also working cooperatively group parties received njdep directive andor epa notice explore potential resolutions directive address risk collateral claims although company believe caused contributed contamination lower passaic river watershed company informed njdep willing discuss njdeps allegations company also private party group continues discuss federal agencies designated trustees natural resources affected contamination passaic river watershed possibility funding cooperative nrd study presumably would dovetail ongoing epa study ideally would joined njdep coordinate actions njdep may seek directive late njdep issued supplemental directive filed suit one site parties seeking compel implementation interim measures unclear whether njdep take additional actions site parties andor whether litigation arise response new claims extent liability company may face either njdep epa respect future claims federal trustees mckesson corp responsible parties yet determined north brunswick nj board education remediation claims october company contacted north brunswick nj board education boe regarding discovery industrial waste materials allegedly including materials er squibb sons expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work work plan approved njdep evaluating need conduct response actions remediate contain potentially impacted ground water due financial constraints late boe asked company contribute funds interim basis assure uninterrupted performance necessary site work company actively monitoring cleanup project including costs discussing boe township terms cooperative funding agreement allocation process municipal records indicate township operated landfill site company investigating historic use site including activities company may responsible date neither boe township asserted claims company njdep air permit new brunswick nj facility december company njdep entered administrative consent order aco concerning alleged violations new jersey air pollution control act implementing regulations companys new brunswick facility pursuant aco company agreed submit permit application creating facilitywide emissions cap pay small administrative fine obligations satisfied early subsequently february aco amended provide company would install new cogeneration turbine new brunswick facility december would obtain applicable air permits december company obtained required operating permit september purchased new cogeneration turbine cost approximately million installed turbine december compliance aco company fulfilled terms conditions aco february received notice termination aco njdep concludes matter annual report mead johnson facility nsps issue october company commenced voluntary environmental audit mead johnson facility mt vernon indiana determine compliance epas new source performance standards nsps applicable operation incinerator december company disclosed possible violations nsps requirement currently process modifying operations fall within exemption requirements date neither epa indiana department environmental management pursued penalties potential violations however company could potentially subject civil penalties past noncompliance nsps december epa responded self disclosure stated intend pursue enforcement action issues time possible however indiana department environmental management could future pursue civil penalties past noncompliance nsps ods regulatory compliance epa investigating industrial commercial facilities throughout us use refrigeration equipment containing ozonedepleting substances ods enforcing compliance regulations governing prevention service repair leaks ods requirements company performed voluntary corporatewide audit facilities us puerto rico use odscontaining refrigeration equipment company submitted audit report epa november identifying potential violations ods requirements several facilities addition matters covered companys audit report letter epa epa previously sent companys wholly owned subsidiary mead johnson request information regarding compliance ods requirements facility evansville indiana company responded request june result identified potential violations evansville facility company currently discussions epa resolve potential violations discovered audit identified result epa request information evansville facility epa determines evansville facility facilities violation applicable ods requirements company could subject penalties andor required convert replace refrigeration equipment use nonods approved substitutes mact compliance puerto rico facilities barceloneta humacao march company commenced voluntary environmental audit barceloneta humacao puerto rico facilities determine compliance epas regulations regarding maximum achievable control technology requirements emissions hazardous air pollutants pharmaceuticals production pharmaceutical mact company submitted epa audit report humacao facility june barceloneta facility july disclosed potential violations pharmaceutical mact requirements facilities company epa currently discussions regarding resolution matter proceedings sec germany investigation october sec notified company conducting informal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents october sec informed company inquiry formal secs inquiry encompasses matters currently investigation german prosecutor munich germany company understands inquiry investigation concern potential violations foreign corrupt practices act german law respectively company cooperating sec german authorities company established accrual represents minimum expected probable losses respect investigation german prosecutor possible time reasonably assess outcome investigations impact company bari italy investigation previously disclosed january company notified prosecutor bari region italy bari prosecutor company investigation result activities two employees region investigation involves company well number doctors pharmacists pharmaceutical companies sales representatives main allegation parties engaged plan defraud national health service bari prosecutor also alleges companies lacked appropriate compliance controls andor processes procedures control activities sales representatives bari prosecutor requested suspend operations pharmaceutical companies investigation appoint judicial administrator preliminary measures pending february company bari prosecutor reached agreement principle settle matter agreement yet finalized company would pay administrative fine amount material company bristolmyers squibb note subsequent events january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca plc astrazeneca develop commercialize two investigational compounds studied treatment type diabetes company received upfront payments million astrazeneca addition company receive milestone payments astrazeneca upon successful achievement various regulatory sales related stages companies agreed upon initial development plans two compounds majority development costs paid astrazeneca subsequent development costs generally shared equally annual report note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin earningsloss continuing operations net earningsloss earnings per common share basic earningsloss continuing operations discontinued operations net net earningsloss diluted earningsloss continuing operations discontinued operations net net earningsloss dividends declared per common share cash cash equivalents marketable securities net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities includes net litigation charges million million first fourth quarters respectively net litigation income million million second third quarters respectively first third fourth quarters include litigation insurance recoveries million million million respectively first second third fourth quarters include restructuring million million million million respectively first third fourth quarters include upfront milestone payments million million million respectively first quarter includes million gain sale product asset first second third fourth quarters include million million million million respectively accelerated depreciation asset impairment contract termination fourth quarter includes debt retirement costs million fourth quarter includes million claim damages earnings per share quarters may add amounts year period computed discrete basis includes litigation charges million million million first second fourth quarters respectively second third quarters include litigation insurance recoveries million million respectively first second third fourth quarters include restructuring items million million million million respectively first fourth quarters include upfront payments licensing agreements million million respectively first second quarters include million million respectively gain sale equity investments first second third quarters include million million million respectively loss sale fixed assets second quarter includes debt retirement costs million fourth quarter includes million deferred income net costs resulting termination collaborative agreement merck muraglitazar third quarter includes gain sale consumer medicines business million bristolmyers squibb common equivalent shares excluded computation diluted earnings per share effect would antidilutive follows millions first second third fourth quarter quarter quarter quarter year three months ended december result net loss basic diluted loss per share equal million weightedaverage shares issuable well million interest expense net tax conversion convertible debt included diluted earnings per share calculation dilutive annual report reports management managements responsibility financial statements management responsible preparation integrity financial information presented annual report accompanying consolidated financial statements prepared conformity accounting principles generally accepted united states america gaap applying certain estimates judgments required managements opinion consolidated financial statements present fairly companys financial position results operations cash flows audit committee board directors meets regularly internal auditors deloitte touche llp dt companys independent registered accounting firm management review accounting internal control structure financial reporting matters internal auditors dt full free access audit committee set forth companys standard business conduct ethics company firmly committed adhering highest standards moral ethical behavior business activities managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance accounting principles generally accepted united states america gaap due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included annual report issued report managements assessment effectiveness companys internal control appears annual report james cornelius chief executive officer andrew rj bonfield chief financial officer february bristolmyers squibb controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report annual report issued report managements assessment effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting annual report report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited accompanying consolidated balance sheet bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income retained earnings cash flows year ended financial statements responsibility company 's management responsibility express opinion financial statements based audit financial statements company years ended december audited auditors whose report dated march expressed unqualified opinion statements conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audit provides reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows year ended conformity accounting principles generally accepted united states america discussed notes consolidated financial statements company adopted statement financial accounting standards sfas r sharebased payment effective january sfas employersaccounting defined benefit pension postretirement plansan amendment fasb statements r effective december also audited accordance standards public company accounting oversight board united states effectiveness company 's internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion management 's assessment effectiveness company 's internal control financial reporting unqualified opinion effectiveness company 's internal control financial reporting deloitte touche llp parsippany new jersey february bristolmyers squibb report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited management 's assessment included managements report internal control financial reporting bristolmyers squibb company subsidiaries company maintained effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission company 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management 's assessment opinion effectiveness company 's internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating management 's assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinions company 's internal control financial reporting process designed supervision company 's principal executive principal financial officers persons performing similar functions effected company 's board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion management 's assessment company maintained effective internal control financial reporting december fairly stated material respects based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission also opinion company maintained material respects effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements year ended december company report dated february expressed unqualified opinion financial statements included explanatory paragraph regarding companys adoption statement financial accounting standards sfas r sharebased payment effective january sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r effective december deloitte touche llp parsippany new jersey february annual report report independent registered public accounting firm board directors stockholders bristolmyers squibb company opinion consolidated balance sheet december related consolidated statements earnings comprehensive income retained earnings cash flows two years period ended december present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows two years period ended december conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecoopers llp philadelphia pa march bristolmyers squibb fiveyear financial summary amounts millions except per share data income statement data net sales earning continuing operations minority interest income taxes earnings continuing operations earnings continuing operations per common share basic diluted average common shares outstanding basic diluted dividends paid common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securities longterm debt stockholders equity company recorded items affected comparability results discussion items years see managements discussion analysis financial condition results operationsexpenses note alliances investments note restructuring note acquisitions divestitures note discontinued operations note shortterm borrowings longterm debt note legal proceedings contingencies excludes discontinued operations oncology therapeutics network years clairol zimmer million weightedaverage shares issuable well million interest expense net tax assumed conversion convertible debt included diluted earnings per share calculation dilutive includes impact adoption statement financial accounting standard sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r discussion sfas see note pension postretirement benefits boardof directors james drobinson iii robert e allen laurie hglimchermd chairmanbristolmyers squibband retired chairman chief executive officer irene heinz given professor immunology cofounder general partner att corporation bcd harvard school public healthand professor rre ventures medicineharvard medical school abe lewis bcampbell chairmanpresident chief executive officer michael grobstein textron incabcd retired vice chairman ernst young vance dcoffman retired chairman chief executive officer leif johansson lockheed martin corporation abcd presidentab volvoand chief executive officer volvo group ac james mcornelius chief executive officerbristolmyers squibband vicki lsatophd chairman emeritusguidant corporation professor management practiceharvard business schooland professor practice audit committee louis jfreeh department molecular cell biology b committee directors former vice chairman general counsel harvard university e corporate governance mbna america banknaab c compensation management rsanders williamsmd development committee senior vice chancellor academic affairs executive committee e science technology committee duke university medical centerand dean duke university school medicine e managementcouncil james mcornelius lamberto andreotti sandra leung chief executive officer executive vice president president senior vice president general counsel worldwide pharmaceuticals elliott sigalmdphd stephen ebear executive vice president senior vice presidenthuman resources chief scientific officer president pharmaceutical research institute andrew rjbonfield executive vice president chief financial officer john ecelentano presidenthealth care group stockholdeir nformation common stock recent certifications companys product names ticker symbolbmy chief executive officer chief financial officer company programs new york stock exchange pursuant section sarbanesoxley product names company programs act filed exhibits companys appearing throughout italics trademarks annual meeting company also filed bristolmyers squibb company one stockholders new york stock exchange recent divisions subsidiary companiesglobal products tuesdaymay annual ceo certification required referred herein registered amhotel dupont section aa new york stock approved ustrademarksunless specifically th market streets exchange listed company manual noted otherwise wilmingtonde information following subjects abilify trademark otsuka stockholder services available wwwbmscom pharmaceutical coltd programs bristolmyers squibb foundation inquiries concerning stockholder accounts sustainabilityenvironmental programs atripla trademark bristolmyers squibb stock transfer mattersincluding address political contributions gilead sciencesllc changesthe elimination duplicate mailings diversity eeo report dividend reinvestment see direct avaproavalideaprovelkarvea plavix deposit dividendsshould directed annual report contains certain forward trademarks sanofiaventis companys transfer agent registrar looking information within meaning private securities litigation reform act delestrogen trademark jones pharmainc mellon investor services llc forwardlooking statements involve washington boulevard substantial risks uncertainties could dovonex trademark leo pharma jersey citynj cause actual results differ materially wwwmelloninvestorcomisd expectations estimates reflected emsam trademark somerset within us forwardlooking statementsplease see pharmaceuticalsinc outside us financial review discussion tdd telephone service hearing description risks uncertainties erbitux trademark imclone impaired within us company undertakes obligation systems incorporated outside us publicly update forwardlooking statement whether result new informationfuture estrace trademark galen chemicals ltd dividend reinvestment plan events otherwise registered stockholders stock must held gleevec bufferin trademarks name hold shares novartis ag companys stock may participate stockholderpaid dividend reinvestment plan glucophage irglucophage xrglucovance dripwhich includes safekeeping metaglip trademarks merck sant saleofstock featureif hold fewer sasan associate merck kgaa sharesyou still eligible participate darmstadtgermany safekeeping saleofstock features well direct registration option ovcon trademark warner chilcott companyinc free copy companys norvir trademark abbott laboratories annual report fiscal year ended december contact trizivir trademark glaxo group ltd secretary bristolmyers squibb company truvada trademark gilead sciencesinc park avenue new yorkny also available wwwbmscominvestors back cover clockwise rightbarbara cubic williamage brennenage alexage barbara husband johnadopted william brennen russiathe boys share rare inherited metabolic disordercalled pku togetherthey prevail help mead johnsons phenylfree phenylfree hp dietary powders bristolmyers squibball rights reserved designedwritten photographed bristolmyers squibb corporate business communications departmentphoto syracuse facilityby ron trinca portions document printed paper manufactured mills certified forest stewardship council fsc sustainable forestry initiative sfinopq together prevailtm park avenue new yorkny wwwbmscom